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2. Abbreviations 
Akt   Protein kinase B 
AMD   Age-related macular degeneration 
ANG   Angiopoietin 
AP    Alkaline phosphotase 
BacMam   Baculovirus mediated gene transduction of mammalian cell 
BCA   Bicinchoninic Acid 
BM   Basement membrane 
c-Kit   Stem cell growth factor receptor 
Co-IP   Co-immunoprecipitation 
C-terminal   Carboxy-terminal 
CTLA   Cytotoxic T lymphocyte protein 
DAG   Diacylglycerol 
DLL4   Delta-like ligand 4 
DMEM   Dulbecco’s modified  Eagle’s  medium 
DNase   Deoxyribonuclease  
DSS   Distal splice site 
DTT   Dithiothreitol 
EBNA-1   Epstein-Barr nuclear antigen 1  
EBV   Epstein-Barr virus 
E.coli   Escherichia coli  
ECD   Extracellular domain 
ECM   Extracellular matrix 
EC(s)    Endothelial cell(s) 
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EDTA   Ethylenediamine tetraacetic acid 
EM   Electron microscopy 
Endo F   Endoglycosidase F 
eNOS   Endothelial nitric oxide synthase 
EPCs   Endothelial precursor cells 
Eph   Ephrin 
ERK   Extracellular signal-regulated kinase 
Fab   Fragment antigen-binding antibody 
FAK   Focal adhesion kinase 
FATP   Fatty acid transport protein 
FBS   Fetal bovine serum 
Fc    Fragment crystallizable 
FGFs   Fibroblast growth factors 
Flk-1   Fetal liver kinase-1 
Flt-1   Fms-like tyrosine kinase-1 
Fyn   Proto-oncogene tyrosine-protein kinase 
Grb   Growth factor receptor bound 
HEK293   Human embryonic kidney cells 
HEPES   4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid 
HIF   Hypoxia-inducible factor 
HRP   Horseradish peroxidase 
HSPG   Heparin sulfate proteoglycan 
Ig    Immunoglobulin 
IMAC   Immobilized metal ion affinity chromatography 
IP3    Inositol 1,4,5-trisphosphate 
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IPTG   Isopropyl β-D-1-thiogalactopyranoside 
IT    Isothermal reaction buffer 
ITC   Isothermal titration calorimetry 
IR    Infrared 
JCSG   Joint Center for Structural Genomics 
JMD   Juxtamembrane domain 
Kd    Equilibrium dissociation constant 
kDa   Kilo-Dalton 
KDR   Kinase insert domain-containing receptor 
KID   Kinase insert domain 
LB    Luria Bertani 
LCP   Lipidic cubic phase 
LED   Light-emitting diode 
MAPK   Mitogen-activated protein kinase 
MEK   Mitogen-activated protein kinase kinase 
MMPs   Matrix metalloproteinases 
MMS   Microseed matrix screening 
MST   Microscale thermophoresis 
mTOR   Mammalian target of rapamycin 
MW   Molecular weight 
NICD   Notch intracellular domain  
Nrp   Neuropilin 
N-terminal  Amino-terminal 
PAE   Porcine aortic endothelial 
PBS   Phosphate-buffered saline  
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PCR   Polymerase chain reaction 
PDGF   Platelet-derived growth factor 
PDGFR   Platelet-derived growth factor receptor 
PDL   Programmed cell death ligand 
PEG   Polyethylene glycol 
PEI   Polyethyleneimine 
PEM    Protein Expression Medium  
PI-3 KINASE  Phosphatidylinositol 3‘-kinase 
PIP2   Phosphatidylinositol (4,5)-bisphosphate 
PIGF   Placenta growth factor 
PKC   Protein kinase C 
PLC   Phospholipase C 
PNGase F  Peptide: N-glycosidase F 
PSF   Progression free survival 
PSS   Proximal splice site 
PTB   Phospho-tyrosine binding 
PVDF   Polyvinylidene fluoride 
RTK   Receptor tyrosine kinase 
SAXS   Small angle X-ray scattering 
scFv   Single chain variable fragment 
SDS-PAGE  Sodium dodecylsulfate polyacryl gel electrophoresis 
SEC   Size exclusion chromatography 
Sf21   Spodoptera frugiperda cells 
SH   Src-homology 
SHB   Src homology-2 protein in beta-cells 
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SHC   Src homology 2 domain-containing transforming protein 
SHP   Src-homology phosphatase 
TB    Terrific Broth 
TBST   Tris-buffered saline  
TGF    Transforming growth factor 
Tm   Melting temperature 
TM   Transmembrane 
TMD   Transmembrane domain 
TSAd   T cell specific adapter  
VD   Vapour diffusion 
VEGF   Vascular endothelial growth factor   
VEGFR   VEGF receptor 
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3. Summary 
Angiogenesis is the formation of new blood vessels from pre-existing vasculature and 
plays an essential role in normal organ development and in specific diseases in all 
higher organisms. Angiogenesis is therefore required already early in embryogenesis 
when the new blood and lymphatic systems develop. In adult organisms angiogenesis 
is required in numerous processes such as in vessel formation and remodeling in the 
female reproductive cycle, during wound healing, or in bone formation and remodeling. 
Aberrant excessive vessel formation, i.e. pathological angiogenesis, plays an 
important role in tumor progression, in diabetic retinopathy, rheumatoid arthritis or in 
psoriasis. The lack of angiogenesis leads to multiple vascular failure such as coronary 
artery disease. It is well established that the correct balance between pro- and anti-
angiogenic growth factors, cytokines, and extracellular matrix components is essential 
for vascular homeostasis. One of the critical regulators of both physiological and 
pathological angiogenesis discovered more than 30 years ago is Vascular Endothelial 
Growth Factor (VEGF), regulating endothelial cell (EC) proliferation, migration, and 
survival but also vascular topology and permeability. VEGF is a family of cysteine 
linked dimeric growth factors consisting of five members, VEGF-A, -B, -C, -D and 
Placenta Growth Factor (PlGF). These soluble or matrix associated proteins bind to 
three type V receptor tyrosine kinases (RTKs), VEGF-receptor (VEGFR)-1 (also known 
as Flt1), VEGFR-2 (KDR/Flk1), and VEGFR-3 (Flt4). VEGFRs consist of an 
extracellular domain (ECD) built from seven immunoglobulin (Ig)-homology domains 
required for ligand binding and subsequent receptor dimerization. A single 
transmembrane (TM) helix connects the ECD to the cytoplasmic part containing a split 
tyrosine kinase domain. Ligand binding to VEGFR ectodomains promotes dimerization 
of receptor monomers, followed by receptor autophosphorylation and kinase 
activation. The activated receptor contains specific tyrosine residues in the kinase 
domain and the carboxy-terminal (C-terminal) domain acting as docking sites for a 
plethora of signaling proteins involved in multiple cellular signaling pathways.  
Ig-homology domains 1-3 (VEGFR-3) or 2-3 (VEGFR-1 or -2) of the ECD form the 
ligand binding site, while domains 4-7 are involved in homotypic receptor contacts 
fulfilling a regulatory function, which was the subject of this thesis. I used isothermal 
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titration calorimetry (ITC) in this study to determine the thermodynamic properties of 
ligand binding and dimer formation. The data show that the free energy of VEGF-A 
binding to domains 1-3 or the full-length ECD of VEGFR-2 is entropy driven and 
enthalpically unfavourable. Most importantly, the Gibbs free energy of VEGF-A binding 
to the full length ECD is 1.12 kcal/mol higher compared to the binding energy of 
domains 1-3. The endothermic component arising from the homotypic receptor 
contacts in domains 4-7 thus reduces the overall binding affinity of the full-length 
VEGFR-2 ECD by about 10 fold. This suggests that the homotypic interactions in 
domain 4-7 play a regulatory role in ligand binding and receptor activation, e.g. by 
promoting conformational rearrangements of receptor monomers required for active 
dimer formation. This mechanism might also prevent spontaneous activation of 
VEGFR-2 in the absence of ligand. 
I also tried to crystallize the ECD of VEGFR-2 in complex with ligand. However, 
although I used a multitude of receptor ECD constructs, I did not obtain diffracting 
crystals. I therefore became involved in an accompanying project in the lab focusing 
on the crystal structure of the full-length VEGFR-1 ECD in complex with VEGF-A. This 
structure revealed distinct homotypic contacts in Ig-homology domains 5 and 7. To 
further characterize the contacts in domain 5 biochemically and to investigate their 
functional relevance in receptor activation I generated mutants disrupting specific 
hydrogen bonds and salt bridges involved in homotypic contact formation. The data 
showed a significant decrease in receptor phosphorylation activity upon stimulation 
with ligand. Similarly, I could show reduced receptor activity when the homologous 
residues were mutated in VEGFR-2. The biochemical characterization of these 
mutants thus document the regulatory role of domain 5 in VEGFR activation and 
identify domain 5 as a promising target for developing allosteric inhibitors of VEGFRs. 
The speciality of drugs proposed to target domain 5 lies in their ability to access the 
target receptor at a regulatory site in the extracellular receptor domain, which is easily 
accessible from the blood stream. In addition, the proposed drugs will be highly specific 
as compared with the currently used kinase inhibitors. 
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4. Zusammenfassung 
Angiogenese ist die Bildung neuer Blutgefässe aus existierenden Gefässsystemen 
und spielt eine essenzielle Rolle während der normalen Entwicklung und einigen 
Krankheiten in allen höheren Organismen. Daher findet Angiogenese schon in der 
frühen Embryogenese statt um neue Blut- und Lymphgefässe zu entwickeln. In 
erwachsenen Organismen ist Angiogenese in einigen Prozessen notwendig, wie der 
Bildung und dem Umbau von Gefässen während des weiblichen 
Reproduktionszykluses, während der Wundheilung und dem Auf- und Umbau von 
Knochen. Abnormale exzessive Gefässbildung, also pathologische Angiogenese, 
spielt eine wichtige Rolle in der Tumorentwicklung, der diabetischen Retinopathie, der 
rheumatischen Arthritis oder der Psoriasis. Der Verlust der Angiogenese wiederum 
führt zu mehreren Gefässversagen wie in der koronalen Arterienerkrankung. Es ist gut 
etabliert, dass das richtige Gleichgewicht zwischen pro-und antiangiogenetischer 
Wachstumsfaktoren, Cytokinen, und extrazellulärer Matrixkomponenten essenziell ist 
für die Gefässhomeostase. Ein kritischer Regulator für die physiologische wie auch 
pathologische Angiogenese, der vaskuläre endotheliale Wachstumsfaktor (VEGF), 
wurde schon vor mehr als 30 Jahren entdeckt. VEGF reguliert endotheliales 
Zellwachstum, -migration und -überleben, aber auch Gefässtopologie und -
permeabilität. VEGF ist ein Familie aus Cystein verbundenen dimeren 
Wachstumsfaktoren , die aus fünf Mitgliedern besteht: VEGF-A, -B, -C, -D und 
Plazenta Wachstumsfaktor (PIGF). Diese löslichen oder Matrix-assoziierten Proteine 
binden drei Typ V Rezeptortyrosinkinasen (RTKs), VEGF-rezeptor (VEGFR)-1 (auch 
Flt1 genannt), VEGF-rezeptor (VEGFR)-2 (KDR/Flk1) und VEGF-rezeptor (VEGFR)-3 
(Flt4). VEGFR besteht aus einer extrazellulären Domäne (ECD) mit sieben 
immunoglobulin(IG)-homologen Domänen und wird für die Ligandbindung und die 
darauffolgende Rezeptordimerisierung benötigt. Eine einzelne transmembrane (TM) 
Helix verbindet die ECD mit dem cytoplasmatischen Teil, welcher eine Tyrosin 
Kinasendomäne beinhaltet. Die Bindung eines Liganden and der VEGFR Ectodomäne 
induziert die Dimerisierung des monomeren Rezeptors gefolgt von der 
Autophosphorylierung des Rezeptors und der Aktivierung der Kinase. Die aktive 
Kinase enthält spezifische Tyrosinseitenketten in der Kinasedomäne und der C-
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terminalen Domäne und agiert als Andockstellen für eine Vielzahl von Signalproteinen, 
die in mehreren zellulären Signalwegen involviert sind. 
Das Thema dieser Dissertation war die Untersuchung der Ligandenbindungsstelle, die 
durch Ig-homogen Domäne 1-3 (VEGFR-3) oder 2-3 (VEGFR-1) der ECD ausgebildet 
wird, sowie der regulatorischen Funktion der Domäne 4-7, die mit dem homotypischen 
Rezeptor interagiert. Es wurde isothermale Titrationskalometrie verwendet, um die 
thermodynamischen Eigenschaften der Ligandbindung und der Dimerisierung zu 
bestimmen. Die Daten zeigen, dass die Bindung von VEGF-A an die Domänen 1-3 
oder die ganze ECD des VEGFR-2 entropisch, hedoch nicht enthalpisch favorisiert ist. 
Wichtig ist, dass die Gibbs-Energie zwischen VEGF-A und der vollen ECD 1.12 
kcal/mol höher als die Bindungsenergie der Domäne 1-3 ist. Die endothermale 
Komponente kommt von homotypischen Rezeptorkontakten in der Domäne 4-7, die 
die Gesamtbindungsaffinität zwischen dem Liganden und der vollen VEGFR-2ECD um 
das zehnfache reduziert. Dies weist auf eine homotypische Interaktion hin, die eine 
regulatorische Rolle spielt, indem sie Konformationsänderungen des monomeren 
Rezeptors fördert, die zur Bildung eines aktiven Rezeptordimers führt. Dieser 
Mechanismus könnte die spontane Aktivierung von VEGFR-2 in der Abwesenheit des 
Liganden verhindern.  
Ich habe versucht die VEGFR2-ECD zusammen mit dem Liganden zu kristallisiern. 
Trotz mehreren versuchen mit verschiedenen ECD-Konstrukten wurden keine Kristalle 
erhalten. Dies führte dazu, dass ich mich an einem verwandten Projekt beteiligte; der 
Kristallisation des VEGFR1-ECD/VEGF-A Komplexes. Diese Kristallstruktur zeigt 
homotypische Interaktionen mit der Ig-homologen Domäne 5 und 7 auf. Um die 
funktionelle Relevanz festzustellen, wurden spezifische Wasserstoffbrücken und 
Salzbrücken, welche wichtig für die Bindung mit der homotypischen Domäne 5 sind, 
durch Mutationen gebrochen. Daten dieser Mutanten zeigten, dass die 
Phosphorylierungsakitivität dieser Rezeptoren signifikant reduziert ist, wenn sie mit 
Liganden stimuliert werden. In gleicher Weise wurde die Aktivität beeinträchtigt, wenn 
die entsprechenden Seiten der Domäne 5 der homologen VEGFR-2 mutiert wurden. 
Die biochemische Charakterisierung dieser Mutanten dokumentiert die regulatorische 
Rolle der Domäne 5 in VEGFR-Aktivierung und identifiziert sie als einen 
vielversprechenden Startpunkt zur Entwicklung allosterischer Inhibitioren für den 
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VEGF Rezeptor. Ein wichtiger Aspekt eines potenziellen Mwdikamentes wäre, dass 
es an die regulatorische Stelle der extrazellulären Rezeptordomäne binden könnte, 
welche aus dem Blut erreichbar ist. Zusätzlich wäre diese vorgeschlagene Droge 
hochspezifisch verglichen mit heutigen Kinaseinhibitoren. 
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5. Introduction 
Angiogenesis is an important process, in which formation of new blood vessels takes 
place via extension or remodeling from the existing capillaries. It is an indispensable 
process required for the vertebrate development. In a developing embryo, the 
cardiovascular system forms in the very beginning to establish the oxygen diffusion, 
metabolite and nutrient exchange in rapidly expanding tissues of the embryo. 
Vasculogenesis is the de novo process of formation of the primitive network of vessels 
from mesoderm derived endothelial precursors (angioblasts). Pericytes and smooth 
muscle cells are recruited to stabilize this early network. This primary capillary plexus 
is progressively remodeled by the angiogenic processes to establish a mature 
circulatory network. Vasculogenesis, mostly known to be limited to embryonic 
development, can also support neovascularization from the bone marrow derived 
endothelial precursor cells (EPCs) in adulthood. Angiogenesis is the essential process 
for the maturation of the new vasculature during embryonic development. During 
adulthood, it is required only during the formation of new capillaries in response to 
injured tissue, during physical training, when physiological metabolic demand 
increases and during menstrual cycle of women. Therefore, ECs are considered 
stable, showing limited turnover in the adult vasculature (Risau, 1997).  Angiogenesis 
can occur by two distinct mechanisms: sprouting and intussusception (Djonov et al., 
2002). During sprouting angiogenesis, the vascular ECs proliferate and migrate 
(sprout) into a proteolytically degraded extracellular matrix (ECM) guided by 
angiogenic signals to form a new branch derived from an existing vessel. During 
intussusception (non-sprouting), the vessel proliferates to extend into the lumen 
leading to splitting of vessel in two. Initial expansion of the capillary plexus takes place 
via both the processes namely sprouting and intussusception but consequent growth 
and remodeling is attained by intussusception. 
5.1. Molecular basis of angiogenesis 
Vessel formation is known to be induced by a variety of molecular players such as 
growth factors, cytokines, growth factor receptors and transcription factors. Out of the 
various models of angiogenesis, the sprouting mechanism has more thoroughly 
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studied molecular basis. Proangiogenic molecules such as VEGF, angiopoietin (ANG-
2), fibroblast growth factors (FGFs) activate the dormant vessels. It leads to 
detachment of pericytes from the basement membrane by the proteolytic degradation 
facilitated by the matrix metalloproteinases (MMPs). VEGF plays a key role by 
increasing the permeability of the EC layer leading to remodeling of the preexisiting 
matrix (Carmeliet et al., 2011). One of the ECs assumes a tip cell like character in 
presence of VEGFRs, neuropilins (Nrps) and Notch ligands. The tip cell extends its 
filopodia and starts migrating towards high levels of VEGF which activates the signaling 
of VEGFR-2 with its co-receptor Nrp1. These cells then start expressing high levels of 
Notch ligand Delta-like ligand 4 (DLL-4), which interacts to Notch receptors on the 
adjacent ECs, releasing the cleaved Notch intracellular domain (NICD). NICD is a 
transcriptional regulator which down regulates the expression of Vegfr2 and Nrp1 on 
the cells adjacent to tip cells while increasing the expression of a decoy receptor, 
VEGFR-1 which has greater affinity for the ligand VEGF. Hence these adjacent cells 
acquire the characteristic of the stalk cells (Lundkvist et al., 2007).  Notch plays a 
crucial role in specification of tip and stalk cells, by acting as a negative feedback loop 
to VEGF signaling (Jakobsson et al., 2009). The growing sprouts follow the guidance 
cues of a VEGF gradient and migrate towards molecules such as semaphorins and 
ephrins. Behind the tip cells the stalk cells proliferate for sprout elongation and lumen 
formation. Macrophages support the fusing of two tip cells (anastomosis) by interacting 
with the filopodia from the two tip cells. A connected lumen is formed after fusing of tip 
cells to allow blood flow which delivers nutrient and oxygen and consequently subsides 
the angiogenic signals. ECs become quiescent and acquire a phalanx phenotype 
which regulates blood flow and tissue perfusion. The ECs express platelet-derived 
growth factor (PDGF) and attract the pericyte precursors which differentiate in 
response to transforming growth factor (TGF-β) into mural cells. This brings 
stabilization in the newly formed vessel by reducing EC proliferation, migration and 
vessel leakage. Levels of angiogenic signal are reduced, whereas paracrine and 
autocrine signals including VEGF, FGF, Ang1 and Notch from ECs and support cells 
maintain ECs in quiescence. The vessel is further matured by recreating cell-cell 
junctions and deposition of basement membrane (BM) to promote vessel stabilization 
(Eichmann et al., 2012) (Figure 1). 
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Figure 1: Molecular mechanism of vessel formation. (a) Quiescent vessel is activated by 
angiogenic factors and tip cell is selected for branch formation. (b) Tip cells are directed by 
guidance signals for migration. Stalk cells proliferate, elongate and form lumen after fusion. 
Stalk cells attract pericytes and basement membrane deposition for attaining stabilization. (c) 
Neovessels are perfused with lumen formation. Quiescent phenotype is attained by re-
establishing junctions, pericyte maturation and release of vascular maintenance signals.  
adapted from (Carmeliet et al., 2011) 
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This complex process of angiogenesis, has crucial involvement of VEGF family 
members. It is evident from the studies of knockout mice. Homozygous gene deletion 
of either VEGF-A or VEGFRs in mice leads to embryonic death in utero between 
embryonic day 8.5 and 10.5, due to abnormal vascular development. Even deletion of 
a single VEGF-A allele is sufficient to lead to lethality at embryonic day 11-12 
(Carmeliet et al., 1996; Ferrara et al., 1996). Subcellular localization also plays a crucial 
role in VEGFR-2 signaling. Signaling of VEGFR-2 from intracellular compartments 
induces arterial morphogenesis (Lanahan et al., 2010). Matrix bound isoforms of VEGF 
are known to stimulate branching, whereas soluble isoforms lead to enlargement of 
vessels. Autocrine VEGF produced by ECs contributes to the attainment of blood 
homeostasis whereas paracrine VEGF produced by tumor and stromal cells leads to 
increase in vessel branching (Lee et al., 2007). 
Vessel perfusion into different areas of the body also involves defining the ECs of an 
arterial or venous specification. Ephrin (Eph) receptor tyrosine kinase family is involved 
in this event. Eph receptors and their ligands (Ephrin) are both TM proteins and require 
cell to cell contact for their signaling. EphrinB2 is preferentially expressed in arterial 
ECs while its receptor EphB4 is mainly expressed in venous ECs (Wang et al., 1998).  
5.2. Pathological angiogenesis 
The imbalance of pro- and anti-angiogenic factors (known as `angiogenic switch‘) can 
lead to pathological angiogenesis. Pathologies hallmarked by excessive vessel growth 
include cancers, retinopathies induced by age (age-related macular degeneration, 
AMD), psoriasis, arthritis or diabetes. Moreover, insufficient vessel growth and 
abnormal vessel regression can lead to neurodegeneration, hypertension, heart and 
brain ischemia and pre-eclampsia and osteoporosis (Carmeliet, 2003). 
Cancers have several modes of vessel formation and they can switch in between these 
modes: (1) Avascular tumors can induce vessel formation by angiogenic sprouting, (2) 
pre-existing vessels can split by a process known as intussuception, (3) tumor cells 
can grow around preexisting vessels known as vessel cooption, (4) tumor cells can 
line along vessels, acting as replacement cells for ECs (vascular mimcry), (5) due to 
cytogenetic abnormalities in chromosomes, putative cancer stem cells are allowed to 
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differentiate into ECs (6) EPCs recruited from bone marrow also contribute to tumor 
angiogenesis (Carmeliet et al., 2011).  
The tumor can tip the balance towards an angiogenic phenotype in presence of several 
factors such as metabolic and mechanical stress, mutation of oncogenes and 
inflammation (Carmeliet et al., 2000). The demand for oxygen and nutrients in a tumor 
of size around 2 mm in diameter exceeds the local supply, making it hypoxic. Hypoxia 
initiates the upregulation of the transcription factor hypoxia-inducible factor 1 (HIF-1) 
which induces the expression of proangiogenic molecules such as VEGF, PIGF, FGFs 
and interleukin-8 (Baish et al., 2000). The tumor vasculature due to imbalance of VEGF 
family ligands, form disorganized structural alterations such as unequal distribution of 
vessel branches, form chaotic networks of leaky vessels and frequent lack of pericytes 
(Nagy et al., 2010). Some tumors begin with well vascularized tumors due to co-option 
on existing vessels. In defense against co-option, the host vessels start to express high 
autocrine levels of Ang2, consequently leading to vessel regression. As the vessels 
undergo apoptosis, the tumor becomes secondarily avascular and hypoxic. The tumor 
rescues itself by secreting high levels of VEGF, to initiate new angiogenic sprouting 
from these vessels for its further survival and growth (Holash et al., 1999). 
Clearly, tumor growth and metastasis depends solely on angiogenesis. The late Judah 
Folkman, in 1971, performed pioneering work in the field. He proposed to block the 
nourishment of tumors by cutting its blood supply as a new anticancer strategy. 
(Folkman, 1971).  
The proliferative retinopathies such as diabetic retinopathy and wet AMD are leading 
cause of vision loss worldwide. Both the disorders are characterized by extensive 
proliferation of new blood vessels, triggered mainly by angiogenic factor VEGF 
(Caldwell et al., 2003; Gariano et al., 2005). The new leaky vessels formed leads to 
retinal edema and sub-retinal fluid accumulation, subsequently resulting in impaired 
vision. Hence, inhibition of VEGF is the strategy used clinically for treating ischemia-
related retinopathies (Kim et al., 2012). 
5.3. Therapeutic approaches 
Since VEGF family members are the crucial regulators of both developmental and 
pathological angiogenesis, many therapeutic approaches target the VEGF/VEGFR 
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signaling system. One of the strategies utilized by the antiangiogenic therapies is to 
prevent VEGF ligand binding to the receptor by blocking either of the binding sites. 
Bevacizumab (Avastin), a humanized monoclonal anti-VEGF antibody has been 
approved by the US Food and Drug Administration in combination with chemotherapy 
or cytokine therapy for many advanced metastatic cancers, including non-squamous 
non-small cell lung cancer, colorectal cancer, renal cell cancer and breast cancer. Anti-
VEGF fragment antigen-binding antibody (Fab) ranibizumab (Lucentis) and a VEGF 
aptamer pegaptanib (Macugen) are used to treat leaky neovessels in patients suffering 
from wet AMD (Biswas et al., 2011; Carmeliet et al., 2011; Carneiro et al., 2011). 
Another approach applied for the clinical treatment is use of small molecule inhibitors. 
These bind to the intracellular domain of the receptor and inhibit the catalytic activity 
of the tyrosine kinase domain, by interfering with the ATP binding pocket (Type I), or 
preventing the kinase domain from attaining the active conformation (Type II). Sunitinib 
(Sutent) and Pazopanib (Votrient) are used to treat renal cell carcinoma, Sorafenib 
(Nexavar) for metastatic renal cell carcinoma and hepatocellular carcinoma, and 
Vandetanib (Zactima) for medullary thyroid cancer. Also aflibercept (Regeneron), the 
“VEGF Trap” which is a soluble chimeric protein constituting Ig-homology domain 2 of 
VEGFR-1 and Ig-homology domain 3 of VEGFR-2, predimerized by a constant region 
(Fc-region) of human IgG1, is used to neutralize the ligands VEGF-A, VEGF-B and 
PlGF in patients with metastatic colorectal cancer as well as wet macular degeneration 
(Holash et al., 2002). To block VEGFR-2 signaling, a fully humanized monoclonal 
antibody targeting the ligand binding site on the receptor ECD called ramucirumab, is 
used for treating advanced gastric or gastro-esophageal adenocarcinoma (Krupitskaya 
et al., 2009). Alitalo and colleagues generated monoclonal antibody against VEGFR-3 
that inhibits homodimer and heterodimer formation but does not block ligand binding 
(Tvorogov et al., 2010). They showed inhibition in sprouting, migration and signal 
transduction of microvascular ECs. 
A new approach in therapeutics which should theoretically result in effective tumor 
growth inhibition, is to use combination of anti-VEGF agents with other angiogenic 
inhibitors or inhibitors from non-related pathways. Since, VEGF-A inhibition studies 
show considerable increase in the number of tumor-infiltrating lymphocytes. Hence 
clinical trials are being performed which use a combination of anti VEGF-A treatment 
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with immune checkpoint inhibitors eg. Cytotoxic T lymphocyte protein 4 (CTLA4) or 
programmed cell death ligand (PDL1) (Shrimali et al., 2010). Also the sequential 
treatments with VEGF-A inhibitors and inhibitors of mammalian target of rapamycin 
(mTOR) such as everolimus (Afinitor Disperz; Novartis) have resulted in increased 
progression free survial (PSF) in patients with metastatic renal cell carcinoma (Motzer 
et al., 2015) . 
Despite of many clinical benefits of these anti-angiogenic therapies, there are several 
more challenges and concerns to be solved. Problem is the development of resistance 
to the treatment. Some tumors become unresponsive during treatment and produce 
other proangiogenic factors and induce angiogenesis independent of the VEGF 
pathway. Vessel pruning by VEGF blockade sometimes aggravates hypoxia, leading 
to recruitment of various immune cell subsets, and release of angiogenic factors such 
as PlGF, FGFs, chemokines and ephrins (Bergers et al., 2008). Depriving a tumor of 
blood vessels, switches it to become more invasive by selecting “hypoxia” resistant 
clones and making it more metastatic. Tumors also adopt other modes of 
vascularization besides sprouting, such as vessel co-option or vascular mimicry and 
recruitment of bone-marrow derived progenitor cells which are less sensitive to VEGFR 
inhibition. 
Hence, there is urgent need for the development of predictive biomarkers which can 
differentiate between responders and non-responders, refining molecular targeting, 
development of appropriate combinatorial therapies and finally more bench to bedside 
studies, to improve the efficacy of the antiangiogenic therapies.  
5.4. VEGFs/VEGFR signaling cascade 
The VEGF family comprises 5 mammalian dimeric glycoproteins designated VEGF-A, 
VEGF-B, VEGF-C, VEGF-D and PlGF. In addition VEGF E, found in parapox viruses 
and VEGF-F, found in snake venoms are highly related structurally to mammalian 
VEGFs (Shibuya, 2003; Yamazaki et al., 2009). VEGFs undergo either proteolytic 
processing (VEGF-C and VEGF-D) and/or alternative splicing (VEGF-A, VEGF-B and 
PlGF), to give rise to distinct isoforms, leading to diverse signaling functions. VEGFs 
bind with high affinity in an overlapping pattern to type V RTKs namely VEGFR-1, 
VEGFR-2 and VEGFR-3, to exert their biological effects (Takahashi et al., 2005). The 
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receptors are dimerized upon ligand binding leading to activation of the tyrosine kinase 
and autophosphorylation of tyrosine residues to initiate multiple signal transduction 
pathways. Signaling output is further modified by binding of co-receptors, such as Nrp, 
heparin sulfate proteoglycans (HSPG) and integrins (Koch et al., 2011).  
VEGFRs have a similar structural arrangement comprising of seven Ig-homology 
domains in the extracellular region, a single TM helix, a juxtamembrane domain (JMD), 
a split tyrosine-kinase and a long tail at C-terminal. The Ig-homology domains 1-3 
present in the ECD are involved in ligand binding to different extents in distinct ligand 
receptor interactions. And the membrane proximal Ig-homology domains 4-7 are 
involved in proper positioning of receptor dimers.  
5.4.1. The ligands 
VEGF-A 
VEGF-A plays a crucial role in vascular development during embryo formation, 
maintenance of proper vessel function in adults and also in disease. It is produced in 
vascular ECs and immune cells. Alternatively spliced variants of human VEGF-A 
encodes eleven different isoforms with distinct biological properties: VEGF-A121, 
VEGF-A145, VEGF-A148, VEGF-A162, VEGF-A165, VEGF-A165b, VEGF-A183, VEGF-A189, 
VEGF-A206 (Bates et al., 2002; Lange et al., 2003), newly discovered VEGF-A111 and 
VEGF-A111b (Gu et al., 2013) . 
The gene of VEGF consists of eight exons: where exon 1, and four residues of exon 
2, encode for the signal peptide; exon 3 and exon 4 encodes for VEGFR-1 and 2 
binding sites; exon 5 encodes a sequence which is recognized for cleavage by plasmin 
and metalloproteinases; exon 6 and 7 respectively encode for the heparin binding site 
and the Nrp binding site; and exon 8 encodes for a unique sequence (Claffey et al., 
1995; Keyt et al., 1996; Lee et al., 2005). On the basis of the presence of sub-exon 8a 
or sub-exon 8b, the VEGF isoforms are classified in two different subfamilies: full 
agonists (VEGF-xxx) and partial agonists (VEGF-xxxb) (Gu et al., 2013) (Figure 2). 
Based on the ability to bind to heparin sulfate or Nrp co-receptors, the isoforms are 
further categorized as cell bound isoforms (VEGF-A189, VEGF-A206), isoforms which 
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have both the soluble and cell bounded properties (VEGF-A165), and soluble isoforms 
which lack the binding domains (VEGF-A121, VEGF-A111) (Houck et al., 1991). 
The distinct isoforms, generated from alternative splicing of VEGF-A, are 
indispensable for normal development. This is evident from different studies using 
transgenic mice. Mice embryos expressing only VEGF-A120 show severe defects in 
lung vascular development, vascularization of retina, and myocardial ischemia. Due to 
congenital birth defects half of the embryos died in perinatal period within 2 weeks after 
birth (Carmeliet et al., 1999; Stalmans et al., 2002).  Knockout of VEGF-A164 or VEGF-
A188 in mice results in lethality after birth or death between embryonic day 9.5 and 13.5 
(Carmeliet et al., 1999). These studies show the importance of the presence of VEGF-
A isoforms containing exon 6-8 encoding the heparin and Nrp binding domain in the 
normal development. 
Mice expressing only VEGF-A164 are reported to be healthy with a normal retinal 
angiogenesis, but mice with only VEGF-A188 have reduced arterial development in 
retinas and disrupted development of secondary ossification centers and knee joint 
dysplasia (Maes et al., 2004). These findings indicate the role of diverse VEGF 
isoforms having distinct functions in the vascular and arterial development with VEGF-
A165 as the central player. 
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Figure 2: Schematic representation of the structure of VEGF-A isoforms. (a) VEGF-A 
gene containing 8 exons. (b) and (c) Alternative splicing of exon 8 at proximal splice site (PSS) 
leads to a full agonist (VEGFxxx) and distal splice site (DSS) creates anti-angiogenic splice 
variant (VEGFxxxb). (Gu et al., 2013) 
VEGF-B  
The VEGF-B gene consists of seven exons and alternative splicing gives rise to two 
isoforms: VEGF-B167 and VEGF-B186. The isoforms differ in their C-terminal due to the 
presence of acceptor splice sites in exon 6 but have an identical 116 amino acid amino-
terminal (N-terminal) region. VEGF-B167 comprises a basic C-terminal which is able to 
tightly bind HSPGs on the cell surface and in the ECM (Olofsson et al., 1996a). VEGF-
B188 is a freely diffusible isoform which consists of a hydrophobic C-terminal and 
undergoes O-glycosylation. But after undergoing proteolytic processing VEGF-B188 
can bind to Nrp-1 (Olofsson et al., 1996b). The homodimers of the both isoforms are 
expressed in numerous tissues simultaneously and bind to VEGFR-1 and Nrp-1 for 
transducing their signal (Makinen et al., 1999).  
VEGF-B is highly expressed in myocardium, skeletal muscle and vascular smooth 
muscle, brown adipose tissue and neuronal tissue (Bry et al., 2014; Enholm et al., 
1997). Although VEGF-B has high sequence homology and similar receptor binding 
patterns as of VEGF-A, reports suggest it has very weak angiogenic activity. The 
knockout of VEGF-B in mice seems to be viable and fertile with no noticeable vascular 
or developmental defects, which is contrasting to a VEGF-A knockout (Kivela et al., 
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2014). However they show smaller hearts and impaired recovery from cardiac 
ischemia and dysfunctional coronary vasculature (Bellomo et al., 2000).  
A recent study has shown VEGF-B as a key regulator of energy metabolism. They 
demonstrate that VEGF-B regulates the fatty acid transport by increasing the 
expression of fatty acid transport proteins (FATPs) across the endothelium. The 
deficient mice for VEGF-B showed a decreased level of lipids in heart, muscle and 
brown adipose tissue while accumulation of lipids in the white adipose tissues instead 
(Hagberg et al., 2010).  
VEGF-B also plays a neuroprotective role facilitated directly by VEGFR-1 expressing 
neuronal cells. Mice lacking VEGF-B show degeneration of sensory neurons, while the 
treatment with VEGF-B, rescue neurons from apoptosis (Dhondt et al., 2011). Hence 
VEGF-B seems to have a wide range of function and a potential molecule through 
which one can study the association between angiogenesis and tissue metabolism. 
VEGF-C 
VEGF-C is secreted as a dimeric protein comprising long N-terminal and C-terminal 
propeptides flanking the VEGF homology domain. This uncleaved VEGF-C undergoes 
two proteolytic maturation steps to yield multiple processed forms. The first proteolytic 
cleavage takes place at the C-terminal by furin which generates an intermediate form, 
having moderate affinity for VEGFR-3. The second cleavage takes place at the N-
terminal and silk homology domain present at the C-terminal by A disintegrin and 
metalloproteinase with thrombospondin motifs 3 (ADAMTS3) resulting in fully mature 
form which is able to bind to VEGFR-3 with higher affinity (Joukov et al., 1996; Joukov 
et al., 1997). This fully processed form of VEGF-C also has a significant affinity for 
VEGFR-2. VEGF-C has a major role in lymphangiogenesis. It is also strongly 
expressed in various normal human tissues such as large intestine epithelium, and 
mammary duct epithelium, skeletal and cardiac muscle, thyroid, ovary, and the 
prostate and a variety of cancerous tissues (Joory et al., 2006). VEGF-C is absolutely 
essential for development of lymphatic vessels as even loss of single allele leads to 
lymphedema. And VEGF-C knockout mice die as embryos due to defective lymphatic 
vasculature and of edema (Karkkainen et al., 2003).    
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VEGF-D 
VEGF-D is produced as a precursor protein, similar to VEGF-C. Proteolytic processing 
generates mature forms which are capable of binding to both VEGFR-3 and VEGFR-
2 leading to growth and development of blood vessels and lymphatics. Surprisingly, 
VEGF-D knockout mice are viable with minimal defects (Baldwin et al., 2005). Though 
VEGF-C and VEGF-D show similar bioactivities but recent studies indicate towards 
their distinct signaling mechanisms . Mature form of VEGF-D consist of distinct amino 
acid residues in the N-terminal α-helix which are required for binding VEGFR-3 and 
VEGFR-2 whereas in VEGF-C same set of residues are involved in binding to both the 
receptors (Davydova et al., 2016). Exact role of VEGF-D is not known yet. But studies 
show VEGF-D influences the metastasis of cancerous cells (Stacker et al., 2001).  
VEGF-E 
VEGF-E submembers are encoded by genome of Orf virus, a parapoxvirus known to 
infect sheep, goats and human (Lyttle et al., 1994). Different subtypes of VEGF-E 
which are derived from several strains of Orf virus: VEGF-ENZ-2,  VEGF-ENZ-7, VEGF-
ENZ-10, VEGF-ED1701 and VEGF-EVR634 (from pseudo cowpox virus strain) (Meyer et al., 
1999; Ogawa et al., 1998; Wise et al., 1999; Wise et al., 2003). Their amino acid 
sequence is only 20% to 25% identical to VEGF-A (Lyttle et al., 1994). They bind with 
high affinity and stimulate VEGFR-2 but not VEGFR-1 nor VEGFR-3. They vary in their 
ability to bind Nrp-1. VEGF-ENZ-2, VEGF-ENZ-10, and VEGF-ED1701 can bind Nrp-1 
whereas VEGF-ENZ-7 and VEGF-EVR634 are unable to bind Nrp-1. VEGF-E NZ-7 
transgenic mice have shown induction of significant angiogenesis with fewer side 
effects, hence it is a potential target to be used as pro-angiogenic factor in the clinics 
(Kiba et al., 2003). 
PlGF 
PlGF is mainly expressed in the placenta but is also found in low levels in other tissues, 
such as the heart, lung, thyroid, liver, skeletal muscle and bone (Persico et al., 1999). 
Alternative splicing of the human PlGF gene generates four different isoforms 
exhibiting different binding properties: PlGF-1 and PlGF-3 are freely diffusible whereas, 
PlGF-2 and PlGF-4 comprise a C-terminal domain encoding the heparin binding 
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domain and hence are cell membrane associated isoforms (Maglione et al., 1993; 
Yang et al., 2003). PlGF binds to VEGFR-1 and sVEGFR-1 (soluble receptor lacking 
TM and intracellular domains) (Kendall et al., 1993). PlGF-2 can also bind to Nrp-1 and 
Nrp-2 due to the presence of additional 21 basic amino acids at the C-terminal 
(Gluzman-Poltorak et al., 2000). 
VEGFR-1 activation by PlGF leads to transphosphorylation and activation of VEGFR-
2 and hence amplifies VEGF-A signaling (Autiero et al., 2003). Though PlGF is very 
similar to VEGF-B in many respects, PlGF is able to induce stronger VEGFR-1 tyrosine 
phosphorylation compared to VEGF-B (Anisimov et al., 2013). Similar to VEGF-B, the 
deletion of PlGF in mice does not affect the development of vessels in the embryo 
(Carmeliet et al., 2001). However PlGF is able to stimulate angiogenesis in pathological 
conditions such as heart and lung ischemia, as efficiently as VEGF-A (Luttun et al., 
2002). PlGF, apart from being expressed in vascular cells, is also found in pathological 
conditions in fibroblasts, leucocytes, hepatocytes, bone marrow derived cells, neurons, 
epithelial cells and tumor cells. Hence PlGF has been a target molecule for being 
clinically exploited posing no severe side effects to normal physiology. But there has 
been conflicting data between pharmacological PlGF blockade studies, which use 
several anti-PlGF antibodies and PlGF knockout studies (Dewerchin et al., 2012). 
Hence, more studies are required to be conducted to know the exact function and 
therapeutic potential of PlGF. 
5.4.2. VEGFRs 
VEGFR-1 
VEGFR-1 is encoded by the Flt-1 (Fms-like tyrosine kinase 1) gene in humans. 
Alternative splicing of this gene gives rise to two isoforms: membrane bound VEGFR-
1 and sVEGFR-1 (Kendall et al., 1993). VEGFR-1 binds with high affinity to VEGF-A, 
VEGF-B, PlGF and some VEGFs in snake venom. VEGF-A binds with more than 10 
fold higher affinity to Ig-homology domains 2 and 3 of VEGFR-1 when compared to 
VEGFR-2 (Wiesmann et al., 1997). However, the kinase domain of VEGFR-1 shows 
weak tyrosine autophosphorylation activity and poorer signal transduction than 
VEGFR-2 (Seetharam et al., 1995; Waltenberger et al., 1994). Study on chimeric 
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VEGFR-1/2 molecules reveal the presence of negative regulatory sequence in the 
juxtamembrane region responsible for attenuation of kinase activity and 
phosphatidylinositol 3’-kinase (PI-3 KINASE) activation (Gille et al., 2000). 
Furthermore, mutation of the amino acid N1050 to D in the activation loop of kinase 
domain of VEGFR-1, lead to increase in its activity (Meyer et al., 2006). Tyrosine 
phosphorylation pattern depends on the type of ligand binding to VEGFR-1 and hence 
resulting in a distinct signaling output (Cunningham et al., 1997; Sawano et al., 1997). 
It is evident from a study showing binding of the ligand VEGF-A to VEGFR-1 that leads 
to phosphorylation of Y1213, whereas PlGF binding phosphorylates Y1309 (Autiero et 
al., 2003). Distinct conformational arrangements arising in the extracellular region of 
VEGFR-1 due to binding of different ligands may be attributed as a reason for different 
signaling outcomes. Several molecules interacting with the phosphorylated tyrosine 
residues in the intracellular kinase domain of VEGFR-1 have been identified, such as 
p85/PI-3 KINASE,  phospholipase C (PLCγ1), Src-homology (SH) phosphatase-2 
(SHP2 or Nck), and growth factor receptor bound-2 (Grb2) protein (Matsumoto et al., 
2001). Due to the weak kinase activity and modest signaling output of the VEGFR-1, 
the characterization of its signaling network has been very challenging and much more 
needs to be explored. 
VEGFR-1 is expressed in various cell types, including vascular ECs, dendritic cells, 
pericytes, macrophages, monocytes and hematopoietic stem cells (Hattori et al., 2002; 
Sawano et al., 2001). VEGFR-1 knock out mice embryos die at embryonic day 8.5-9 
due to increased proliferation of EPCs and disorganized vessel formation (Fong et al., 
1995). However, mice expressing kinase domain deleted VEGFR-1 have normal 
vasculature and are viable (Hiratsuka et al., 1998). Thus, VEGFR-1 has been 
suggested to act as a decoy receptor during embryonic development by sequestering 
excess VEGF-A and preventing over activation of VEGFR-2. Moreover, the membrane 
localization of the receptor plays a crucial role, since 50% of mice expressing sVEGFR-
1 die at embryonic day 8.5 to 9.0 due to disorganized vasculature (Hiratsuka et al., 
2005). Further the occurrence of sVEGFR-1 consisting of the first six Ig-homology 
domains, acting as a ligand scavenger was demonstrated from the study of Shibuya et 
al (Shibuya et al., 1990). sVEGFR-1 is known to be expressed in the human placenta 
and its overexpression has pathological implications such as causing pre-eclampsia. 
(Fan et al., 2014; Maynard et al., 2003). The negative regulatory role of VEGFR-1 is 
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also evident from a study which shows the existence of VEGFR-1/2 heterodimers, 
involved in blocking of VEGF-A induced extracellular-signal-regulated kinase (ERK1/2) 
activation and Ca2+ entry (Cudmore et al., 2012). Apart from being able to negatively 
regulate the homodimer activity of VEGFR-2, the phosphorylated VEGFR-1 is also 
involved in transphosphorylation of VEGFR-2 (Autiero et al., 2003).  Though the 
underlying mechanisms by which VEGFR-1 and VEGFR-2 regulate each other 
remains to be revealed. 
VEGFR-2 
The human VEGFR-2 (also called KDR, Kinase insert domain-containing receptor) 
gene was cloned in 1991 and was found to be located at chromosome 4 (Terman et 
al., 1991). The canonical activation of VEGFR-2 occurs by binding to alternatively 
spliced variants of VEGF-A, VEGF-E and proteolytically processed forms of VEGF-C 
and VEGF-D. Ig-homology domains 2 and 3 are involved in ligand binding. Moreover, 
there is a study showing in cultured cells, existence of pre-formed receptor dimers with 
certain kinase activity (Sarabipour et al., 2016). VEGFR-2 also exists as a soluble 
isoform (sVEGFR-2) in various tissues such as the skin, heart, spleen, kidney, ovary, 
and in plasma. It is believed to act as a scavenger for VEGF-C and hence negatively 
regulates VEGFR-3 induced lymphangiogenesis (Albuquerque et al., 2009; Ebos et 
al., 2004).  
VEGFR-2 is the major player involved in angiogenesis and vasculogenesis. It mediates 
migration, proliferation, cell survival and permeability in ECs by binding to VEGF-A 
ligand. VEGFR-2 knockout mice die at embryonic day 8 to 9 due to lack of a functional 
vasculature similar to mice deficient for VEGF-A (Shalaby et al., 1995). Apart from 
being expressed in vascular and lymphatic ECs, VEGFR-2 is also found in neuronal 
cells, hematopoietic stem cells and retinal cells (Kabrun et al., 1997; Shiote et al., 2005; 
Yang et al., 1996). Although VEGFR-2 has lower binding affinity to ligand VEGF-A 
compared to VEGFR-1, astonishingly VEGFR-2 exhibits strong kinase activity upon 
ligand binding. The dimerization of VEGFR-2 leads to conformational changes and 
activation by autophosphorylation of multiple intracellular tyrosine residues. Each 
phosphotyrosine residue serves as a binding site for regulatory proteins via their SH 
or phospho-tyrosine binding (PTB) domains, leading to distinct downstream signaling. 
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The chief autophosphorylation sites in human VEGFR-2 bound to VEGF-A are: Y801 
in the JMD, Y951 in the kinase insert domain (KID), Y1054 and Y1059 in the activation 
loop and Y1175 and Y1214 in the C-terminal (Kendall et al., 1999; Matsumoto et al., 
2005; Takahashi et al., 2001). Phosphorylation of Y951 residue leads to binding of T 
cell specific adapter (TSAd) protein via its SH2 and PTB domains (Matsumoto et al., 
2005). TSAd then further interacts with cytoplasmic tyrosine kinase c-Src via its SH3 
domain to regulate cytoskeleton components such as actin, cell-cell adhesion 
molecules and matrix components. Src additionally phosphorylates focal adhesion 
kinase (FAK) at cell-cell junctions which then regulates cell shape, adhesion and vessel 
permeability (Claesson-Welsh, 2016; Matsumoto et al., 2005). Phosphorylation sites 
Y1054 and 1059 are required by the receptor for acquiring complete kinase activation 
and catalytic activity (Dougher et al., 1999; Kendall et al., 1999; Manni et al., 2014a). 
Tyrosine 1175 is the chief phosphorylation site which interacts with PLC-γ via its SH2-
domain and leads to its activation. Phosphorylated PLC-γ then hydrolyses the 
membrane phospholipid phosphatidylinositol (4,5)-bisphosphate (PIP2) releasing 1,2-
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 triggers the release of 
intracellular calcium and DAG activates protein kinase C (PKC). PKC in turn then 
activates the Ras-independent mitogen-activated protein kinase (MAPK) pathway 
(Raf-MEK-ERK) leading to changes in gene transcription and thereby cell migration, 
proliferation and cell fate specification (Cunningham et al., 1997; Koch et al., 2012; Xia 
et al., 1996). PLC-γ signaling plays a crucial role in vasculogenesis. A study with mice 
shows, both plc-γ gene deletion and mutation of site Y1173 (in humans Y1175) leads 
to death of embryo in 9.0 days due to decreased vasculogenesis and erythropoiesis 
(Sakurai et al., 2005). Phosphorylation at site Y1175 initiates multiple downstream 
signaling cascades. The same site also binds to other adaptor proteins, SHB (Src 
homology-2 protein in beta-cells) and Src homology 2 domain-containing transforming 
protein (SHC2 or SCK) (Koch et al., 2011). Phosphorylated SHB binds to FAK which 
regulates cell migration and cell attachment (Abedi et al., 1997). The inactivation of 
genes of adaptor proteins in mice leads to impaired vessel function and tumor growth 
(Koch et al., 2012). Activated SHB also stimulates lipid kinase PI-3 KINASE, which 
further activates Protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS). 
This leads to increased cell survival and nitric oxide-induced vascular permeability 
(Roskoski, 2007). Phosphorylated Y1214 recruits Nck and proto-oncogene tyrosine-
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protein kinase (Fyn), and subsequently activates the p38MAPK pathway which 
stimulates migration in ECs (Lamalice et al., 2004) Figure 3.  
 
 
Figure 3: VEGF-A165 mediated signal transduction of VEGFR-2 (Koch et al., 2012) 
 
VEGFR-3 
VEGFR-3 (also called Flt-4) binds to ligands VEGF-C and VEGF-D with its Ig-
homology domains 1 and 2 present in the ECD (Jeltsch et al., 2006; Leppänen et al., 
2011). VEGFR-3 is synthesized as a precursor molecule and proteolytically processed 
at the fifth Ig-homology domain in the ECD. The two split ECD domains are bound by 
a disulfide bridge (Pajusola et al., 1994). VEGFR-3 is mainly known for its requirement 
in lymphatic endothelial development but is also cited for its mechanistic role in early 
vessel development. Tip cells also expresses VEGFR-3, in blood vascular cells during 
early embryonic development (Nilsson et al., 2010). VEGFR-3 knockout mice die at 
embryonic day 10 to 11 due to defective vascular development (Dumont et al., 1998). 
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VEGFR-3 binding to ligands VEGF-C and VEGF-D leads to phosphorylation of 
residues at C-terminal: Y1230, Y1213, Y1265, Y1337 and Y1363 (Dixelius et al., 
2003). Upon phosphorylation, site Y1337 recruits SHC and Grb2, leading to activation 
of Ras and mitogenic signaling (Fournier et al., 1995). Akt activation via PI-3 KINASE 
and p42/p44 MAPK activation via PKC are other known downstream signaling 
cascades of phosphorylated VEGFR-3 (Makinen et al., 2001). VEGFR-2 and VEGFR-
3 can form heterodimers upon binding to ligand VEGF-C. Interestingly a change in 
autophosphorylation pattern of VEGFR-3 present in the heterodimers is observed, 
which might also lead to distinct downstream signaling as compared to the 
homodimeric form. The two residues Y1337 and Y1363 present at the C-terminal do 
not get phosphorylated of the above five autophosphorylation sites (Dixelius et al., 
2003). VEGFR-2/3 heterodimers regulate migration and proliferation of lymphatic ECs 
and are found to be present on tip cell filopodia of developing blood vessels and 
immature lymphatic sprouts (Nilsson et al., 2010). VEGFR-3 can also be activated 
independent of ligands by c-Src activation via integrins leading to vessel expansion in 
lymphatic system and regulating interstitial fluid uptake (Galvagni et al., 2010).  
5.5. Aims of the thesis 
The establishment of the blood and lymphatic vascular system are crucial 
requirements for the development of an embryo (Karkkainen et al., 2003). In addition, 
dysregulated vasculogenesis and angiogenesis in adults has implications in numerous 
pathological conditions (Shibuya, 2011). The members of the VEGF family are known 
to be key regulators in both the physiological and pathological vessel development 
(Shibuya, 2014; Smith et al., 2015). The five VEGF ligands interact with three type V 
RTKs, VEGFR-1, VEGFR-2 and VEGFR-3 with overlapping specificity (Koch et al., 
2011). The ECD of VEGFRs comprises seven Ig-homology domains. The first 3 
domains mediate ligand binding, whereas the membrane proximal domains 4-7 are 
involved in ligand-induced receptor dimerization. Ligand binding allows dimerization of 
the ECD in a precise conformation, followed by exact positioning of the TM and 
intracellular domains for initiating autophosphorylation of the kinase domain and 
subsequent activation of downstream signaling. Our previous low resolution single 
particle electron microscopy (EM) and small angle solution scattering (SAXS) data 
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suggested homotypic contacts in domains 4-7 (Kisko et al., 2011; Ruch et al., 2007).  
To gain information on the molecular details of the homotypic interactions occuring in 
VEGFR-2 required for activation of the receptor, we applied several strategies for 
crystallization of VEGFR-2 ECD complexes. In order to study the function of individual 
Ig-domains in receptor activation we investigated the interaction of VEGFR-2 ECD with 
ligand using various biophysical techniques. 
We and others have shown that homotypic interactions occuring between receptor 
dimerization upon ligand binding are indispensible for VEGFR-2 and -3 activation 
(Hyde et al., 2012; Leppänen et al., 2013; Yang et al., 2010). Domains 4-7 of VEGFRs 
thus represent novel allosteric receptor-regulatory sites. 
Our aim was to investigate the structure of ligand induced homotypic contacts in full 
length ECD/ligand complexes of VEGFR-1. We validated the biological relevance of 
the molecular details found in the structural study by carrying out functional studies in 
cell culture. This will provide an insight for the future development of highly specific 
inhibitory drugs. 
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6. Materials and Methods 
6.1. Cloning, expression and purification of VEGFR-2 ECD 
subdomains for crystallization experiments 
6.1.1. Cloning of a VEGFR-2 ECD subdomain construct for insect cell 
expression 
The construct VEGFR-2 domains 2-5 was polymerase chain reaction (PCR) amplified 
and cloned into the insect cell expression vector pFL by PCR subcloning (Geiser et al., 
2001) using the following primers. 
Fwd 5’-
CTGCGTGGAGACCAGAGCCGCATCTGTTCAAGATTACAGATCTCCATTTATTGC
TTCT -3’  
Rev 5’- GTGATGGTGATGGTGATGTCTGCCCTCGATACCCCTGGTCACGTGG -3’.  
6.1.2. Cloning of VEGFR-2 constructs for baculovirus mediated 
transduction in mammalian (HEK293S GnTi-) cells 
The cDNA of VEGFR-2 ECD subdomains 1-7, 2-7 and 1-3 were PCR amplified from 
their respective pcDNA3 plasmids using Phusion High-Fidelity DNA polymerase 
(Finnzymes) and the following primers. 
Fwd 5’- 
GCTGGCTAGCGTTTAAACTTAAGCTTGGTACCATGGAGAGCAAGGTGCTGCT -3’ 
Rev 5’- 
CGGGCCCTCTAGACTCGAGCGGCCGCTTATCAGTGATGGTGATGGTGATG -3’.  
Following incubation at 72°C for 10 min with Taq Plus Precision polymerase 
(Stratagene), the amplicons were ligated to the pGEM-T vector (Promega). The inserts 
were cut from these vectors with NheI and XhoI (Fermentas), purified from TAE 
agarose gels with the Qiaquick gel extraction kit (Qiagen) and ligated to pFL plasmids. 
The VSV-G cDNA was PCR amplified using Phusion High-Fidelity DNA polymerase 
(Finnzymes) and the following primers: 
Fwd 5’- AGCACGTGGGATCCGAATTCAAC-3' 
Doctoral thesis Mayanka Asthana 
 
38 
  
 
Rev 5’- CTGCACTCTAGAGGGGTGAATTCCATA-3' 
The PCR amplicons and pUCDM (Fitzgerald et al., 2006) were digested with BamHI 
and XbaI (Fermentas), purified from TAE agarose gels with the Qiaquick gel extraction 
kit (Qiagen) and ligated using T4-ligase (Fermentas). 
The Cre/LoxP recombination reaction between the acceptor plasmid pFL carrying the 
VEGFR-2 ECD subdomains and the donor plasmid pUCDM carrying VSV-G was 
performed at 37°C for 60 min (New England BioLabs). Escherichia coli (E. coli) DH10β 
cells were transformed with the reaction mixture by electroporation and incubated for 
1 h at 37°C. Then they were plated on agar plates containing ampicillin and 
chloramphenicol. The colonies were picked and plasmid DNA was extracted with a 
Miniprep kit (Qiagen). The constructs were verified by sequencing the plasmid-DNA 
(Microsynth AG). 
6.1.3. Cloning of mouse mVEGFR-2 ECD constructs for expression 
in mammalian (HEK293 EBNA) cells 
The mouse VEGFR-2 ECD subdomain constructs were PCR amplified from an 
artificially synthesized sequence (Genewiz) encoding the mouse VEGFR-2 ECD cDNA 
using the primers shown in Table 1. 
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mVEGFR-2 
Construct 
5’-3’ Primer Sequence 
 
Domains 1-7 
Fwd 5’- CTCGTCTCTAGACGCCTCTGTGGGTTTGCCTGG -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGCAAGTTGGTCTTTTCCTGGGCAC-3’ 
 
Domains 2-7 
Fwd 5’- CTCGTCTCTAGACCGAGATTACAGATCACCATTCATCGC -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGCAAGTTGGTCTTTTCCTGGGCAC-3’ 
 
Domains 1-6 
Fwd 5’- CTCGTCTCTAGACGCCTCTGTGGGTTTGCCTGG -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGTAGGATGATGAGCTGTTTGACCAGG-3’ 
 
Domains 2-5 
Fwd 5’- CTCGTCTCTAGACCGAGATTACAGATCACCATTCATCGC -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGCCTGATCACATGGAAGGAGATGACC -3’ 
 
Domains 1-3 
Fwd 5’- CTCGTCTCTAGACGCCTCTGTGGGTTTGCCTGG -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGAGGCTTTGTGTGAACTCGGACAAAT-3’ 
 
Domains 4-7 
Fwd 5’- CTCGTCTCTAGAC ACAAAGCCTTTTATTGCTTTCGGTAGTG-3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGCAAGTTGGTCTTTTCCTGGGCAC-3’ 
 
Domains 5-7 
Fwd 5’- CTCGTCTCTAGACGTCCCACCCCAGATCGGTGAG-3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGG
AACAGCACCTCCAGCAAGTTGGTCTTTTCCTGGGCAC-3’ 
Table 1:  Primers used for cloning mouse VEGFR-2 ECD subdomains in the pCEP4-Pu vector 
for expression in mammalian (HEK293 EBNA) cells. 
 
The PCR products and the backbone of the pCEP4-Pu plasmid (obtained from Dr. 
Richard Kammerer) were digested with the NheI and NotI restriction enzymes prior to 
ligation using T4-ligase (Fermentas). 
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6.1.4. Cloning of glycosylation lacking VEGFR-2 constructs for 
mammalian (HEK293 EBNA) cell expression 
An artificially synthesized sequence (Genewiz) for human VEGFR-2 ECD with all 
asparagine residues substituted with glutamine residues was used as a template for 
PCR amplification of ECD subdomains using Phusion high-fidelity DNA polymerase 
(Finnzymes) and the primer shown in Table 2.  
 
Construct 5’-3’ Primer Sequence 
 
Domains 1-3 
mutant 
Fwd 5’- CTC GTC GCT AGC CTC CGT GGG ACT CCC TTC -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGGA
ACAGCACCTCCAGGTGCACCCTCACGAAGGTGCTCTG-3’ 
 
Domains 2-5 
mutant 
Fwd 5’- CTCGTCGCTAGCC GACTACAGGAGCCCCTTTATCGCCTCC -3’ 
Rev 5’-
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGGA
ACAGCACCTCCAGTCTTGTGACGTGGAAGGAGATCACCCTC -3’ 
 
Domains 1-3 
wild-type 
Fwd 5’-CTCGTCGCTAGCC GGTTTGCCTAGTGTTTCTCTTGATCTGCC -3’ 
Rev 5’-
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGGA
ACAGCACCTCCAGATGGACCCTGACAAATGTGCTGTTCTTC -3’ 
 
Domains 2-5 
wild-type 
Fwd 5’-
CTCGTCGCTAGCCGATTACAGATCTCCATTTATTGCTTCTGTTAGTGACC -
3’ 
Rev 5’-
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGGA
ACAGCACCTCCAGGGTCACGTGGAAGGAGATCACCCTCTC -3’ 
 
Domains 1-7 
wild-type 
Fwd 5’-CTCGTCGCTAGCC GGTTTGCCTAGTGTTTCTCTTGATCTGCC -3’ 
Rev 5’- 
TGCTTAGCGGCCGCTCATCAGTGATGGTGATGGTGATGGGGGCCCTGGA
ACAGCACCTCCAGCTCCAAGTTCGTCTTTTCCTGGGCAC-3' 
Table 2: Primers used for cloning of wild-type and glycosylation-lacking mutant (asparagines 
mutated to glutamines) human VEGFR-2 ECD subdomains in the pCEP4-Pu vector used for 
expression in mammalian (HEK293 EBNA) cells. 
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The amplified inserts were cloned into the HEK293 EBNA expression plasmid pCEP4-
Pu following a classic restriction digestion/ligation method, using the NheI and NotI 
restriction enzymes. 
6.1.5. Protein production of ligands 
Human VEGF-A121 and pox virus VEGF-E NZ2 with an N-terminal 6xhistidine tag were 
produced in Pichia pastoris by Thomas Schleier as described before (Scheidegger et 
al., 1999).  
6.1.6. Production and purification of human VEGFR-2 ECD 
subdomain proteins in insect cells 
All human VEGFR-2 ECD variants were expressed in Spodoptera frugiperda (Sf)21 
insect cells, which were maintained in suspension in serum-free InsectXpress medium 
(Lonza) at 27°C with agitation at 90 rpm. Recombinant baculovirus was produced in 
Sf21 cells in serum-free Insect-XPRESS medium (Lonza) at 27°C. Large scale protein 
expression of ECD and dimeric Ig homology domains 2-7 (VEGFR-2 domains 2-7 
GCN4) was carried out in a 5-l benchtop fermenter sparged with an air/oxygen mix on 
demand to maintain a 36% O2 saturation. The culture in the vessel was agitated at 140 
rpm impeller speed and maintained at 27°C and pH 6.2. All other ECD variants were 
expressed in baffled Erlenmeyer flasks. Sf21 cell cultures were infected with 
recombinant baculovirus when they had reached a density of 1x106 cells/ml. The 
supernatant was harvested 72 h after infection by centrifugation at 1000xg, 
concentrated using a tangential flow ultrafiltration device with a 10 kDa cut-off 
membrane (for the VEGFR-2 domains 2-4 construct a 3 kDa cut-off membrane was 
used instead) to a 500 ml volume and buffer exchanged with 50 mM HEPES pH 7.5, 
300 mM NaCl. The proteins were purified by immobilized metal ion affinity 
chromatography (IMAC) using 5 ml His-Trap HP columns (GE Healthcare). Non-
specifically bound proteins on the resin were washed away with buffer (50 mM HEPES 
pH 7.5, 300 mM NaCl) supplemented with 40 mM imidazole. The strongly bound 
proteins were then step eluted with high (400 mM) amounts of imidazole. VEGFR-2 
ECD and VEGFR-2 domains 1-3 were eluted with a 0-500 mM imidazole gradient in 
Tris buffered saline (50 mM Tris, 300mM NaCl) at pH 8.0. The proteins were further 
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purified by size exclusion chromatography (SEC) on a Superdex 200 HR 16/600 
column (GE Healthcare) equilibrated with 50 mM HEPES pH 7.5, 150 mM NaCl. 
Complexes for crystallization were formed by mixing VEGFR-2 ECD variants with 
ligands in 1:2 molar ratio and purified by SEC on Superdex 200.  
6.1.7. Production and purification of mouse VEGFR-2 ECD 
subdomains in mammalian cells 
The HEK293 EBNA cell line (R620-07, Invitrogen) was maintained in Dulbecco’s  
modified Eagle’s medium (DMEM) High Glucose supplemented with L-Glutamine (1-
26F03-I, Bioconcept), 10% fetal bovine serum (FBS) and 250 μg/ml of G418 (108321-
42-2, InvivoGen). Four μg of plasmid pCEP4-Pu containing the mVEGFR-2 ECD 
subdomain cDNA were dissolved in 0.4 ml serum-free medium and were mixed with 8 
μl of PEI (Polyethyleneimine, stock 1mg/ml, Aldrich 408727, 25 kDa branched). The 
mixture was incubated for 10 min at room temperature to allow for DNA-PEI complex 
formation. The mixture was then added to HEK293 EBNA cells grown in a 6-cm culture 
dish, in which the medium was replaced with 1.2 ml DMEM containing 0.5% FBS, and 
was incubated for 3 h. Then, 0.8 ml of DMEM with 2% FBS was added to the culture 
and the cells were incubated for 20 h. Finally, the medium was exchanged with DMEM 
containing 10% FBS, 250 μg/ml G418 (108321-42-2, InvivoGen) and 1 μg/ml 
puromycin (A11138-30, Gibco) for selection of transfected cells. The cells were 
maintained under selection pressure for 7 days. Positive clones of transfected cells 
were selected and expanded to scale-up the production of mVEGFR-2 ECD 
subdomains. Briefly, two 15-cm culture dishes, each with a confluent monolayer of 
selected cells that had been gradually adapted in DMEM with 1% FBS were transferred 
to a sterile baffled Erlenmeyer shaking flask containing 50 ml Protein Expression 
Medium (PEM) without L-glutamine (12661-013, Gibco) supplemented with 2 mM 
Glutamax (35050-038, Gibco), 250 μg/ml G418 (108321-42-2, InvivoGen) and 1 μg/ml 
puromycin. The suspension cultures were grown at 37°C, 5% CO2 with agitation at 100 
rpm. The cell density of the cultures were maintained below 3x106cells/ml and scaled 
up to a volume of approximately 2 l. This expanded culture was centrifuged at 1000xg 
in a fixed-angle rotor for 30 min at 4°C. The culture supernatant was passed through a 
0.45-μm filter and, concentrated with a 10 kDa molecular weight (MW) cut-off 
tangential flow concentrator to an approximate volume of 500 ml. The sample was 
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buffer exchanged twice with 500 ml of buffer containing 50 mM HEPES pH 7.5, 300 
mM NaCl and further concentrated to 250 ml. It was then loaded on a 5 ml His-Trap 
HP column (GE Healthcare) and washed with 50 mM HEPES pH 7.5, 300 mM NaCl, 
20 mM imidazole. The protein was eluted with a gradient of 40-500 mM imidazole and 
concentrated to 5 ml using a 10 kDa MW cut-off centrifugal concentrator. The sample 
was filtered with a 0.45-μm syringe filter and passed over a Superdex 200 16/60 
column (GE Healthcare). VEGFR-2 ECD variants were mixed with human VEGF-A121 
for complex formation and purified by SEC as described in section 6.1.6. 
6.1.8. Cloning, expression and purification of soluble Fab 
Previous members of the group (Thomas Schleier and Dr. Sandra Markovic-Mueller) 
had selected a single chain variable fragment (scFv) from the ETH2-Gold phage-
display library that could bind to VEGFR-2 domain 1 (Silacci et al., 2005).  Initially, the 
scFv antibody fragment bearing a flexible polypeptide linker Gly4SerGly4SerGly4 was 
cloned into the phagemid vector pHEN followed by reformatting into a Fab (termed 
ADH9) by subcloning into the pMX9 vector. Then, Mach1 E. coli competent cells were 
transformed with this construct (Fab ADH9 in the pMX9 vector) by electroporation. The 
cells were subsequently grown in Terrific Broth (TB) medium supplemented with 0.1% 
glucose plus chloramphenicol (17 μg/ml) at  37°C and induced with 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) when the culture reached an OD 600 of 0.8. After  
induction,  the  culture  was  grown  at  30°C  for  12 h, centrifuged  at 2500xg at  4°C 
for  15 min  and  the  pellet was resuspended  in lysis  buffer containing 50 mM Tris pH 
7.5, 150 mM NaCl, 1 mg/ml lysozyme, 20 ug/ml DNase and 2 complete protease 
inhibitor  tablets (11836170001 Merck). The  cells  were  homogenized  with a Turrax 
disperser (IKA) and  lysed  in a  high-pressure  Emulsiflex  C-3 homogenizer  
(Avestin®)  at  15000  psi.  Non-lysed cells,  cell  debris, and  aggregates  were  
removed  by centrifugation  at  13000xg  for  45 min. The Fab was  purified  from  the  
filtered  supernatant by IMAC on a 1 ml His-Trap HP column (GE Healthcare),  
equilibrated with 5 ml  binding  buffer:  50  mM  Tris  pH  7.5,  150  mM  NaCl,  10  mM  
imidazole.  Samples were eluted with elution buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 
500 mM imidazole. The proteins were further purified by SEC on a Superdex 200 HR 
16/600 column (GE Healthcare) equilibrated with 20 mM HEPES pH 7.5, 150 mM 
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NaCl. Eluted fractions, containing the Fab were collected, concentrated, frozen in liquid 
nitrogen and stored at -80°C. 
6.2. Biochemical and biophysical characterization of recombinant 
proteins 
6.2.1. Limited proteolysis 
Five microliter of VEGFR-2 domains 1-7/VEGF-A121 complex at a concentration of 10 
mg/ml was digested with 5 μl of several proteases namely Glu-C, trypsin, papain, α-
chymotrypsin and subtilisin (Sigma-Aldrich) at various ratios (1:10, 1:100 and 1:1000 
of the 1 mg/ml of stock solutions) in buffer containing 50 mM HEPES pH 7.5 and 150 
mM NaCl. The mixture was incubated for 90 min or 16 hr at room temperature and 4°C 
respectively. The reaction was stopped by boiling for 1 min at 90°C in Laemmli buffer 
(0.25 M  Tris-HCl pH 6.8, 0.5 M DTT, 10% SDS, 50% glycerol, 0.5% Bromophenol 
Blue). Samples were stored at -20°C prior to analysis by sodium dodecylsulfate 
polyacryl gel electrophoresis (SDS-PAGE). 
6.2.2. Differential scanning fluorimetry 
The extent of protein unfolding was measured for the purified VEGFR-2 domains 1-7, 
2-7 and 1-3 proteins in their monomeric form as well as in complex with VEGF-A121 in 
one of the following buffers: (1) phosphate-buffered saline (PBS) containing 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, (2) 10 mM HEPES pH 7.5, 100 
mM NaCl, and (3) 25 mM HEPES pH 7.5, 500 mM NaCl, at a final concentration of 20 
?M. Next, SYPRO Orange dye (5000x, Invitrogen) was added to the protein solutions 
to a final dilution of 10x. Melting curves were measured by heating the samples from 
25°C to 95°C at 1°C increments with a 5 sec incubation at each increment using a 
Rotor-Gene Q real time PCR machine (Rotor disc 72, Qiagen). Fluorescence intensity 
was measured using excitation/emission wavelengths of 485 nm/575 nm. Data 
analysis was performed with the Rotor-Gene Q series software 2.0.2. 
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6.2.3. Isothermal titration microcalorimetry  
VEGFR-2 ECD and VEGFR-2 domains 1-3 were purified by SEC using a Superdex 
200 column (GE Healthcare) equilibrated with 20 mM HEPES pH 7.5 buffer, containing 
150 mM NaCl before being used for ITC. The relevant fractions were pooled, 
concentrated. All samples were filtered and degassed prior to analysis. VEGF-A121 ITC 
titrations against VEGFR-2 ECD and VEGFR-2 domains 1-3 were carried out at 4°C 
using an iTC200 calorimeter (MicroCal; GE Healthcare). VEGFR-2 constructs were 
used in the calorimeter cell at a concentration of 10-30 μM and the VEGF ligands in 
the syringe at 150-250 μM. To increase the signal-to-noise ratio, the following 
parameters were used: one initial injection of 0.6 μl followed by 14 more injections of 
2.6 μl at an injection speed of 1 μl/s, with data filter of 1 s and 500 s recovery time 
between each peak. The data were concatenated using the ConCat program 
(MicroCal) and processed and analyzed using Origin Version 7.0 software (OriginLab) 
supplemented with the ITC plug-in provided by the instrument manufacturer. 
6.2.4. Microscale thermophoresis (MST) 
VEGF-A121 was labeled using the Monolith NT Protein Labeling kit BLUE-NHS (MO-
L003, NanoTemper Technologies) by optimizing the manufacturer’s guidelines. The 
concentration of labeled VEGF-A121 was maintained constant at 100 nM. The 
corresponding unlabeled binding partner (VEGFR-2 domains 1-7 and 1-3) was titrated 
in 2:1 dilutions, with the highest final concentration chosen about 20-fold above the Kd 
expected from previously published ITC results (Brozzo et al., 2012). Thus, the highest 
final concentrations were 25 μM for VEGFR-2 domains 1-7 and 0.98 μM for VEGFR-2 
domains 1-3. The measurements were performed at 4°C in 20 mM HEPES buffer, pH 
7.5 containing 150 mM NaCl. Hydrophilic capillaries (NanoTemper Technologies) were 
used for the measurements on a Monolith NT.115 system (Nano Temper 
Technologies) using 100% LED and 20% IR-laser power. Laser on and off times were 
set at 30 s and 5 s respectively. Domains 1-7 quantification was carried out by fitting 
the three data sets that had the same concentration range using the Prism software. 
Since the three datasets overlapped very well with no systematic offset in the Y-axis, 
the fitting was done without normalisation. All points were fitted as a single data set, 
rather than taking the mean and weighting the fit by the error on the mean, as the 
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former method makes no assumptions about the sampling error in the three 
experiments. 
6.3. Functional analysis of Ig-homology domain 5 mutants of 
VEGFR-1 and 2 
6.3.1. Cloning of VEGFR-1 mutants for functional analysis 
VEGFR-1 was PCR amplified and cloned into the mammalian expression vector 
pcDNA3.1+ (Invitrogen) by PCR subcloning (Geiser et al., 2001) using the following 
primers: 
Fwd 5’-TTTTTGGTACCGCCACCATGGTCAGCTACTGGG-3’  
Rev 5’-TTTTTGCGGCCGCTTATCAAGCGTAGTCTGGGACGTCGTATGGGTAAC-
3’.  
TM mutations (TM_ANGG and TM_ΔSSS) were introduced into pcDNA3.1+ VEGFR-
1 wild-type construct by PCR subcloning (Geiser et al., 2001) using appropriate primers 
(Table 3). We applied site-directed mutagenesis for generating the domain 5 
interaction mutations on wild-type and TM activated constructs. For introducing the 
third mutation we used the mutated constructs as a template for subsequent site-
directed mutagenesis. 
Mutations 5’-3’ Primer Sequence 
 
Domain 5_E513A/K517A 
Fwd 5’- 
GGCAATAATAAAGGGAAAGAATGCCATGGCTAGC 
ACCTTGGTTGTGGCTGACTCTAGAATTTCTGG-3’ 
Rev 5’- 
GCTAGCCATGGCATTCTTTCCCTTTATTATTGCCATGCG
CTGAGTGATGCTCTCAATTCTGTTTC-3’ 
 
Domain 5_T455W/E513K/ 
K517A 
Fwd 5’- 
CTGACTTGTTGGGCATATGGTATCCCTCAACCTACAATC
AAGTGGTTC-3’ 
Rev 5’- 
GTTGAGGGATACCATATGCCCAACAAGTCAGGATTTGTC
TGCTGCCCAGTGG-3’ 
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Domain 5_T455E /K517A 
Fwd 5’- 
CATCACTCAGCGCATGGCAATAATAGAAGGAAAGAATGC
CATGGCTAGCACCTTG-3’ 
Rev 5’- 
CTAGCCATGGCATTCTTTCCTTCTATTATTGCCATGCGCT
GAGTGATGCTCTC-3’ 
 
Domain 5_T455E / E513A 
/K517A 
Fwd 5’- 
CAGCAGACAAATCCTGACTTGTTGGGCATATGGTATCCC
TCAACCTACAATC-3’ 
Rev 5’- 
GTTGAGGGATACCATATGCCCAACAAGTCAGGATTTGTC
TGCTGCCCAGTGGGTAG-3’ 
 
TM_ANGG 
Fwd 5’- 
GAAAAGGGCCAACGGCGGTGAAATAAAGACTGACTACC
TATCAATTATAATGGAC-3’ 
Rev 5’- 
AGTCTTTATTTCACCGCCGTTGGCCCTTTTCATTTTTCGG
ATAAAGAGGGTTAATAGGAG-3’ 
 
TM_ANGG_ 
Domain 5_ E513K /K517A 
Fwd 5’- 
GGCAATAATAAAGGGAAAGAATGCCATGGCTAGCACCTT
GGTTGTGGCTGACTCTAGAATTTCTGG-3’ 
Rev 5’- 
GCTAGCCATGGCATTCTTTCCCTTTATTATTGCCATGCG
CTGAGTGATGCTCTCAATTCTGTTTC-3’ 
 
TM_ANGG_ Domain 
5_T455W/E513K/ K517A 
Fwd 5’- 
CTGACTTGTTGGGCATATGGTATCCCTCAACCTACAATC
AAGTGGTTC-3’ 
Rev 5’- 
GTTGAGGGATACCATATGCCCAACAAGTCAGGATTTGTC
TGCTGCCCAGTGG-3’ 
 
 
 
TM_ΔSSS 
Fwd  5’-
CCGAAAAATGAAAAGGGAAATAAAGACTGACTACCTATC
AATTATAATGGAC-3’ 
Rev 5’- 
GTAGTCAGTCTTTATTTCCCTTTTCATTTTTCGGATAAAG
AGGGTTAATAGGAG-3’ 
 
TM_ΔSSS_ 
Domain 5_ E513K /K517A 
Fwd 5’- 
GGCAATAATAAAGGGAAAGAATGCCATGGCTAGCACCTT
GGTTGTGGCTGACTCTAGAATTTCTGG-3’ 
Rev 5’- 
GCTAGCCATGGCATTCTTTCCCTTTATTATTGCCATGCG
CTGAGTGATGCTCTCAATTCTGTTTC-3’ 
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TM_ΔSSS_ 
Domain 5_ T455W/E513K/ 
K517A 
Fwd 5’- 
CTGACTTGTTGGGCATATGGTATCCCTCAACCTACAATC
AAGTGGTTC-3’ 
Rev 5’- 
GTTGAGGGATACCATATGCCCAACAAGTCAGGATTTGTC
TGCTGCCCAGTGG-3’ 
 
 Table 3: Primers used for cloning VEGFR-1 mutants for functional analysis.  
The constructs were amplified by PCR using Phusion High-Fidelity DNA polymerase 
(Finnzymes). Template DNA was digested by adding 1 μl of DpnI (Fermentas) to the 
PCR product mixture and incubating for 8 h at 37°C. Subsequently, electrocompetent 
E.Coli DH10β were transformed with 0.5 μl of the digested PCR mixture and plated on 
Luria Bertani (LB)-Ampicilin agar plates. Positive colonies were picked after 16 h 
incubation at 37°C and inoculated in 5 ml overnight cultures. Plasmid DNA was then 
extracted with a Miniprep kit (Qiagen). The mutations were verified by sequencing 
plasmid DNA (Microsynth AG). 
6.3.2. Cloning of VEGFR-2 mutants for functional analysis 
Our starting material was wild-type VEGFR-2 cloned in the pBE vector (a modified 
pEGFP-N1 vector; Takara Bio Europe/Clontech), suitable for mammalian expression. 
We also subcloned VEGFR-2 domain 7 R726A from the expression vector 
pcDNA5/FRT (Invitrogen) into the pBE vector. The pBE vector was PCR amplified 
using the following primers: Fwd 5’-
GAAAAGACGAACTTGGAAATCATTATTCTAGTAGGCACGGCGGTG-3’ and Rev 5’-
CATCGCTGCTCCCCGAAGAGCTCGCTCCGGCTC-3’. The homology regions 
needed for integration are underlined. The insert VEGFR-2 domain 7 R726A was 
amplified with the following primers: Fwd 5’-
CTTCGGGGAGCAGCGATGGAGAGCAAGGTGCTGCTGGCCGTC - 3’ and Rev 5’-
GATTTCCAAGTTCGTCTTTTCCTGGGCACCTTTATTATGAAAAATGCCTC-3’. The 
underlined non-annealing 5’ tails were complementary to the homology regions of the 
5’ ends of the primers used above for the vector linearization. PCR amplified plasmid 
and insert were assembled in vitro using the Gibson assembly (Gibson et al., 2009).  
(Figure 4). 
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Figure 4: Schematic representation of Gibson assembly using PCR-linearized plasmids.  
The VEGFR-2 domain 5 T446E/K512A and T446E/ E508K/K512A mutations were 
introduced into the pBE VEGFR-2 construct by cloning two overlapping fragments of 
the gene harbouring mutations into the vector backbone in a single Gibson assembly 
(Gibson et al., 2009)  reaction using the primers shown in Table 4. 
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Mutations 5’-3’ Primer Sequence 
 
Domain 5_E508K/K512A 
Fwd 5’- 
AAAGGAAAAAACGCAACTGTAAGTACCCTTGTTATCCAAG
CGGCAAATG-3’ 
Rev 5’- 
CTTACAGTTGCGTTTTTTCCTTTAATTAGAGCAAATTGATTT
TTATTAACTTC-3’ 
 
Domain 5_T446E/K512A 
Fwd 5’- 
TCAATTTGCTCTAATTGAAGGAAAAAACGCAACTGTAAGTA
CCCTTGTTATCCAAGCGGCAAATG-3’ 
Rev 5’- 
CTTACAGTTGCGTTTTTTCCTTCAATTAGAGCAAATTGATT
TTTATTAACTTC-3’ 
 
Domain 5_T446E/ 
E508K/K512A 
 
Fwd 5’- 
CAAACGCTGACATGTGAAGTCTATGCCATTCCTCCCCCGC
ATC-3’ 
Rev 5’- 
GAATGGCATAGACTTCACATGTCAGCGTTTGAGTGGTGCC
GTAC-3’ 
 
Domain 7_R726A_Domain 
5_ T446E/K512A 
Fwd 5’- 
TCAATTTGCTCTAATTGAAGGAAAAAACGCAACTGTAAGTA
CCCTTGTTATCCAAGCGGCAAATG-3’ 
Rev 5’- 
CTTACAGTTGCGTTTTTTCCTTCAATTAGAGCAAATTGATT
TTTATTAACTTC-3’ 
 
Domain 7_R726A_ Domain 
5_T446E/ E508K/K512A 
 
Fwd 5’- 
CAAACGCTGACATGTGAAGTCTATGCCATTCCTCCCCCGC
ATC-3’ 
Rev 5’- 
GAATGGCATAGACTTCACATGTCAGCGTTTGAGTGGTGCC
GTAC-3’ 
Table 4: Primers used for cloning VEGFR-2 mutants for functional analysis. 
The PCR products were digested with 1 μl DpnI ((New England Biolabs) in the 
presence of NEB4 buffer for 8 h at 37°C, and then purified using the MiniElute PCR 
purification kit (Qiagen). An insert-plasmid mastermix was prepared such that each 
Gibson assembly reaction consisted of 2.7 μl 5x isothermal reaction buffer (5x IT 
buffer), 2 μl insert-plasmid mastermix (containing 75 ng plasmid and an 8-fold molar 
excess of insert), 5.3 μl 1:1000 diluted T5 exonuclease (New England Biolabs, 10’000 
Doctoral thesis Mayanka Asthana 
 
51 
  
 
U/ml), 1.6 μl of 1:10 diluted Phusion HF DNA polymerase (NEB, 2’000 U/ml), 1.3 μl 
Taq DNA ligase (NEB M0208L, 40’000 U/ml, undiluted) and H2O to a final volume of 
13.5 μl. The 5x IT buffer consisted of 25% PEG 8000 (Sigma-Aldrich), 500 mM Tris 
HCl pH 7.5, 50 mM MgCl2, 50 mM DTT, 1 mM of each dNTP (New England Biolabs) 
and 5 mM NAD+ (New England Biolabs). The reactions were incubated in the PCR 
machine at 50°C for 1 h. Chemically competent E.Coli Mach1 cells were transformed 
with 2 μl of the above assembly mixture and plated on LB-Kanamycin agar plates. Cell 
colonies were picked after an incubation of 16 h at 37°C and inoculated in 5 ml 
overnight cultures. Plasmid DNA was extracted with a Miniprep kit (Qiagen). The 
mutations were verified by sequencing the plasmid DNA (Microsynth AG). 
6.3.3. Cloning of VEGFR-1/2 chimeric constructs for functional 
analysis 
For cloning the chimeric VEGFR-1/2 constructs, consisting of VEGFR-1 ECD (residues 
1-752) and the intracellular domain of VEGFR-2 (residues 759-1356) we PCR-
amplified wild-type, domain 5_E513K/K517A and domain 5_T455W/E513K/K517A 
VEGFR-1 ECD from their respective constructs in the pcDNA 3.1+ vector using the 
following primers: Fwd-
5’CTTCGGGGAGCAGCGATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTG-3’ 
and Rev-5’ 
GATTTCCAAGTTCGTCTTTTCCGAGGTTCCTTGAACAGTGAGGTATGCTGAAC-3’ 
The DNA fragments were integrated into the wild-type VEGFR-2 pBE plasmid by 
replacing VEGFR-2 ECD using the Gibson assembly as described in section 6.3.2. For 
this, the pBE VEGFR-2 plasmid was linearized using the following primers: Fwd 5’-
TAAAGGTTTTACTGCTTTAAAAAACTCCCACATCCCCCTGAACTGAAAC-3’ and 
Rev 5’- CATCGCTGCTCCCCGAGCTCGCTCCGGCTC-3’. 
6.3.4. Cloning of VEGFR-1 for lenti viral expression 
In order to stably transfect PAE cell lines expressing domain 5 mutants using lenti 
viruses, we PCR-amplified wild-type, domain 5_E513K/K517A and domain 
5_T455W/E513K/K517A VEGFR-1 from their respective constructs in the pcDNA 3.1+  
vector using the following primers: 
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Fwd  5’- 
ATCCACCGGTCGCCACCATGATGGTCAGCTACTGGGACACCGGGGTCC-3‘ and 
Rev 5’- 
GATTGTCGACGCGGCCGCTTTATATCAAGCGTAGTCTGGGACGTCGTATGG-3‘  
and subcloned them into the transfer vector plasmid pRRLSIN.cPPT.PGK-GFP.WPRE 
(Addgene) by Gibson assembly as described in section 6.3.2. For this, the 
pRRLSIN.cPPT.PGK-GFP.WPRE plasmid was linearized and amplified using the 
following primers: 
Fwd 5’ 
GGACCCCGGTGTCCCAGTAGCTGACCATCATGGTGGCGACCGGTGGAT-3‘and 
Rev 5’- 
CCATACGACGTCCCAGACTACGCTTGATATAAAGCGGCCGCGTCGACAATC-3‘ 
Chemically competent E.Coli Mach1 cells were transformed with the above assembly 
mixture and plated on LB-Ampicillin agar plates. Cell colonies were picked after 
overnight incubation at 37°C and inoculated in 5 ml overnight cultures. Plasmid DNA 
was extracted with a Miniprep kit (Qiagen). The mutations were verified by sequencing 
the plasmid DNA (Microsynth AG). 
6.3.5. Cell Culture 
Porcine aortic endothelial cells (PAE), human embryonic kidney epithelial 293 cells 
(HEK293), HEK293T and NIH3T3 cells were grown in DMEM supplemented with 10% 
FBS and 1% penicillin–streptomycin. Cells were cultured in a humidified atmosphere 
at 37°C and 5% CO2. 
6.3.6. Transient transfections 
NIH3T3 cells were seeded in 3.5-cm dishes and allowed to reach 60% confluence, at 
which point their medium was replaced with 1.6 ml fresh DMEM containing 0.5% FBS. 
Four μg plasmid DNA carrying either the VEGFR-1/2 or VEGFR-2 cDNA was dissolved 
in 0.4 ml serum-free culture medium and mixed with 8 μl PEI. After 10 min incubation 
at room temperature, allowing for the successful formation of a DNA-PEI complex, the 
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mixture was added to the cells. Following 5 h incubation at 37°C, an additional 2 ml 
DMEM containing 10% FBS was added and the cells were incubated for 20 h prior to 
analysis.  
Alternatively, HEK293 and NIH3T3 cells, grown to 60% confluence in 3.5-cm dishes, 
were transfected with plasmid DNA containing the VEGFR-1 or VEGFR-2 cDNA using 
either FuGENE (Promega) or Lipofectamine 2000 or 3000 (Invitrogen) according to the 
manufacturer’s instructions. 
6.3.7. Generation of stably transfected PAE cells by chemical 
transfections 
PAE cells were plated 6-9 h prior transfection in 10-cm dishes. Cells were 40-50% 
confluent prior to transfection. Twenty μg linearized plasmid DNA containing the 
VEGFR-1 cDNA dissolved in 2 ml serum-free DMEM were mixed with 40 μl PEI. The 
mixture was incubated for 10 min at room temperature. The medium in the culture 
dishes was replaced with 6 ml DMEM containing 0.5% FBS and the DNA/PEI complex 
was added for 5 h. Cells were passed into ten 10-cm plates 40 h after transfection in 
different dilutions (1:5, 1:10, 1:50, 1:100, 1:200, 1:400, 1:600, 1:800, 1:1000, 1:2000) 
and selection was applied by adding 500 μg/ml G418 (Geneticine) to the medium. 
Single cell colonies were picked with clone rings with grease after 14 days and 
transferred to 1-cm wells to grow in the presence of selection drug. Once cells were 
90% confluent they were passed in 6-cm plates and frozen into aliquots. 
6.3.8. Generation of stably transfected PAE cells by lentiviral 
transductions 
HEK293T cells plated at 85-90% confluence in 10-cm culture dishes were used for 
transfections. Twelve μg of transfer vector containing the VEGFR-1 cDNA was mixed 
with 4 μg each of the packaging plasmids pMDLg/pRRE and pREV, and 4 μg of the 
envelope plasmid pVSVg-PMD2.G in 2 ml serum-free medium (Opti-MEM; Life 
technologies). Seventy two μg PEI was added to this mixture and incubated at room 
temperature for 10 min. Subsequently, 5 ml fresh DMEM was added to it. The plated 
cells were incubated for 3 h with the above mixture. Afterwards, 5 ml DMEM containing 
5% FBS was added and the cells were incubated for 72 h at 37°C. The supernatants 
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were collected and centrifuged for 5 min at 180xg to remove cell debris, and stored at 
4°C. Prior to transfection, they were concentrated by ultracentrifugation at 80,000xg 
(24,000 rpm on a SW-28 ultracentrifuge rotor) for 1.5 h at 4°C and resuspended in 100 
μl PBS. The concentrated virus solution was added to PAE cells grown in 3.5-cm 
dishes at 60% confluence for 24 h. To increase the efficiency of infection, polybrene 
(Hexadimethrine bromide, Sigma H9268) was added to a final concentration of 4 μg/ml. 
After 24 h, the medium was changed to 2 ml DMEM containing 10% FBS, and the cells 
were incubated for 72 h at 37°C prior to VEGFR-1 expression analysis.    
6.3.9. Immunocytochemistry 
PAE cells stably expressing VEGFR-1 were grown on glass coverslips coated with 
Poly-L-Lysine (P4707, Sigma) to 60% confluence. Cells were fixed with 3.7% 
formaldehyde in PBS for 20 min at 37°C, permeabilized for 10 min with 0.1% (wt/vol) 
NP-40 in PBS, and blocked for 20 min in 5% (wt/vol) bovine serum  albumin (BSA) in 
PBS at room temperature. The samples were sequentially exposed to primary (1:400) 
and fluorescently labelled secondary (1:1000) antibodies in PBS containing 1% BSA, 
and embedded in Gelvatol (15% Gelvatol [Celanese Corporation, Lanaken, Belgium], 
33% glycerol, 0.1% sodium azide). The coverslips were washed thrice with PBS after 
each step. Images were acquired with an Olympus IX8 equipped with an Andor 
iXonEM camera and with a Leica SP5 laser scanning confocal microscope at 60X 
magnification. 
6.3.10. VEGF receptor activity assay 
PAE, HEK293, or NIH3T3 cells were  serum  starved in DMEM  supplemented  with  
1%  BSA  and  stimulated  with  VEGF or PlGF for 10 and 5 min respectively, at 37°C. 
Cell lysates were prepared in lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 0.5% 
[wt/vol] Triton X-100) supplemented with a protease inhibitor  cocktail  (Complete  Mini 
EDTA-free,  Roche Diagnostics),  phosphatase  inhibitors  (200  μM Na3VO4, 10 mM 
NaF, 10 mM sodium pyrophosphate, 30 mM p-nitrophenly-phosphate, 80 mM 
glycerophosphate, and  20  μM  phenylarsine  oxide) and 10% glycerol. The 
Bicinchoninic Acid (BCA) assay (Pierce BCA Protein assay kit; Thermo Fischer 
Scientific) was used to determine the total amount of protein in the lysates. Lysates 
Doctoral thesis Mayanka Asthana 
 
55 
  
 
were  diluted  with Laemmli buffer  (0.25M  Tris-HCl pH 6.8, 0.5M DTT, 10% SDS, 50% 
Glycerol, 0.5% Bromophenol Blue), incubated at 95°C for 1 min, resolved on 8%  SDS 
polyacrylamide gels, transferred to polyvinylidene (PVDF,GE Healthcare) membranes, 
and immunoblotted with primary antibodies (dilution 1:1000) followed by secondary 
alkaline phosphatase-coupled  antibodies  (dilution 1:10000),  and  developed  with   
the Novex  AP  Chemiluminescent Substrate (Invitrogen). The signal was detected on 
a GE Healthcare ImageQuant RT ECL scanner and densitometrically quantified using 
the ImageJ gel analysis plugin. 
The antibodies used were as follows: pY1175-VEGFR-2 (2478, Cell Signaling), 
tVEGFR-2 (2479, Cell Signaling), α-tubulin (T5168 Sigma-Aldrich), anti-rabbit IgG 
HRP-linked (7074S, Cell Signaling), anti-mouse   IgG HRP-linked   (7076S,   Cell   
Signaling). Alkaline phosphotase (AP) conjugated secondary antibodies were obtained 
from Jackson  ImmunoResearch. The fluorescently labeled  Dylight 488 secondary 
antibody was purchased from Abcam. The protein marker used for all SDS-PAGE and 
western blot experiments was PageRuler™ Plus Prestained Protein Ladder, 10 to 250 
kDa (26619, ThermoFisher). 
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7. Results 
7.1. Structural characterization of VEGFR-2 ECD complexes 
7.1.1. Expression and purification in insect cells 
A great motivation for this project was the limited structural information available on 
the ECD of VEGFR-2. Our main aim was to perform biophysical and structural studies 
in order to understand the regulatory role of the various extracellular Ig-homology 
domains in VEGFR-2 activation. To achieve this goal, we engineered several multi-
domain fragments of VEGFR-2 ECD for high-level expression in insect cells. We also 
included VEGFR-2 domains 2-7 GCN4 in our study, which contains the two-stranded 
coiled-coil domain of the yeast transcription activator GCN4 at the C-terminal followed 
by the membrane proximal end of VEGFR-2 ECD (Table 5). Such design may mimic 
the stability provided to the ECD by the transmembrane domains (TMD) in the native 
form of the receptor, present in the cell membrane. 
For expression in insect cells, we used the Multibac baculovirus expression vector pFL 
(Berger et al., 2004) or the commercially available pFASTBAC-1 vector (Invitrogen). 
The constructs VEGFR-2 domains 1-7, 2-7 and 2-7 GCN4 in pFL and VEGFR-2 
domains 1-3 in pFASTBAC-1 were already present in the laboratory. The construct 
VEGFR-2 domains 2-5 was cloned during this work into one of the two multiple cloning 
sites of pFL. All constructs contained the endogenous VEGFR-2 signal sequence to 
trigger protein secretion and a C-terminal 8xhistidine tag with a preceding factor Xa 
cleavage site for removal of the tag. The pFL and pFASTBAC plasmids with the various 
ECD constructs were used to generate baculovirus for Sf21 insect cell infection and 
consequent recombinant protein expression. Several types of media were tested for 
the growth of Sf21 cells in suspension. We found that the medium from Lonza 
promoted cell growth, while reducing cell clumping of Sf21 cells in suspension (Figure 
5). To further minimize cell clumping, we also assessed the growth of cells in 
suspension in different vessels, including square bottles, flat-bottom and baffled 
Erlenmeyer flasks and a small-scale bioreactor. We found that the small-scale 
bioreactor minimized cell clumping and promoted cell growth. VEGFR-2 domains 1-7  
and 2-7 GCN4 were expressed in a 4 l Sf21 culture in a small-scale bioreactor, 
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whereas all other proteins were expressed in 4 l cultures in baffled Erlenmeyer flasks. 
Due to technical difficulties we were able to optimize expression of only two constructs 
in the bioreactor. The optimal purification protocol involved a first step of IMAC to 
remove most of the impurities, followed by a second step of SEC for removing 
remaining aggregates. The cultures in Erlenmeyer flasks gave yields ranging from 0.5–
1.6 mg per l of cultured cells, whereas protein expression in the bioreactor resulted in 
a final yield of 10-13 mg/l due to better aeration than in shaker cultures. This gave 
sufficient material for carrying out initial characterization and crystallization 
experiments.  
The elution profiles of the purified proteins from a calibrated Superdex 200 column is 
shown in Figure 6. The elution profiles of constructs VEGFR-2 domains 1-7, 2-7, 2-7 
GCN4 and 2-5 indicates a homogenous receptor preparation. On the other hand, the 
elution profile of the VEGFR-2 domains 1-3 construct shows clear signs of 
polydispersity. The first two peaks, at 48 ml and 64 ml respectively, correspond to the 
aggregates and oligomers eluted at the void volume (45 ml), whereas the monomeric 
protein was eluted at a retention volume of 84 ml, as shown in Figure 6d. The protein 
purity of all the constructs judged from SDS-PAGE was found to be 95%. However, 
SDS-PAGE of the eluted fractions showed diffuse bands and the proteins were 
detected at higher MW than expected (calculated MW are as follows: domains 1-7: 88 
kDa, domains 2-7: 78 kDa, domains 2-7GCN4: 80.2 kDa, domains 1-3: 39.4 kDa, 
domains 2-5: 51.5 kDa). This can be attributed to heterogeneous glycosylation of the 
proteins expressed in insect cells (potential N-glycosylation sites are shown in Table 
5). To improve this, we designed new constructs for expression in mammalian cells. 
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Figure 5: Test of different media for their suitability for suspension culture of Sf21 cells. 
Growth curves of Sf21 cells in suspension were monitored for three different culture media: 
Insect-XPRESS (Lonza), SF4-Baculo Express ICM (Bioconcept) and SF900 II SFM (Gibco). 
Cells cultured in the Insect-XPRESS medium achieved maximum cell density, while showing  
the least clumping. 
 
Domain 
boundaries 
Amino 
acids 
 
Domains 1-7 20-764 
 
Domains 2-7 118-
756  
 
Domains 2-7GCN4 118-
756  
 
Domains 1-3 20-335 
 
 
Domains 2-5 118-
550  
 
 
 
Table 5: VEGFR-2 ECD recombinant proteins expressed in insect cells. 
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Figure 6:  SEC profiles of VEGFR-2 ECD subdomains expressed in insect cells. Soluble 
proteins were produced in Sf21 cells and purified from the culture supernatant by IMAC and 
SEC. The Superdex S200 elution profiles (left panel) with their corresponding SDS-PAGE 
analysis (right panel) are shown. (a) VEGFR-2 domains 1-7 (b) VEGFR-2 domains 2-7 (c) 
VEGFR-2 domains 2-7 GCN4 (d) VEGFR-2 domains 1-3 (e) VEGFR-2 domains 2-5. Black 
bars indicate the fractions that were loaded for SDS-PAGE. 
7.1.2. Expression and purification in mammalian cells 
VEGFR-2 has 18 potential N-gylcosylation sites within the extracellular domain. As 
insect cells are unable to produce sialylated complex glycans, we expressed VEGFR-
2 ECD subdomains in mammalian cells in order to obtain near native-like post-
translational modifications in the secreted proteins. Since complex glycans could 
interfere with protein crystallization, we used HEK293S GnTi− cells which lack the 
capability to process N-linked glycans on glycoproteins from the high mannose to the 
complex mature form resulting in more homogeneously glycosylated protein. 
Furthermore, these proteins greatly facilitate enzymatic removal of the bulk of the 
attached N-linked glycans via Endoglycosidase F (EndoF) (Reeves et al., 2002). 
7.1.2.1. Baculovirus mediated gene expression of VEGFR-2 ECD subdomains in 
mammalian cells 
We expressed VEGFR-2 ECD subdomains by adapting the baculovirus mediated gene 
transduction of mammalian cells (BacMam) system as shown in Figure 7. In contrast 
to other commonly used viral vectors, baculoviruses are insect cell viruses that can be 
modified to express proteins in mammalian cells without initiating a replication cycle. 
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The viruses can be manipulated to accommodate large inserts of foreign DNA and 
have a good biosafety profile. 
Three different constructs were made having different genes of interest: VEGFR-2 
domains 1-7 (residues 20-764), 2-7 (residues 118-756) and 1-3 (residues 20-335) 
containing the factor Xa cleavage site and an 8xhistidine tag. VEGFR-2 domains 1-7 
would provide insights for the full extracellular domain. VEGFR-2 domains 2-7 was 
also cloned to remove the flexible domain 1, which might cause difficulty in crystal 
formation. VEGFR-2 domains 1-3 was cloned to get more insight into the contribution 
of domain 1 in ligand binding to domains 2 and 3. The acceptor vector was 
reengineered from the pFL vector (Fitzgerald et al., 2006), and carried the gene of 
interest, a mammalian promoter (CMV), mammalian transcriptional regulatory 
elements and a poly A signal. The acceptor vector was recombined by cre-loxP 
recombination to a donor vector containing a VSV-G gene under an insect cell 
promoter (polh). The VSV-G gene was incorporated for enhancing virus titer. E.Coli 
DH10EMBacYFP were transformed with the donor-acceptor plasmid pairs, and the 
resulting bacmid DNA was used to transfect Sf21 and produce the baculoviruses. The 
resultant baculovirus was concentrated 400 times by ultracentrifugation through a 
sucrose cushion (25% w/w sucrose, 5 mM NaCl and 10 mM EDTA), and 100 μl of this 
concentrated virus was used to infect HEK293S GnTi- cells in 6-well plates. However, 
the protein yields from BacMam transductions in HEK293S GnTi- cells were not 
significantly higher when compared to PEI transfections in HEK293T cells, even when 
concentrated baculovirus was used (Figure 8). In addition, the protein yield (~50 
μg/100 ml of culture) did not meet our requirements for milligram quantities of soluble 
proteins produced in a relatively short time for crystallization trials.  
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Figure 7. Strategy for VEGFR-2 ECD subdomain expression by baculovirus mediated 
gene transduction in mammalian cells. The ECD variant gene is inserted into an acceptor 
vector (pSI-AA), which is recombined to a VSV-G bearing donor vector (pUCDM) to generate 
the dimeric expression vector. E.Coli DH10EMBacYFP cells are then transformed with the 
dimeric expression vector to generate the bacmid DNA, which is used for infecting Sf21 cells 
for baculovirus production.  The baculovirus is in turn used for transducing HEK293S GnTi- 
cells for protein production. The purified proteins can be enzymatically deglycosylated by 
EndoF. 
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Figure 8: Comparison of different expression systems for the production of VEGFR-2 
ECD subdomains. The various VEGFR-2 ECD subdomains (D1-7, D1-2 and D1-3) were 
expressed in HEK293T and HEK293S GnTi- cells by either chemical transfection or using the  
BacMam strategy. The expression levels of the various VEGFR-2 ECD subdomains was 
probed in the culture supernatants by western blotting using an anti-His antibody, which 
recognizes the histidine tag of all three recombinant proteins. 
7.1.2.2. Expression and purification of mouse VEGFR-2 ECD subdomains in 
HEK293 EBNA cells 
In order to achieve protein expression in sufficient quantities to carry out structural 
analysis experiments, we assessed stable gene expression in mammalian cells. In 
these studies, we used the mouse homologue of VEGFR-2. The human and mouse 
VEGFR-2 ECD have high degree of sequence identity (80% by CLUSTALW). Stable 
cell lines expressing mouse VEGFR-2 ECD subdomains (Table 6) were generated in 
HEK293 EBNA cells, which express the Epstein-Barr nuclear antigen 1 (EBNA-1). The 
product of the EBNA-1 gene drives the episomal amplification of expression plasmids 
carrying the origin of replication derived from the Epstein-Barr virus (EBV). Thus, these 
cells under selection pressure (Puromycin) are expected to increase recombinant 
protein expression levels by permitting more plasmid copies to persist in the 
transfected cells throughout the production phase. 
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All the constructs were cloned in the pCEP4-Pu vector and carried a 6xhistidine tag 
and a C-terminal precision protease cleavage site to allow tag removal. The stable 
HEK293 EBNA cells expressing VEGFR-2 domains 2-5, 1-3 and 4-7 were not 
expanded due to very weak expression.  On the other hand, stable cells expressing 
VEGFR-2 domains 1-7, 2-7, 1-6 and 5-7 could be upscaled to 4 l cultures in Erlenmeyer 
flasks. The recombinant proteins were purified by IMAC followed by a second 
purification step of SEC. The SEC profiles show VEGFR-2 domains 1-7, 1-6 and 5-7 
eluting with a predominantly monodisperse peak, whereas VEGFR-2 domains 2-7 
gave a broad polydisperse peak indicating oligomerization (Figure 9). The eluted 
fractions were analyzed by SDS-PAGE. Due to N-glycosylation, the proteins ran at a 
higher MW (domains 1-7: 120 kDa, domains 2-7: 110 kDa, domains 1-6: 100 kDa and 
domains 2-5: 70 kDa) than their theoretical MW (domains 1-7: 86.5 kDa, domains 2-7: 
75.4 kDa, domains 1-6: 75 kDa and domains 5-7: 39.3 kDa). High protein yields were 
obtained upon purification, in the range of 2.5-4.2 mg/l.  All recombinant proteins, either 
glycosylated or deglycosylated with Peptide: N-glycosidase F (PNGase F) and Endo F 
were used for crystallization experiments. 
 
Domain 
boundaries 
Amino 
acids 
 
Domians 1-7 20-762 
 
Domains 2-7 123-762 
 
Domains 1-6 20-661 
 
Domains 5-7 421-762 
 
 
Table 6: Mouse VEGFR-2 ECD subdomain recombinant proteins expressed in HEK293 EBNA 
cells. 
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Figure 9: SEC profiles of mouse VEGFR-2 ECD subdomains expressed in mammalian 
cells. Soluble proteins were produced in HEK293 EBNA cells and purified from the culture 
supernatant by IMAC and SEC. The Superdex S200 elution profiles (left panel) with their 
corresponding SDS-PAGE (right panel) are shown. (a) mVEGFR-2 domains 1-7 (b) mVEGFR-
2 domains 2-7 (c) mVEGFR-2 domains 1-6 (d) mVEGFR-2 domains 5-7. Black bars indicate 
the fractions that were loaded for SDS-PAGE. 
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Since we achieved higher expression with the mouse VEGFR-2 ECD constructs in 
HEK293 EBNA cells than with the human VEGFR-2 ECD constructs in insect cells 
(section 7.1.2.1), we decided to use this expression system for human VEGFR-2 ECD 
subdomains as well. Additionally, mammalian cells should provide a more 
physiologically relevant environment for VEGFR-2. However, glycosylation may be a 
bottleneck for obtaining crystals. Thus, we cloned constructs of human VEGFR-2 ECD 
subdomains (domains 1-7, 2-5 and 1-3) in the pCEP4-Pu vector, with all asparagine 
residues replaced with glutamine residues, leading to proteins lacking any N-
glycosylation. However, the transfected HEK293 EBNA cells did not survive, possibly 
due to accumulation of glycosylation-lacking misfolded proteins. This suggests that at 
least some of the N-glycosylation sites are absolutely essential for proper protein 
folding.  
7.1.3. Crystallization of VEGFR-2 ECD complexes 
Recombinantly produced proteins underwent extensive crystallization screening using 
commercial 96-well screens (Table 7), both at 4°C and 20°C. Complexes of VEGFR-2 
ECD subdomains with different ligands (VEGF-A121 or VEGF-E) were either pre-
formed and purified by SEC or formed in situ in the crystallization drop. Co-
crystallization of receptor with ligand was preferred to crystallization of monomeric  
receptor for two reasons: (a) the receptor-ligand complex is the more biologically 
relevant form of the receptor, and (b) complex formation may substantially stabilize the 
receptor and increase the chances of crystallization. Additionally, mutiprotein 
complexes containing ligand, antibody fragments (scFV and Fab) and recombinant 
VEGFR-2 ECD proteins were also subjected to crystallization screening. Hanging–
drop and sitting-drop methods for vapour diffusion (VD), or in lipidic cubic phase (LCP) 
in batch, were used with two different drop ratios per reservoir (1:1 and 1:2 
protein:reservoir volume) for crystallization trials. Furthermore, we used seeding with 
crystals of VEGFR-1, a VEGFR-2 homologue, for initiating crystal growth or inducing 
nucleation and growth at a lower level of supersaturation than might otherwise 
spontaneously occur. The crystals of VEGFR-1 domains 1-6 and 2-7 were crushed 
and used as seed stock to be dispensed into all the conditions of the screen, following 
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the random microseed matrix screening (MMS) technique. In situ limited proteolysis 
was also performed by adding either α-chymotrypsin or subtilisin in a 1:100 (w/w) ratio 
to the complexes just before crystallization (Table 8). 
 
 Commerial Screens 
 
Supplier 
Joint Center for Structural Genomics 
(JCSG) core screen I-IV suites 
Qiagen 
pH clear I-II Qiagen 
Additive screen HT Molecular dimension 
PEG suite Qiagen 
Morpheus  Molecular dimension 
Proplex Molecular dimension 
saltRX Hampton research 
Stura footprint screen Molecular dimension 
PACT premier screen Molecular dimension 
Table 7: Commercial screens used for crystallization trials. 
7.1.3.1. Co-crystallization of VEGFR-2 ECD subdomains with ligands 
For co-crystallization experiments, VEGFR-2 ECD subdomains and ligands VEGF-A121 
and VEGF-E were expressed and purified separately. SEC-purified and concentrated 
proteins were mixed in a 1:2 molar ratio and subjected to another round of SEC to 
isolate the complex. The SEC profiles of human and mouse VEGFR-2 ECD variants 
in complex with either VEGF-A121 or VEGF-E from a Superdex 200 column are shown 
in Figure 10 and Figure 11 respectively. The two separate peaks correspond to the 
VEGFR-2 ECD subdomain-ligand complex and to unbound ligand, as confirmed by 
SDS-PAGE: both receptor and ligand were present in the peak corresponding to the 
complex. The peak corresponding to the complex was collected, concentrated to 2-6 
mg/ml and used for crystallization screening. 
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Figure 10: SEC profiles of human VEGFR-2 ECD subdomains complexed with ligands. 
The receptor subdomains and ligands were mixed in 1:2 molar ratio and purified over a 
Superdex 200 column. (a) VEGFR-2 domains 1-7 co-eluting with VEGF-A121 in a peak with 
retention volume 18.3 ml. The excess VEGF-A121 elutes at 29.3 ml. (b) VEGFR-2 domains 2-
7GCN4 co-eluting with VEGF-A121 in a peak with retention volume 60 ml. The excess VEGF-
A121 elutes at 70 ml. (c) VEGFR-2 domains 1-3 co-eluting with VEGF-A121 in a peak with 
retention volume 78.2 ml. The excess VEGF-A121 elutes at 92.5 ml. (d) VEGFR-2 domains 2-
5 co-eluting with VEGF-E in a peak with retention volume 72 ml. The excess VEGF-E elutes 
at 92.9 ml. (e) VEGFR-2 domains 2-5 co-eluting with VEGF-A121 in a peak with retention 
volume 72 ml. The excess VEGF-A121 elutes at 92.3 ml. The results of SDS-PAGE analysis of 
the various SEC fractions under reducing conditions are shown in the right panel. The coloured 
bars indicate the fractions from the corresponding SEC peaks that were loaded for SDS-PAGE. 
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Figure 11: SEC profiles of mouse VEGFR-2 ECD variants complexed with ligand. The 
mouse receptor subdomains were mixed with human ligands in 1:2 molar ratio and purified 
over a Superdex 200 column. (a) mVEGFR-2 domains 1-7 co-eluting with VEGF-A121 in a peak 
with retention volume 63.5 ml. The excess VEGF-A121 elutes at 92.5 ml. (b) mVEGFR-2 
domains 2-7 co-eluting with VEGF-A121 in a peak with retention volume 14.5 ml. The excess 
VEGF-A121 elutes at 18 ml. (c) mVEGFR-2 domains 1-6 co-eluting with VEGF-A121 in a peak 
with retention volume 70.5 ml. The excess VEGF-A121 elutes at 97.8 ml. The coloured bars 
indicate the fractions from the corresponding SEC peaks that were loaded for SDS-PAGE. 
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7.1.3.2.  Co-crystallization of VEGFR-2 ECD/VEGF-E with scFV 
Since we did not obtain any crystals from the experiments described in section 7.1.3.1, 
we used scFv A7 as a chaperone to facilitate the crystallization of VEGFR-2 ECD-
ligand complexes. ScFv A7 targets the ligand binding domains 2-3 without interfering 
with VEGFR-2 ECD/VEGF-A complex formation. The antibody was isolated from the 
ETH-2 Gold library, expressed in E.coli Mach 1 cells, and characterized by Dr. Dragana 
Avramovic, as previously described (Ballmer-Hofer et al., 2018). For carrying out co-
crystallization trials, VEGFR-2 ECD, VEGF-E and scFv A7 were mixed in a molar ratio 
of 1:2:3, and purified by SEC (Figure 12). The chromatograph shows a main peak at 
25 ml, expected to correspond to the trimeric complex, with a shoulder that could be 
due to the binding of oligomeric scFvs. The eluted fractions were subjected to SDS-
PAGE analysis, which confirmed the co-elution of all three proteins; the fractions from 
the shoulder showed the presence of scFvs with a MW between 25 and 37 kDa. The 
unbound scFv A7 and VEGF-E, which were present in excess, eluted at higher 
retention volumes of 42 ml and 38 ml respectively. The fractions comprising the 
complex were concentrated and used for crystallization trials.  
Despite screening a broad range of crystallization conditions no crystals were 
obtained. The co-crystallization of scFv A7 with VEGFF-2 ECD and VEGF-E was 
possibly impaired because the flexible GS-linker connecting the heavy and light 
segments of the binding protein may interfere with the formation of crystal contacts.  
 
 
Figure 12: SEC profile of the VEGFR-2 domains 1-7/VEGF-E/scFv A7 complex. 
Recombinant VEGFR-2 domains 1-7, VEGF-E and scFv A7 were mixed in 1:2:3 molar ratio 
and purified over a Superdex S200 column. The left panel shows the SEC profile of VEGFR-2 
domains 1-7 co-eluting with VEGF-E and scFv A7 at a retention volume of 25 ml. Excess scFv 
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A7 and VEGF-E elute at higher retention volumes, i.e 42 ml and 38 ml respectively. The right 
panel shows SDS-PAGE analysis of the eluates under reducing and non-reducing conditions. 
The black bars indicate the fractions from the corresponding SEC peak that were loaded for 
SDS-PAGE. 
7.1.3.3. Co-crystallization of VEGFR-2 ECD/VEGF-A121 with Fab  
To overcome potential problems with the flexible linker present in the scFv we used a 
Fab fragment that contains the variable and one of the constant regions of the light and 
heavy antibody chains for co-crystallization trials. Additionally, the Fab offers a larger 
hydrophilic surface that may support the formation of additional crystal contacts. 
We used a Fab antibody fragment that binds to the flexible domain 1 of VEGFR-2 ECD. 
This could provide more stability to ECD when complexed with ligand and hence 
increase the likelihood of crystallization. The Fab ADH9 fragment was expressed by 
IPTG induction using the Mach1 E. coli strain. The recombinant Fab was extracted 
from the periplasm and the lysate was purified by IMAC. Subsequently, the Fab was 
subjected to SEC and the elution profile shows two major peaks (Figure 13). The first 
peak of aggregates eluted near the void volume (Peak1: 49.6 ml); the second 
polydisperse peak (Peak2: 86.6 ml) shows the presence of Fab oligomers. The protein 
yield after purification was in the range of 0.5-1.5 mg/l. The Fab fractions under SDS-
PAGE conditions showed a MW of approximately 50 kDa. 
 
 
Figure 13: SEC profile of the Fab fragment. IMAC-purified Fab ADH9 was further purified 
over a Superdex S200 column, resulting in a broad elution peak at a retention volume of 86.6 
ml (left panel). The right panel shows the SDS-PAGE analysis of the eluted fractions. The black 
bar indicates the fractions from the corresponding SEC peak that were loaded for SDS-PAGE. 
The band corresponding to Fab ADH9 ran at approximately 50 kDa. 
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For co-crystallization experiments, VEGFR-2 ECD was mixed with VEGF-A121 and 
ADH9 Fab in a 1:2:3 molar ratio and purified by SEC using a Superdex S200 column. 
Co-elution was confirmed by a shift in the elution volume towards higher molecular 
weight, from 18.3 ml corresponding to the VEGFR-2 domains 1-7/VEGF-A121 complex 
(Figure 10a) to 18 ml (Figure 14). Also the presence of all three components with 
appropriate MW of VEGFR-2 domains 1-7 (~86.5 kDa), Fab ADH9 (~50 kDa) and 
VEGF-A121 (~30kDa) in the eluted fractions, as shown by SDS-PAGE under non-
reducing conditions, confirmed the formation of a triple complex between Fab ADH9, 
VEGFR-2 domains 1-7 and VEGF-A121. However, the peak corresponding to unbound 
Fab fragment at 23.9 ml did not resolve completely from the major peak of the complex. 
Nonetheless, the fractions corresponding to the complex were collected, concentrated 
to 2-6 mg/ml and used for crystallization trials, which however were unsuccessful. 
Since the complex did not elute as a single monodisperse peak but had a small 
shoulder, which indicates possible dissociation or heterogeneity, VEGFR-2 domains 
1-7/VEGF-A121 complexes and ADH9 Fab were purified individually and mixed prior to 
crystallization in a lower (1:2) molar ratio. Still, none of these experiments yielded any 
crystals. 
 
Figure 14: SEC profile of the VEGFR-2 domains 1-7/VEGF-A121/Fab ADH9 complexes. 
VEGFR-2 domains 1-7, VEGF-A121 and Fab ADH9 were mixed in 1:2:3 molar ratio and purified 
over a Superdex S200 column. The trimeric complex eluted at a retention volume of 18 ml. 
The excess Fab ADH9 and VEGF-A121 eluted at 23.9 ml and 29 ml respectively. The right 
panel shows SDS-PAGE analysis of the eluates under reducing and non-reducing conditions. 
Fractions from the first peak (black bar) show a band around 100 kDa, corresponding to 
VEGFR-2 domains 1-7 (Expected MW: 86.5 kDa). The band at around 50 kDa corresponds to 
Fab ADH9 and the band between 37 kDa and 25 kDa to VEGF-A121 (Expected MW: 30kDa). 
The fractions corresponding to excess Fab ADH9 are indicated with a green bar. 
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Construct 
 
Method of 
crystallization 
 
Temperature of 
incubation of 
plates (ºC) 
 
Concentrations 
used for 
crystallization 
hVEGFR-2 domains 
2-5 /VEGF-A121 
VD 20 and 4 2-5 mg/ml 
hVEGFR-2 domains 
2-5 /VEGF-E 
VD 20 and 4 2-5 mg/ml 
hVEGFR-2 domains 
1-3/VEGF-A121 
VD 20 and 4 2-6 mg/ml 
hVEGFR-2 domains 
2-7GCN4/ VEGF-A121 
VD 20 and 4 2-5 mg/ml 
hVEGFR-2 ECD/ 
VEGF-A121/ Fab 
ADH9 
VD, MMS, 
α-chymotrypsin to 
the drop 
20 and 4 2-6 mg/ml 
hVEGFR-2 
ECD/VEGF-E/ scFV 
A7 
VD 20 2-6 mg/ml 
hVEGFR-2 
ECD/VEGF-A121 
 
VD, MMS, LCP, 
α-chymotrypsin 
and subtilisin to 
the drop 
20 and 4 2-6 mg/ml 
hVEGFR-2 
ECD/VEGF-E 
VD 20 3-6 mg/ml 
mVEGFR-2 
ECD/VEGF-A121 
VD, MMS, LCP, α- 
chymotrypsin to 
the drop 
20 and 4 2-6mg/ml 
mVEGFR-2 domains 
2-7/ VEGF-A121 
VD 20 and 4 2-6mg/ml 
mVEGFR-2 domains 
1-6/VEGF-A121 
VD 20 and 4 2-6mg/ml 
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mVEGFR-2 domains 
5-7 
VD 20 and 4 2-6mg/ml 
 Table 8: Summary of crystallization trials of VEGFR-2 ECD complexes. 
 
7.2. Biochemical and biophysical characterization of VEGFR-2    
ECD complexes 
7.2.1. Analysis of unstructured regions in VEGFR-2 ECD 
Although we were able to express and purify many VEGFR-2 ECD variants (section 
7.1.1 and 7.1.2), we failed to obtain crystals from any of them. This could be due to 
long stretches of disordered regions within protein domains, which may hinder 
crystallization. In these cases, more sophisticated protein engineering might become 
necessary to displace these disordered residues. One approach would be to replace 
these regions with equivalent residues of homologue proteins that are known or 
predicted to be less flexible. Alternatively, the predicted disordered residues can be cut 
out and the ends joined by short flexible linkers. We investigated intrinsic disordered 
regions in VEGFR-2 ECD computationally using a prediction algorithm called 
FoldIndex (Prilusky et al., 2005). This is an ab initio method, which predicts the 
inherently unstructured regions in the protein taking into account a balance between 
attractive and repulsive forces. Figure 15 shows that VEGFR-2 ECD is predicted to 
have 5 disordered regions. Two of these disordered segments are quite long consisting 
of 35-40 residues. One of them corresponds to Ig-homology domain 3 and the other 
lies in Ig-homology domain 5. The smaller (5-7 residues) unstructured segments are 
in Ig-homology domain 6 and 7, and the linker region connecting Ig-homology domains 
4 and 5. 
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Figure 15: Schematic representation of probability of disorder in human VEGFR-2  ECD 
protein predicted by the FoldIndex algorithm. FoldIndex plot for VEGFR-2 ECD. Positive 
and negative numbers represent ordered and disordered protein, respectively. Amino acid 
sequences suggested as being ordered are shown in green, whereas disordered sequences 
are shown in red.   
7.2.1.1. Limited proteolysis 
Limited proteolysis was attempted on the VEGFR-2 ECD/VEGF-A121 complex with a 
series of dilutions of proteases to find conditions leading to the digestion of the 
unstructured parts while leaving the rest of the protein intact. Comparing the limited 
proteolysis experiments from shorter to longer incubation times also helped in 
identifying the protease that yielded a more stable fragment upon digestion. Figure 16 
shows that digestion with 1:10 and 1:100 GluC and papain and 1:1000 α-chymotrypsin 
Domain 3 Domain 5 
Domain 3 
Domain 5 
Domain 6 
Domain 7 
Domain linker 4-5 
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did not have any effect on the protein. On the other hand, incubation with 1:10 trypsin, 
and 1:100 α-chymotrypsin and subtilisin gave much smaller fragments in the range of 
50-37 kDa. Higher concentrations (1:10) of α-chymotrypsin and subtilisin resulted in a 
very fast (within 90 min) and complete proteolysis. Treatment with 1:1000 subtilisin 
gave bigger stable fragments in the range of 100-50 kDa. Figure 16d shows the results 
of limited proteolysis with subtilisin of deglycosylated VEGFR-2 ECD/VEGF-A121 
complex: the fragments generated by 1:1000 subtilisin appeared sharper in SDS-
PAGE. Based on these results, we carried out in-situ proteolysis by adding α-
chymotrypsin and subtilisin to complexes right before setting up crystallization 
experiments. However, no crystals were obtained. Future experiments to identify the 
stable region boundaries of the proteolytic fragments by mass spectrometry may help 
designing new constructs more suitable for crystallization. 
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Figure 16: Limited proteolysis analysis of the VEGFR-2 ECD/VEGF-A complex. (a), (b) 
and (c) SDS-PAGE analysis of VEGFR-2 ECD/VEGF-A complex digested with proteases (Glu-
C, trypsin, papain, α-chymotrypsin, subtilisin) at dilutions 1:10, 1:100 and 1:1000 for 90 min at 
room temperature (RT) and overnight (o/n) at 4°C. (d) SDS-PAGE analysis of deglycosylated 
VEGFR-2 ECD/VEGF-A complex with PNGase F(1:100) and digested with 1:1000 subtilisin.  
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7.2.2. Thermal stability assay 
In order to investigate the thermal stability of human VEGFR-2 subdomains 1-7, 2-7 
and 1-3 upon binding of ligand VEGF-A121 in different buffers, we performed a 
fluorescence-based thermal shift assay using an environmentally sensitive dye, Sypro 
Orange. Melting curves were obtained in the following buffers: (1) PBS, (2) 10 mM 
HEPES pH 7.5, 100 mM NaCl, and (3) 25 mM HEPES pH 7.5, 500 mM NaCl. Unfolding 
of monomeric proteins showed high melting temperature (Tm) values ranging from 
54°C to 63°C (Figure 17). VEGFR-2 domains 2-7 and 1-3 complexed with ligand 
showed a shift towards higher Tm values compared to their corresponding monomers, 
indicating a stabilization effect due to ligand binding in all three buffers. However, 
ligand binding to VEGFR-2 domains 1-7 showed a slight decrease in the Tm value 
suggesting destabilization. Although in all the buffers the proteins were highly stable, 
we chose the low ionic strength buffer for carrying out further biophysical experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colour Name Colour Name 
 
R2 D17 PBS  R2 D27 A 500 mM NaCl 
 
R2 D17 A PBS  R2 D13 500 mM NaCl 
 
R2 D27 PBS  R2 D13 A 500 mM NaCl 
 
R2 D27 A PBS  R2 D17 100 mM NaCl 
 
R2 D13 PBS  R2 D17 A 100 mM NaCl 
 
R2 D13 A PBS  R2 D27 100 mM NaCl 
 
R2 D17 500 mM NaCl  R2 D27 A 100 mM NaCl 
 
R2 D17 A 500 mM NaCl  R2 D13 100 mM NaCl 
 
R2 D27 500 mM NaCl  R2 D13 A 100 mM NaCl 
(a) 
(b) 
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Figure 17: Effect of buffers on thermal stability of VEGFR-2 ECD subdomains and their 
complexes. (a) First derivative curves of thermal denaturation (“melting”) of VEGFR-2 
domains 1-7, 2-7 and 1-3, monomeric or complexed with VEGF-A121, in buffers (1) PBS, (2) 10 
mM HEPES pH 7.5, 100 mM NaCl, and (3) 25 mM HEPES pH 7.5, 500 mM NaCl. The protein 
solution was heated in the presence of a hydrophobic dye (SYPRO Orange). (b) Bar graph 
showing the Tm in degree Celsius, calculated from the melting curves shown in (a), for the 
different constructs and buffers.  
7.2.3. Thermodynamic analysis of VEGFR-2 ECD complexes 
To assess the contributions of the membrane proximal Ig-domains 4-7 to the binding 
of full-length ECD (domains 1-7) to the ligand, we investigated the heat energies 
associated with complex formation by ITC. We compared the thermodynamic 
parameters for VEGF-A121 binding to VEGFR-2 full-length ECD with that to the minimal 
ligand-binding domains 1-3. The recombinant receptor proteins used were produced 
in insect cells and purified as described in section 7.1.1. The obtained isotherms 
(Figure 18) indicate that binding of VEGF-A121 to VEGFR-2 ECD is entropically driven 
and enthalpy disfavoured. The derived binding constant for domains 1-7 was 0.9 μM, 
while the binding constant for domains 1-3 was only 0.14 μM. Surprisingly, the 
presence of the membrane proximal Ig-homology domains in the full-length construct 
reduces the binding affinity.  
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(b) 
 
Figure 18. Quantification of VEGFR-2 ECD/VEGF-A interaction by ITC. (a) Raw titration 
data (upper panel) and integrated and concentration normalized isothermograms (lower panel) 
of VEGF-A121 binding to the VEGFR-2 domains 1-3 (left) and domains 1-7 (right) constructs. 
Solid lines in the isothermograms represent the best fit according to the “One Set of Sites” 
model. (b) Thermodynamic signature of complex formation, showing the Gibbs free energy 
(ΔG), enthalpy (ΔH), and entropy (-TΔS) associated with receptor-ligand binding. 
 
These results were also confirmed by another biophysical technique, MST. MST is a 
technique used to study binding affinities of interacting biomolecules in solution, 
resembling their natural environment (Jerabek-Willemsen et al., 2011). An infrared 
laser is used for local heating and the molecule mobility in the resulting temperature 
gradient is analyzed by fluorescence. MST allows quantitative analysis of protein 
interactions from low amounts of sample without requiring an immobilization step. 
However, it fails to provide any kinetic information (i.e association and dissociation 
rates) of the reaction. For the measurements, the ligand VEGF-A121 was fluorescently 
labelled using an optimized primary amine labelling kit protocol (section 6.2.4). The 
studies were conducted by titrating the unlabelled binding partner VEGFR-2 domains 
1-7 or 1-3, to a fixed concentration of labelled VEGF-A121. The binding constant for the 
full-length ECD construct was measured to be between 0.77 and 1.24 μM (95% 
confidence interval) (Figure 19a), which is in agreement with the binding affinity value 
for the same construct obtained by ITC. The binding affinity of VEGFR-2 domains 1-3 
for VEGF-A121, however, could not be precisely determined, and it was estimated by 
(a) Time (min) Time (min) 
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simulation to be approximately 10 nM (Figure 19b). One should bear in mind that MST 
works poorly for affinities higher than the low nano-molar range. The binding data 
obtained from both techniques corroborate the hypothesis that the membrane proximal 
domains (domains 4-7) reduce the receptor affinity for the ligand by approximately 10 
fold.  
 
 
Figure 19. Quantification of VEGFR-2 ECD/VEGF-A121 interaction by MST. (a) Unlabeled 
VEGFR-2 domains 1-7 was titrated into a fixed concentration of labeled VEGF-A121. The Kd 
value calculated from the fit is in the range of 0.7662 to 1.244 μM (95% confidence interval). 
Measurements were performed in triplicates. (b) Unlabeled VEGFR-2 domains 1-3 was titrated 
into a fixed concentration of labeled VEGF-A121.The Kd value based on fits and simulations 
was estimated to be in the low nanomolar range. 
 
 
 
 
 
 
(a) 
(b) 
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7.3. Functional analysis of ligand binding and activation of 
VEGFR-1 
7.3.1. Functional analysis of VEGFR-1 domain 5 mutants 
The crystal structure of the VEGFR-1 dimer complexed with VEGF-A supports the 
hypothesis that homotypic contacts between the two receptor monomers occur in 
domain 5 (Section 7.4). In particular, the highly conserved amino acids T455 (β strand 
B), K517 (β strand E) and E513 in the D-E loop of domain 5 are involved in inter-chain 
hydrogen bonds and salt bridges. In order to investigate the functional significance of 
the domain 5 interface in the receptor dimer, we generated mutant constructs unable 
to form these non-covalent interactions and studied their ability to respond to VEGF-A 
activation.  
Several mutants were generated in which charged residues were replaced with neutral 
amino acids (E513A, K517A) or vice versa (T455E). Also, the T455W mutation was 
introduced to substitute a polar amino acid (T) with a non-polar bulky residue (W). 
However, these single mutants were not used in our study because, their individual 
effect on receptor activation might have been too small to lead to any gain or loss of 
function. Instead, the double mutant T455E/K517A was used based on a previous 
study by Leppaenen et al, which used the equivalent VEGFR-3 T446/E/K516A mutant 
to validate the importance of domain 5 interface in VEGF-C-induced VEGFR-3 
activation (Leppänen et al., 2013). Furthermore, the double mutant E513A/K517A was 
generated to study the effect of loss of charge in the domain 5 interface in receptor 
activation.  
However, before we could investigate the effect of domain 5 homotypic interactions in 
VEGFR-1 activation, a suitable activity assay had to be established. Although VEGFR-
1 contains a classical tyrosine kinase domain, it shows poor kinase activity even in 
overexpressing ECs, and therefore, its signaling activity remains elusive (Waltenberger 
et al., 1994). On the other hand, the homologous protein VEGFR-2 shows strong 
kinase activity upon ligand binding (Shibuya, 2006). The structural basis for the 
strikingly different kinase activity between these highly conserved proteins can be 
attributed to a set of amino acid residues present in the juxtamembrane regions of 
VEGFR-1, leading to the inhibition of its phosphorylation activity (Gille et al., 2000). 
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These non-conserved amino acids are three serine residues in VEGFR-1, which are 
replaced by the sequence ANGG in VEGFR-2 (Figure 20). In order to enhance the 
activity of VEGFR-1, we designed juxtamembrane mutant constructs that either lacked 
the three serine residues or contained the ANGG sequence from VEGFR-2 instead. 
Initially, the mutants were transiently expressed in HEK293 cells. However, the inability 
to specifically detect total VEGFR-1 present in these cells due to the lack of a suitable 
antibody led to non-conclusive results and prevented us from using these constructs 
for further experiments. 
 
 
Figure 20: Alignment of juxtamembrane regions of VEGFR-1 and VEGFR-2.  Adapted 
from Gille et al.   
We henceforth set to optimize the functional assay by using stably transfected PAE 
cell lines as an alternative expression system, which also offers a more physiological 
environment for functional studies of VEGFR-1. A series of control experiments were 
performed on stable PAE cell lines expressing wild-type VEGFR-1, where several 
commercial antibodies were tested for their ability to specifically detect the total levels 
of VEGFR-1 by western blot. Antibodies from Abcam (ab32152) and Santa Cruz 
Biotechnology (sc-31173) were not suitable since they gave false positive results in 
the non-transfected cells, and the antibody available from R&D systems (AF321) did 
not show any band at the expected molecular weight (150 kDa). We obtained the best 
results with the antibody offered from Cell Signaling (2893S), which was both specific 
and selective in detecting VEGFR-1 in whole cell lysates (Figure 21a). However, the 
antibody from Santa Cruz Biotechnology (sc-31173) worked well in 
immunocytochemical staining of PAE cell lines stably expressing wild-type VEGFR-1, 
confirming its correct localization at the plasma membrane (Figure 21b; VEGFR-1 
staining in green). A summary of our experiments with various VEGFR-1 antibodies, 
showing their different applicability, is shown in Table 9. 
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(b) 
(a) 
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Figure 21: Antibodies used for VEGFR-1 detection. (a) Immunoblot analysis on cell lysates 
from non-transfected or VEGFR-1-expressing PAE cell lines using several antibodies against 
VEGFR-1. Samples from equal cell numbers  were loaded in each gel. (b) Immunostaining of 
non-transfected or VEGFR-1-expressing PAE cells using the Santa Cruz anti-VEGFR-1 
antibody and a Dylight 488-labeled secondary antibody. Left panel: Dylight 488 fluorescence 
image; middle panel: phase contrast image; right panel: overlay. 
 
 
Antibodies 
 
 
Dilution 
  
Blocking/ 
dilution 
buffer 
 
Incubation 
Time/temperature 
 
Immuno-
floresce
nce 
 
Western blot 
Flt-1 (C17) 
(sc-31173 
Santa Cruz 
Biotechnolog
y, Inc.) 
 
1:400 
 
1% BSA in 
PBS 
One hour at room 
temperature 
Good × 
VEGF 
Receptor 1 
Antibody  
(2893S Cell 
Signaling) 
 
1:1000 
 
5% BSA in 
TBST 
 
 
Overnight at 4°C × 
Good 
 
Anti Flt-1 
(AF321 R&D 
systems) 
 
1:200 
 
5% BSA in 
TBST 
 
One hour at room 
temperature 
_ × 
Anti-VEGF 
Receptor 1 
[Y103] 
(ab32152 
Abcam) 
 
1:1000 
 
5% BSA in 
TBST 
 
 
Overnight at 4°C 
× _ 
Anti-
phospho-Flt-
1 (Tyr1213)  
(07-758 
Millipore) 
 
1:1000 
3% milk in 
TBST with 
washes in 
water 
 
 
Overnight at 4°C 
_  
Good 
Anti-Phospho 
Flt-1 
(Tyr1213) 
(AF4170 
R&D 
systems) 
 
1:1000 
 
5% milk for 
blocking 
and 2% milk 
for antibody 
in TBST 
 
One hour at room 
temperature 
_ × 
Table 9: Antibodies tested for detection of VEGFR-1 expression in PAE cells. TBST: Tris-
buffered Saline, 0.1 % Tween-20. 
Next, we studied the parameters regulating ligand-induced VEGFR-1 activation in 
stable PAE cell lines. We tested two VEGFR-1 ligands, PlGF and VEGF-A165, at 
different concentrations and with different stimulation times, and assessed VEGFR-1 
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activation by detecting Y1213 phosphorylation by western blot (Figure 22). We chose 
Y1213 based on studies of VEGFR-1-associated proteins, which revealed that 
phosphorylated Y1213 within VEGFR-1 is a major binding site for PI-3 KINASE and 
Nck (Igarashi et al., 1998). VEGF-A165 was recombinantly produced in our laboratory, 
whereas PlGF was obtained from three different sources: Reliatech (PlGF-2, 300-020), 
R&D systems (264-PG-010) and Peprotech (100-06). We detected VEGFR-1 
phosphorylation only upon stimulation with PlGF from Peprotech and VEGF-A165. PlGF 
was able to stimulate VEGFR-1 phosphorylation when used at 0.25 nM or 1.5 nM for 
5 min, whereas VEGF-A165 required 10 min of stimulation to give comparable results 
(Figure 22a). Maximal receptor activation was achieved after stimulation with 0.25 nM 
PlGF from Peprotech for 5 min (Figure 22b). 
 
Figure 22: Ligand-induced VEGFR-1 activation. (a) PAE cells stably expressing VEGR-1 
were stimulated with various concentrations of VEGF-A121 or PlGF from different sources, for 
different time points. The levels of Y1213 phosphorylated and total VEGFR-1 were assessed 
in whole cell lysates by western blotting.  (b) Western blot analysis of time-course of VEGFR-
1 phosphorylation (Y1213) in stable PAE cells expressing wild-type VEGFR-1 when stimulated 
with 0.25nM PlGF. 
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Having established an expression system and kinase assay to study VEGFR-1 
activation, we proceeded to study the activity of domain 5 double (E513A/K517A; 
T455E/K517A) and triple (T455W/E513A/K517A; T455E/E513A/K517A) VEGFR-1 
mutants. The constructs were cloned into the mammalian expression vector pcDNA3.1 
and used to generate stable PAE cell lines through chemical transfection (PEI; Aldrich 
408727, 25 kDa branched). Most of the mutants showed weak expression levels 
compared to the wild-type (Figure 23a). Alternatively, we generated PAE cell lines 
stably expressing wild-type, domain 5_E513A/K517A and domain 
5_T455W/E513A/K517A VEGFR-1 by lentivirus transduction. However, the 
expression levels of the various VEGFR-1 constructs in the PAE cell lines generated 
by lentiviral transduction were poor compared to the expression of wild-type VEGFR-
1 in PAE cell lines generated by PEI transfection (Figure 23b). We suspect that the 
large size of the inserts (4 kb) reduced the viral packaging efficiency and hence led to 
weak expression of recombinant proteins. Therefore, we were unable to use these cell 
lines to study receptor phosphorylation of the domain 5 mutants upon ligand activation, 
and we sought an alternative system using chimeric VEGFR-1/2 constructs as 
described in the following section 7.3.2.  
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Figure 23: Stable PAE clones expressing wild-type and domain 5 mutants of VEGFR-1. 
(a) PAE cells lines expressing either wild-type, T455E/K517A, E513K/K517A or 
T455E/E513K/K517A VEGFR-1 were generated by chemical transfections with PEI. Whole 
cell lysates from different cell clones were analyzed by western blotting using an anti-VEGFR-
1 antibody (2893S Cell Signaling). Samples from equal number of cells were loaded..  (b) PAE 
cells lines expressing either wild-type, E513K/K517A or T455E/E513K/K517A VEGFR-1 were 
generated by lentriviral transduction. Whole cell lysates were analyzed by western blotting 
using an anti-VEGFR-1 antibody (2893S Cell Signaling). The expression levels of VEGFR-1 
were compared to those from PAE cells transfected with wild-type VEGFR-1 using PEI.  Equal 
protein loading was confirmed with an anti-β-actin antibody. 
7.3.2. Functional analysis of chimeric VEGFR-1/2 domain 5 mutants 
As an alternative strategy to study VEGFR-1 activation and its dependency on the 
homotypic interactions involving domain 5, we generated chimeric VEGFR-1/2 
constructs, consisting of the extracellular domain of VEGFR-1 (residues 1-752; wild-
type, domain 5_E513K/K517A and domain 5_T455W/E513K/K517A), followed by the 
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intracellular domain of VEGFR-2 (residues 759-1356). Stable PAE cell lines were 
generated by chemical transfections (PEI; Aldrich 408727, 25 kDa branched). Upon 
clonal selection, the total expression levels of the chimeric receptor was assessed by 
Western blot using an anti-VEGFR-2 antibody, since the anti-VEGFR-1 antibody was 
specific for the intracellular domain of the receptor (Figure 24). We obtained a strong 
expressing clone for wild-type chimeric VEGFR-1/2 (clone 8; lane 3) but only weak 
expressing clones for the domain 5 mutants. Because of the unequal expression of 
wild-type and mutant PAE cell lines we were unable to carry out quantitative kinase 
activity studies in this system. 
 
 
Figure 24: Stable PAE clones of VEGFR-1/2 wild-type and domain 5 mutants. PAE cells 
lines expressing either wild-type, E513K/K517A or T455E/E513K/K517A VEGFR-1/2 chimeras 
were generated by PEI transfections. Whole cell lysates from different cell clones were 
analyzed by western blotting using an anti-VEGFR-2 antibody. Samples from equal number of 
cells were loaded. 
However, we could achieve similar expression levels between wild-type and domain 
5_E513K/K517A VEGFR-1 constructs in transiently transfected NIH3T3 cells. 
Consequently, the cells were stimulated with 0.25 nM PlGF (Peprotech; 100-06) for 5 
min according to our previous results (Figure 22) and receptor activation was assessed 
in whole cell lysates by immunoblotting with an antibody specific for pY1175, the major 
phosphorylation site of VEGFR-2. Wild-type VEGFR-1/2 showed considerably higher 
phosphorylation activity compared to chimeric mutant E513K/K517A (Figure 25). 
Similar kinase assays using the triple mutant T455W/E513K/K517A were inconclusive 
due to unequal expression of mutant and wild-type receptors. However, the results with 
the double mutant indicate that the homotypic contacts in domain 5 revealed by our 
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VEGFR-1 ECD/VEGF-A structure are functionally relevant and thus crucial for ligand 
induced dimerization and receptor activation. 
 
Figure 25: Effect of domain 5 mutations on activation  of chimeric VEGFR1/2 constructs. 
NIH3T3 cells transiently expressing chimeric VEGFR-1/2 [VEGFR-1 ECD (residues 1-752) and 
intracellular domain of VEGFR-2 (residues 759-1356)] wild-type and domain 5 mutants were 
stimulated with 0.25 nM PlGF for 5 min. Phosphorylation activity was determined in whole cell 
lysates by immunoblotting with pY1175 and tVEGFR-2 (total) antibodies. Samples from equal 
number of cells were loaded. 
7.3.3. Functional analysis of VEGFR-2 domain 5 mutants 
To further verify the relevance and universality of the domain 5 homotypic contacts 
observed in our VEGFR-1 structure in receptor activation, we mutated the 
corresponding residues (T446, E508 and K512) in the domain 5 of VEGFR-2. We first 
tested whether HEK293 cells expressing wild-type VEGFR-2 were a suitable system 
to study ligand-induced receptor activation. Transient transfection were carried with 
several different transfection agents and the total levels of VEGFR-2 were assessed 
by immunoblotting. Lipofectamine 2000 and Lipofectamine 3000 showed superior 
transfection efficiency when compared to Fugene (Figure 26). Mock transfected cells 
were used as a negative control. However, the basal levels of receptor activation were 
too high. The spontaneous transactivation of the receptor kinase, possibly because of 
overexpression at the cell membrane, prevented us from using these cells to study the 
effect of domain 5 homotypic interactions on ligand-induced receptor activation (Figure 
27).  
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Figure 26: Effect of different transfection agents on the expression of VEGFR-2 in 
HEK293 cells. HEK293 cells were transfected with the pBE VEGFR-2 plasmid, using different 
transfection reagents: Lipofectamine 2000, Fugene and Lipofectamine 3000. Cells were 
harvested 25 h post-transfection and whole cell lysates were analyzed by western blotting 
using an anti-VEGFR-2 antibody. Samples from equal number of cells were loaded. 
 
Figure 27: VEGFR-2 overexpression in HEK293 cells prevents ligand-induced activation. 
HEK293 cells transiently expressing VEGFR-2 wild-type and domain 5 mutants were 
stimulated with 1.5 nM VEGF-A165. Phosphorylation activity was determined in whole-cell 
lysates by immunoblotting with pY1175 and total VEGFR-2 antibodies. Samples from equal 
number of cells were loaded. 
 
On the contrary, we were successful in generating NIH3T3 cells expressing wild-type 
VEGFR-2 with low basal activity that was sensitive to ligand stimulation. The cells were 
transiently transfected using Lipofectamine 2000 and PEI, with PEI transfections being 
more efficient and giving clearer protein bands compared to Lipofectamine 2000 
transfection. Therefore, we used transient transfections of NIH3T3 cells with PEI to 
express the domain 5 T446E/K512A and T446E/ E508A/K512A VEGFR-2 mutants. 
The cells were stimulated with 1.5 nM VEGF-A165 for 10 min and receptor activation 
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was assessed in whole cell lysates by immunoblotting with an antibody specific for 
pY1175. Receptor phosphorylation was greatly reduced in domain 5 double 
(T446E/K512A) and triple (T446E/ E508A/K512A) mutants compared to the wild-type 
(Figure 28). This shows that the conserved key residues involved in domain 5 
interactions are crucial for VEGF-A-induced VEGFR-2 tyrosine autophosphorylation. 
In order to investigate the mutual importance of domain 5 and 7 homotypic interactions 
in VEGFR-2 activation, we made additional mutant constructs: domain 7_R726A, 
domain 7_R726A_domain 5_ T446E/K512A, domain 7_R726A_ domain 5_T446E/ 
E508K/K512A. The mutation R726A in domain 7 has been reported earlier to 
significantly reduce kinase activation due to the inability to form the inter-receptor salt 
bridge leading to destabilization of the receptor dimers (Hyde et al., 2012; Yang et al., 
2010). Also, an analogous mutation R737A in domain 7 of VEGFR-3 together with 
domain 5 homotypic mutations showed an additional inhibitory effect in activation of 
VEGFR-3 (Leppänen et al., 2013). However, these constructs could not be tested 
during this work due to lack of time. 
 
Figure 28: Effect of domain 5 mutations on VEGFR-2 activation. NIH3T3 cells transiently 
expressing VEGFR-2 wild-type and domain 5 mutants were stimulated with 1.5 nM VEGF-A165. 
Phosphorylation activity was determined in whole-cell lysates by immunoblotting with pY1175 
and total VEGFR-2 antibodies. Samples from equal number of cells were loaded. 
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7.4 Structure of the full-length VEGFR-1 ECD in complex with 
VEGF-A 
In this section, a re-print of the publication of results obtained during PhD is attached 
to give an overview. My contribution is the biochemical analysis of receptor mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Article
Structure of the Full-length VEGFR-1 Extracellular
Domain in Complex with VEGF-A
Graphical Abstract
Highlights
d First full-length structure of the VEGFR-1 ectodomain bound
to its cognate ligand
d Description of unique strategy to determine crystal structures
at medium resolution
d Characterization of VEGFR ligand speciﬁcity and homotypic
receptor interactions
d Paradigm for type V receptor tyrosine kinase activation and
therapeutic inhibition
Authors
Sandra Markovic-Mueller,
Edward Stuttfeld,
Mayanka Asthana, ..., Kaisa Kisko,
Guido Capitani, Kurt Ballmer-Hofer
Correspondence
kurt.ballmer-hofer@unibas.ch
In Brief
Markovic-M€uller et al. describe the ﬁrst
full-length ectodomain structure of a type
V receptor tyrosine kinase, VEGFR-1, in
complex with its cognate ligand, VEGF-A.
The structure reveals the details of
regulatory homotypic receptor
interactions representing putative targets
for therapeutic receptor inhibition.
Accession Numbers
5T89
Markovic-Mueller et al., 2017, Structure 25, 341–352
February 7, 2017 ª 2016 Elsevier Ltd.
http://dx.doi.org/10.1016/j.str.2016.12.012
Structure
Article
Structure of the Full-length VEGFR-1
Extracellular Domain in Complex with VEGF-A
Sandra Markovic-Mueller,1,5,6 Edward Stuttfeld,2,5 Mayanka Asthana,1,5 Tobias Weinert,1 Spencer Bliven,1,4
Kenneth N. Goldie,3 Kaisa Kisko,1 Guido Capitani,1 and Kurt Ballmer-Hofer1,7,*
1Paul Scherrer Institute, Laboratory of Biomolecular Research, 5232 Villigen, Switzerland
2Biozentrum, University of Basel, 4056 Basel, Switzerland
3Center for Cellular Imaging and Nano Analytics (C-CINA), Biozentrum, University of Basel, 4056 Basel, Switzerland
4National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
5Co-ﬁrst author
6Present address: leadXpro AG, PARK INNOVAARE, 5234 Villigen, Switzerland
7Lead Contact
*Correspondence: kurt.ballmer-hofer@unibas.ch
http://dx.doi.org/10.1016/j.str.2016.12.012
SUMMARY
Vascular endothelial growth factors (VEGFs) regulate
blood and lymph vessel development upon activation
of three receptor tyrosine kinases: VEGFR-1, -2,
and -3. Partial structures of VEGFR/VEGF complexes
based on single-particle electron microscopy, small-
angle X-ray scattering, and X-ray crystallography
revealed the location of VEGF binding and domain
arrangement of individual receptor subdomains.
Here, we describe the structure of the full-length
VEGFR-1 extracellular domain in complex with
VEGF-Aat 4 A˚ resolution.We combinedX-ray crystal-
lography, single-particle electron microscopy, and
molecular modeling for structure determination and
validation. The structure reveals themolecular details
of ligand-induced receptor dimerization, in particular
of homotypic receptor interactions in immunoglob-
ulin homology domains 4, 5, and 7. Functional
analyses of ligand binding and receptor activation
conﬁrm the relevance of these homotypic contacts
and identify them as potential therapeutic sites to
allosterically inhibit VEGFR-1 activity.
INTRODUCTION
The formation of functional blood and lymphatic vessels is a
keystone during embryo development and is essential for sup-
plying all organs with oxygen and nutrients and for disposal of
catabolites. Vascular endothelial growth factors (VEGFs) are
themain drivers of vasculogenesis, the de novo formation of ves-
sels, and angiogenesis, the formation of new vessels frompreex-
isting vasculature (reviewed in Smith et al., 2015; Shibuya, 2014;
Moens et al., 2014). VEGFs activate VEGFR-1, -2, and -3, repre-
senting the type V subfamily of receptor tyrosine kinases (RTKs)
in the human kinome (Shibuya, 2013).
Mutation or ablation of a speciﬁc VEGFR gave rise to distinct
disease proﬁles (Shibuya, 2014), documenting signal diversity
among these three receptors. Both ablation of VEGFR-1
and -2 were embryonic lethal; the former due to severe disorga-
nization of blood vessels (Fong et al., 1995) and the latter
because of the complete absence of endothelial cells (Shalaby
et al., 1995). Interestingly, mice expressing kinase-deﬁcient
VEGFR-1 instead of wild-type showed only minor vascular de-
fects (Hiratsuka et al., 1998, 2001). Deregulated expression of
a soluble splice variant of VEGFR-1, encompassing only the
extracellular domain (ECD) and acting as a ligand trap (Kendall
and Thomas, 1993), is associated with vascular defects such
as the placental deﬁciency preeclampsia (Luttun and Carmeliet,
2003; Maynard et al., 2003) or corneal (Ambati et al., 2006) and
retinal avascularity (Luo et al., 2013).
RTK activation requires ligand-mediated dimer or multimer
formation, which instigates transmembrane signaling resulting
in activation of the intracellular kinase domain (Lemmon and
Schlessinger, 2010). The exact structural changes driving this
process are unique for each RTK subfamily and are not known
for VEGF receptors.
A low-resolution structure of a VEGFR-2 ECD/ligand complex
showed that of the seven immunoglobulin homology domains (Ig
domains) comprising the receptor ECD, Ig domains 1–3 form the
ligand binding site while domains 4–7 are involved in homotypic
receptor contacts, presumably regulating receptor dimerization
and activation (Ruch et al., 2007). In addition, high-resolution in-
formation for Ig domains D2–3 and D1–2 of VEGFR-2 and -3,
respectively, bound to VEGF (Lepp€anen et al., 2010, 2013;
Brozzo et al., 2012) is available. For VEGFR-1, there are X-ray
structures for VEGF-A, -B, and placental growth factor (PlGF),
respectively, in complex with D2 (Christinger et al., 2004; Wies-
mann et al., 1997; Iyer et al., 2010). These structures show
how the membrane distal Ig domains mediate ligand binding,
in particular how three highly variable loops present in all VEGF
family ligands interact with the receptor ECD. High-resolution in-
formation on the VEGFR membrane-proximal Ig domains has so
far been obtained by crystallizing speciﬁc subdomains in isola-
tion. The crystal structure of Ig domain 7, together with functional
experiments using receptor mutants (Yang et al., 2010), revealed
the importance of homotypic contacts between the conserved
residues R726 and D731 present in the EF loop for ligand-
induced activation of VEGFR-2. A recent crystal structure of Ig
domains 4–5 of VEGFR-3 pointed to additional receptor-recep-
tor interactions in D5 (Lepp€anen et al., 2013). These D5
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interactions were a consequence of crystal packing. However,
similar to the D7 contacts observed earlier for VEGFR-2 (Yang
et al., 2010; Hyde et al., 2012; Ruch et al., 2007), functional anal-
ysis showed that these contacts are indispensable for receptor
activation. We focused on the structural characterization of
full-length VEGF receptor ECD complexes and succeeded in
determining the structure of the VEGFR-1 ECD in complex with
VEGF-A at 4 A˚ resolution. The structure allows for the ﬁrst time
detailed visualization of ligand binding and ligand-induced ho-
motypic interactions in a complete VEGF receptor ECD/VEGF
complex and opens new possibilities for future drug design.
RESULTS
Structure Determination of the VEGFR-1 Extracellular
Domain/VEGF-A Complex
We determined the structural organization of the full-length ECD
of VEGFR-1 in complex with VEGF-A using X-ray crystallog-
raphy. Human VEGFR-1 baculovirus expression constructs
encompassing Ig domains D1–7, D1–6, and D2–7 (Figure 1A)
were expressed in insect cells, puriﬁed, and crystallized in com-
plex with VEGF-A. Complex formation between ligand and re-
ceptor ECD proteins and monodispersity of the complexes was
determined by size-exclusion chromatography coupled to
multi-angle light scattering (SEC-MALS) and small-angle X-ray
scattering (SAXS; Supplemental Experimental Procedures).
VEGF-A co-eluted from an SEC column with the VEGFR-1 ECD
(Figure S1A), and molecular weight determination by SEC-MALS
indicated 1:1 dimer formation of the full-length VEGFR-1 ECD
with VEGF-A (Figure S1B). In addition, an increase in the radius
of gyration (Rg) and of the maximal length of the complex
(Dmax) in the presence of ligand was observed in the distance dis-
tribution function determined by SAXS, conﬁrming the presence
of a stable ligand/receptor complex (Figure S1C).
After various optimization rounds, we obtained crystals of the
D1–6 complex diffracting to 4 A˚ that were suitable for structure
determination (Table 1). Crystals belonged to space group C2
with one complex per asymmetric unit and a solvent content of
70%. Enabled by a novel data collection strategy (Weinert
et al., 2015), the structure of the VEGFR-1 D1–6/VEGF-A com-
plex was solved by a combination of molecular replacement
(MR) and single-wavelength anomalous dispersion (SAD) using
iodide-soaked crystals (Figure 1B). The resulting electron den-
sity map revealed the D2 region and the ligand, positioned by
molecular replacement, and contained continuous electron den-
sity for the missing Ig domains (Figure S2). D3, D4, and D5 were
placed by additional rounds of phased molecular replacement,
and proper sequence assignment was performed by replacing
the molecular replacement search models with the correspond-
ing homology models generated by the SWISS-MODEL homol-
ogy modeling server. Because of their less well-deﬁned electron
density and the lack of good homology modeling templates, D1
and D6 were modeled using the Foldit structure prediction game
(Cooper et al., 2010). The best D1 and D6 models were selected
for further manual reﬁnement based on their performance as
search models in molecular replacement (Figure S3).
Anomalous scattering of selenium-methionine (Se-Met) is a
powerful structure and sequence validation tool. In the absence
of diffracting Se-Met derivative crystals, we turned to sulfur SAD
to validate our ﬁnal model of the VEGFR-1 D1–6/VEGF-A com-
plex (Figure 2). With weakly diffracting crystals, careful data
collection was crucial to obtain the accuracy necessary for res-
olution of the small anomalous signals. Despite the crystals dif-
fracting only to 4 A˚ resolution, more than half of all anomalous
scatterers, including every disulﬁde bridge in the Ig domains
and the VEGF-A ligand, as well as several methionines were as-
signed in the anomalous difference Fourier maps, verifying sub-
unit placement as well as sequence assignment (Figure 2B). In
addition, positive electron density present in the Fo  Fc maps
for N-linked glycans around the asparagine residues predicted
to be glycosylated further aided in exact sequence assignment.
To complete the molecular structure of the VEGFR-1 ECD, we
also used crystals of the VEGFR-1 D2–7/VEGF-A complex
diffracting to 4.8 A˚. The D1–6 complex structure was used as a
search model for molecular replacement of the D2–7/VEGF-A
complex (Figure 1C). To create a composite model of the
D1–7/VEGF-A complex, we superimposed the two structures,
D1–6/VEGF-A and D2–7/VEGF-A (root-mean-square deviation
[RMSD] of 1.76 A˚ for 1,128 residues of the D2–6 region) and
connected the D7 portion of the D2–7/VEGF-A model with the
D1–6/VEGF-A-based model (Figure 1D).
Overall Architecture of the VEGFR-1 ECD/VEGF-A
Complex
The structures of the D1–6 and the D2–7 VEGF-A complexes both
show 2:2 stoichiometry and contain two sets of 1:1 complexes in
the asymmetric unit related by 2-fold non-crystallographic
symmetry (NCS). In the composite model of the VEGFR-1 ECD/
VEGF-A complex (Figure 1D), two receptor chains are bridged
with the dimeric VEGF-A ligand in the D2–3 region and related
by 2-fold symmetry throughout the long axis of the complex.
The complex has overall dimensions of 160 A˚ 3 230 A˚ 3
80 A˚ and is characterized by the existence of three cavities:
the upper one formed between the VEGF-A dimer D3 and D4 do-
mains of two receptor chains (dimensions 65 A˚ 3 50 A˚); the
middle one between the D4 and D5 domains (30 A˚ 3 15 A˚);
and the lower one between the D5, D6, and D7 domains (55 A˚
3 50 A˚). VEGF-A binding to D2 and D3 induces a twisted
arrangement between these two domains, with a bending angle
of 135. This is followed by intertwining of receptor chains in
D4–5 bringing two protomers in close proximity to each other.
The twist angle between D4 and D5 within the same chain is
60. Additional homotypic contacts are observed betweenD7do-
mains. In ourmodel the D7 dimer deviates from the D1–6/VEGF-A
2-fold axis, which is a consequence of crystal packing of the D2–
7/VEGF-A complex. This ﬁnding suggests ﬂexibility in the D6–7
region due to a longer linker between these two domains.
To conﬁrm the overall structure of the VEGFR-1 ECD/VEGF-A
complex, we additionally visualized the complex by negative
stain electron microscopy (Figure 3A). The calculated class aver-
ages showed excellent agreement with projections of the crystal
structure (Figure 3B). All class averages show dimeric VEGFR-1
ECD chains bridged by VEGF-A. Interestingly, a slight bend is
observed in the membrane-proximal region, conﬁrming the
kinked D6–7 region seen in the D2–7/VEGF-A crystal structure.
As there is a clear preference for the complex to adsorb to the
grid showing the front view, only one class was generated of
the side view.
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Structure and Glycosylation of Individual Ig Domains
This is the largest structure determined so far in the VEGF
receptor family and allows us to describe the structure and
arrangement of the individual Ig domains of VEGFR-1. With
the exception of D6, all Ig domains of VEGFR-1 belong to the I
Figure 1. Structure of the VEGFR-1 Extracel-
lular Domain in Complex with VEGF-A
(A) Schematic overview of the domain organization
of VEGFR-1. Crystallized constructs are indicated.
Cartoon representation of the VEGFR-1 D1–6/
VEGF-A complex (B) and of the VEGFR-1 D2–7/
VEGF-A complex (C) structures. The chains of
the VEGF-A homodimer are shown in purple and
orange, the two chains of VEGFR-1 D1–6 in yellow
and magenta, and the VEGFR-1 D2–7 chains
in light and dark gray. N-linked glycans are de-
picted as spheres. The N- and C-terminal residues
of VEGF-A, and VEGFR-1 D1–6 and D2–7,
respectively, visualized in the two structures are
indicated.
(D) Composite model of the VEGFR-1 ECD/VEGF-A
complex. One half of the complex is represented as
surface with N-linked glycans depicted as spheres
and the other half as a cartoon with N-linked gly-
cans depicted as sticks. The D7 homodimer shown
in gray was positioned by superimposing VEGFR-1
D2–7/VEGF-A onto VEGFR-1 D1–6/VEGF-A. The
dimensions of the complex and the axis of rotation
relating the two views are also shown.
set of the Ig domain superfamily. D1 (res-
idues 32–130) was modeled by Foldit
players and subsequently rebuilt during
reﬁnement. Although the experimental
electron density map suggested large
disordered regions, the 2Fo Fc maps al-
lowed us to build all residues except the
D-E loop (residues 78–84), which was
disordered. Additional electron density
around N100 conﬁrmed the presence of
an N-linked glycan, and the position of a
disulﬁde bridge between C53 and C107
was validated by sulfur-SAD experi-
ments. The structure of D2 (residues
132–225) was solved before (Wiesmann
et al., 1997), and our structure addition-
ally shows N-glycosylation of N164 and
N196. D1 is bent away by 80 from D2
and has no contact with the ligand. The
bent conformations of the D1–2 modules
of VEGFR-1 and VEGFR-3 (Lepp€anen
et al., 2013) are very similar and can be
aligned with an RMSD of 1.66 A˚ for 161
residues (Figure S4). D3 (residues 226–
330) is an elongated Ig domain with
N-glycosylation of N251 and N323. D4
(residues 333–426) is a smaller Ig domain
not disulﬁde bridged between the b
sheets and lacking b strand 4. D4 is gly-
cosylated at N402 and N417. D5 (resi-
dues 428–554) is the largest Ig domain in VEGF receptors due
to a long C-D loop that connects two b sheets. Residues 474–
486 within this region were disordered and therefore omitted
from the ﬁnal model. In D5, we observed N-glycosylation of
N547 and veriﬁed the positions of the disulﬁde bridge between
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C454 and C535 and of all methionines by S-SAD (Figure 2). With
our data, we obtained for the ﬁrst time structural information on
D6 of VEGF receptors, which belongs to the C2 set of Ig do-
mains. D6 (residues 555–654) contains strands of intermediate
length in both b sheets, a disulﬁde bridge between C577 and
C636, and an N-linked glycan at N625. D7 (residues 661–750)
was modeled using D7 of VEGFR-2 (PDB: 3KVQ) as a template.
Due to the low resolution of the VEGFR-1 D2–7 complex data-
set, we do not further discuss its structural details. However,
D7 of the two protomers form a dimeric arrangement as
described in the crystal structure of isolated VEGFR-2 D7
(Yang et al., 2010).
VEGF-A Interacts with D2 and D3 of VEGFR-1
Ligand binding to VEGFR-1 takes place in Ig domains 2 and 3.
With our structure, we can now describe the complete ligand
binding site of VEGFR-1, while earlier published VEGFR-1 com-
plex structures contained only D2 (Christinger et al., 2004; Iyer
et al., 2010; Wiesmann et al., 1997). In the VEGFR-1 D1–6/
VEGF-A model, residues 13–108 of VEGF-A121 are visible in
the electron density. Each receptor chain interacts with both
VEGF-A protomers (Figure 4A). The surface buried on one recep-
tor chain by the bound VEGF-A dimer is 1,500 A˚2, with D2 and
D3 contributing similar interface areas (800 A˚2 for D2 versus
700 A˚2 for D3). VEGF-A residues interacting with D2 are part
of the N-terminal helix a1 of the ligand protomer A (M17, F18,
Y21, Q22, and Y25) and of strands b2 (I46, K48), b4 (Q79, M81,
I83), and b5 (Q89, I91) of protomer B (Figure 4B). While the inter-
face between ligand and D2 is largely hydrophobic, the contacts
with D3 are hydrophilic, comprising a number of possible ionic
interactions. There is an overall positive charge of the D3 region
that comes in contact with the ligand. We identiﬁed several
charged residues from all three loops (L1, L2, and L3) of VEGF-A
interacting with D3. The most prominent conserved residue is
E64 in L2 that engages ﬁve charged residues located in D3 of
the receptor (N259, R261, R280, Q284, and N290) in
hydrogen-bond- and salt-bridge-type interactions. Another res-
idue from L2, D63, forms salt bridges with R224 located in the
D2–3 linker (Figure 4C). In addition, E44 in L1 and K84 in L3
form hydrogen bonds with Q263 of D3. Loops 1 and 3 also carry
hydrophobic residues such as P40, I43, and P85 that form a
complementary surface with D3 of VEGFR-1. I43 protrudes
Table 1. Data Collection and Reﬁnement Statistics
VEGFR-1 D1–6/VEGF-A VEGFR-1 D2–7/VEGF-A
Data Collection
Crystal Native Iodide-SAD Sulfur-SAD Native
Wavelength (A˚) 1 1.6 2.066 1
Space group C2 C2 C2 C2
Unit cell
a, b, c (A˚) 166.7, 123.1, 167.4 166.7, 125.1, 167.9 166.6, 125.0, 168.3 163.5, 121.5, 141.6
a, b, g () 90.0, 109.6, 90.0 90.0, 109.6, 90.0 90.0, 109.4, 90.0 90.0, 90.02, 90.0
Resolution (A˚) 50–4.0 (4.14–4.0) 50–4.1 (4.21–4.1) 50–4.0 (4.11–4.0) 50–4.8 (4.972–4.8)
Rmeas (%) 19.5 (194.7) 18.8 (221.6) 16.8 (277.4) 11.3 (190.4)
CC1/2 0.998 (0.607) 1 (0.749) 1 (0.695) 0.999 (0.755)
I/sI 9.53 (1.28) 16.35 (1.76) 23.72 (1.50) 10.57 (1.15)
Completeness (%) 99.6 (99.4) 99.8 (99.9) 99.5 (95.9) 99.8 (99.85)
Redundancy 6.9 (7.1) 27.9/24.5 60.2 (26.7) 6.9 (6.8)
Reﬁnement
Resolution (A˚) 20–4.0 20–4.8
No. of reﬂections 26,740 13,416
Rwork/Rfree 28.5/31.5 34.5/38.2
No. of atoms 11,400 11,106
Protein 11,078 10,882
Glycan 322 224
Water – –
B Factors
Protein 182.5 301.8
Glycan 236.2 301.2
Water – –
RMSDs
Bond lengths (A˚) 0.004 0.004
Bond angles () 0.71 1.02
Only one crystal was used to obtain each of the above datasets. Values in parentheses are for the highest resolution shell.
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into the hydrophobic pocket on the D3 surface formed by V262,
M264, V278, and F292. Due to the low resolution of our structure,
some of the above described interactions remain tentative.
Structural comparison of receptor binding epitopes for the
VEGFR-1 ligands VEGF-A, PlGF, and VEGF-B shows that all
three ligands interact similarly with the D2 of VEGFR-1 (Fig-
ure S5). The interaction between the loop L2 of the three ligands
with D3 is also very similar since D63 of VEGF-A is strictly
conserved and E64 is conserved in PlGF and substituted by
aspartate in VEGF-B. Differences are observed in the way the
three ligands interact through the loops L1 and L3 with D3 of
VEGFR-1. While the sequence and structure conservation in
these regions is high between VEGF-A and PlGF, this is not the
case for VEGF-B. Superposition of the VEGFR-1 D2/VEGF-B
complex onto our structure tentatively reveals the structural
arrangement of loops L1 and L3 of VEGF-B in relation to receptor
domain D3. These loops are moved away from D3 and are not
involved in any receptor/ligand interactions in agreement with
a recent study (Anisimov et al., 2013) showing that VEGF-B
does not require D3 for high-afﬁnity binding. Anisimov et al.
also showed that VEGF-B does not promote signaling down-
stream of VEGFR-1. PlGF and VEGF-A, on the other hand, are
angiogenic ligands, and the interaction of L1 with D3 is important
for receptor activation.
VEGFR-1 D4 and D5 Form Homotypic Interactions in the
Presence of Ligand
The structure of the VEGFR-1 D1–6/VEGF-A complex reveals
homotypic interactions in D4 and D5, covering altogether a sol-
vent-accessible area of 1,073 A˚2 per chain (Figures 5A and
5B). The interface between Ig domain 4 is small (201 A˚2 per
chain) and includes several residues that may take part in
hydrogen-bond interactions. R351 in the A-B loop interacts
with K379 from the C-E loop, and K393 of the C-E loop could
be positioned to interact with the backbone of either S380 or
A381 of the adjacent C-E loop (Figure 5C). Determining which
interaction is more likely is difﬁcult at the resolution of our data-
set. The interactions between the residues in the E-F loop pro-
posed earlier based on a KIT ECD structure (Yuzawa et al.,
2007) and the VEGFR-2 D7 structure (Yang et al., 2010) are
not visible in our data.
The homotypic contacts in D5 are, like in VEGFR-3, centered
on the fully conserved residues T455 (b strand B) and K517 (b
strand E) that form hydrogen bonds with the backbone atoms
of S436 and A434 of the other chain (Figure 5C). Furthermore,
a glutamate residue in the D-E loop (E513) conserved in all
VEGFRs interacts via hydrogen bond with Q429 and via a salt
bridge with K433 of the other chain. While the fully conserved
residues are part of the rigid b sheet, their interacting partners
Figure 2. Native-SAD as Validation Tool
(A) Ribbon representation of VEGFR-1 D3 (upper panel) and VEGFR-1 D5 dimer (lower panel) with sulfur peaks detected in anomalous difference Fourier maps.
The map is contoured to 4s.
(B) Ribbon representation of the VEGFR-1 D1–6/VEGF-A complex structure with 86 sulfur atoms presented as spheres. Fifty-one sulfur atoms (60%)
colored in red were detected at 3s in anomalous difference Fourier maps. The sulfur atoms colored in yellow belong mostly to methionines and were not
detected.
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are not conserved and belong to the ﬂexible strands A and A0 and
the helical protrusion between them.
Homotypic Contacts in D4–7 Increase Ligand Binding
and Are Essential for Receptor Activation
The puriﬁed receptor ECD was monomeric, indicating that the
homotypic interactions in D4–7 are weak and apparently depend
on ligand-mediated receptor dimerization (Figure S1). We used
isothermal titration calorimetry to assess the contribution of the
membrane-proximal Ig domains 4–7 to the binding afﬁnity of
the full-length ECD of VEGFR-1 for VEGF-A. Similar to VEGFR-3
(Lepp€anen et al., 2013), D1–7 of VEGFR-1 had signiﬁcantly
higher afﬁnity for the ligand than D1–3 (Figure 6A). The binding
afﬁnity of VEGFR-1 D1–7 for VEGF-A was in the low nanomolar
range (2 nM) while the afﬁnity of VEGF-A for VEGFR-1 D1–3
was 20 times lower (i.e.,  50 nM). Binding of VEGF-A to D1–3
was entropically favored while binding to D1–7 was enthalpically
driven (Figure 6B). Thus, the presence of Ig domains 4–7
increased binding afﬁnity for VEGF-A, presumably due to stabi-
lization through homotypic receptor-receptor contacts in D4–7.
Based on the structural data described here and in our earlier
work (Lepp€anen et al., 2010, 2013; Brozzo et al., 2012; Ruch
et al., 2007; Kisko et al., 2011), we predicted that the contacts
in D5 are essential for receptor function. We mutated the
residues involved in the D5 interaction and determined receptor
activity in transfected NIH3T3 cells. The activity of VEGFR-1 was
too low to obtain high-quality biochemical data; therefore, we
mutated the corresponding residues in D5 of VEGFR-2 based
on a homology model of this domain (for details of the mutants
used, see Figure 6D). In the mutant T446E/K512A, residue
T446 was replaced by E and K512 by A, thus preventing
hydrogen-bond and salt-bridge formation in the dimeric receptor
complex. This mutant showed drastically reduced ligand-
induced receptor phosphorylation (Figure 6C). Taken together,
these data show that the contacts in D5 revealed by our
VEGFR-1 ECD/VEGF-A structure are essential for receptor
activation.
DISCUSSION
We present here the ﬁrst full-length VEGF receptor ECD struc-
ture in complex with one of its ligands, revealing all structural
details of VEGF-A binding to VEGFR-1. Most importantly, our
structure shows the structural details of the homotypic contacts
in D4–7 in the context of the full-length receptor ECD. The func-
tional analysis of these interactions proves their relevance for re-
ceptor activation. We propose that the exact positioning of
ligand-bound receptor protomers in active dimers, which is
essential for kinase activation, is mediated by the concerted
interplay of receptor/ligand interactions in D2–3 and receptor-re-
ceptor interactions in D4, D5, and D7.
Receptor Binding Speciﬁcity of Distinct VEGF Ligands
Using chimeric receptor constructs, it was proposed earlier that
D2 is responsible for the ligand speciﬁcity of VEGFRs (Davis-
Smyth et al., 1996; Cursiefen et al., 2004; Holash et al., 2002).
Structural and biochemical analysis also showed that D3 did
not signiﬁcantly increase afﬁnity of VEGFR-1 ECD constructs to-
ward VEGF-A (Wiesmann et al., 1997). Based on these earlier
studies, interaction with D3 seems therefore not to increase
the receptor binding afﬁnity of VEGF. Our structure shows signif-
icant interaction of all three loops of VEGF with D3, suggesting
Figure 3. Negative -Staining EM Analysis of the VEGFR-1 D1–7/VEGF-A Complex
(A) A gallery of 24 2D class averages from image classiﬁcation is shown.
(B) Comparison of the VEGFR-1D1–7/VEGF-A EMclass averageswith the compositemodel shown in Figure 1. Representative class averages (labeled with a star
in [A]) are compared with selected 2D projections and with the corresponding 3D volume models of the VEGFR-1 D1–7/VEGF-A complex. The volumes were
ﬁltered at 25 A˚ resolution. The class average in (B) was rotated by 180 relative to its orientation in (A). Scale bars represent 10 nm.
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that, in the full-length receptor, both D2 and D3 are required for
receptor signaling. D3/VEGF interaction apparently triggers re-
ceptor ECD intertwining, thus inducing homotypic interactions
in D4–5 and D7, which are essential for receptor activation. We
propose that the D3/VEGF interaction plays a role as a sensor
for modiﬁcation of homotypic interactions in D4–7 depending
on the strength of the induced twist between D2 and D3. This
might ultimately lead to different functional output by distinct
VEGF ligands. With the structure of the VEGFR-1 ECD/VEGF-A
complex and the comparison of receptor binding epitopes in
VEGF-A, PlGF, and VEGF-B, we provide a structural basis for un-
derstanding the different signal outputs generated by these three
VEGFR-1 ligands (Figure S5).
The next question that arises is why do VEGF-C, -D, and -E not
bind to VEGFR-1? Sequence conservation between different
VEGF family members varies in the three binding loops. While
the residues in loop L2 are highly conserved within the VEGF
family, there are signiﬁcant sequence and structural differences
in the N-terminal helix a1 and in loops L1 and L3, which presum-
ably deﬁne receptor speciﬁcity of the ligands. The interactions
between residues E44 in L1 and K84 in L3 of VEGF-A with D3
of VEGFR-1 are not conserved in VEGF-C, -D, and -E (Figure S6),
and may thus determine receptor speciﬁcity.
Structural comparison of VEGF-A binding to VEGFR-1, as
described here, with binding to VEGFR-2 (PDB: 3V2A) shows
similar types of interactions. The ligands in the two structures
have very similar structures and can be aligned with an RMSD
of 0.86 A˚ for 190 aligned residues. The difference exists in the
orientation of D3 toward D2, where VEGF-A binding to
VEGFR-1 induces a stronger twist by 11 between D2 and D3
(Figure S4). With the exception of E64 in VEGFR-1, which en-
gages more residues in salt-bridge- and hydrogen-bond-type
interactions, loop L2 interacts similarly with D3 of VEGFR-1 or
VEGFR-2.
To fully understand the differences in the signaling output by
VEGFRs upon binding to a particular VEGF ligand, one needs
to consider also the role of co-receptors. Distinct ligands pro-
mote ternary complex formation, which has an impact on recep-
tor trafﬁcking and signaling (Ballmer-Hofer et al., 2011).
Role of Homotypic Receptor Contacts in VEGFR
Activation
Our structural analysis describes for the ﬁrst time the details of
homotypic contacts in the membrane-proximal domain of type
V RTKs in the context of a full-length ligand-bound receptor
ECD. In addition, we show that mutation of the interacting
interface attenuates receptor activity. This is in agreement with
earlier ﬁndings showing that homotypic contacts in D4–7 are
indispensable for activation of VEGFR-3 (Lepp€anen et al.,
2013) and VEGFR-2 (Yang et al., 2010), and documents the
strong similarity with type III RTKs such as PDGFR (Yang et al.,
2008) and KIT (Yuzawa et al., 2007; Reshetnyak et al., 2015;
Yang et al., 2010). Mutation of the interface of the homotypic
contacts renders KIT oncogenic (Reshetnyak et al., 2015) and
Figure 4. Binding Interface between VEGF-A and VEGFR-1 D2–3
(A) Cartoon representation of D2 and D3 of one receptor chain colored in yellow and VEGF-A chains in orange (chain A) and purple (chain B). Secondary structure
elements are labeled. Three loops in VEGF-A are designated L1, L2, and L3.
(B) VEGFR-1 interaction with the VEGF-A monomer A including N-terminal helix a1 and loop 2 (upper panel) and with the VEGF-A monomer B including loops 1
and 3 (lower panel). The key residues of the ligand are highlighted as sticks and labeled. VEGFR-1 charge distribution at the interaction surface is presented as a
surface potential model (calculated with the APBS module in PyMol).
(C) Interactions of charged residues in VEGF-A L2 (upper panel) and L1 and L3 (lower panel) with VEGFR-1 D3. Hydrogen bonds and salt bridges are shown as
green dashed lines.
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promotes ligand-independent kinase activation. In agreement
with this, we showed earlier that antibody-like molecules such
as DARPins (Stumpp et al., 2008; Binz et al., 2004) binding D4
or D7 of VEGFR-2 block receptor signaling (Hyde et al., 2012).
Ligand-induced homotypic ectodomain contacts in the mem-
brane-proximal domain are thus required for tight control of
type III and V receptors. A detailed comparison of type III and
V receptor ECD structures and possible implications for the
mechanism of receptor activation was published recently by Ver-
straete et al. (2011).
Receptor-receptor interactions in D4 revealed in this work are
in agreement with earlier studies on VEGFR-1 (Barleon et al.,
1997) and VEGFR-2 (Shinkai et al., 1998) that pointed at the
importance of this domain in ligand-induced receptor dimeriza-
tion. Similar interactions were, on the other hand, not observed
in the VEGFR-3 D4–5 structure (Lepp€anen et al., 2013). Since
theD4 interactions in VEGFR-1 occur through theC-E loop,which
is longer in this receptor compared with the other homologs, they
might only be relevant for VEGFR-1 functionality. In our structure,
we did not observe the previously proposed D4 interactions be-
tween residues in the E-F loop of KIT (Yuzawa et al., 2007).
Homotypic interactions in D5 have interesting structural char-
acteristics, with one interacting side composed of a rigid b sheet
(b strands B, D, and E) and the other side being more ﬂexible
(strands A and A0; Figure 5C). The ﬂexible strands A and A0 are
directly linked to D4, suggesting an order of homotypic contact
formation following ligand binding (i.e., formation of interactions
in D4 will be transmitted downstream to D5). This may also
explain heterodimer formation giving rise to VEGFR-1/VEGFR-
2 (Cudmore et al., 2012) and VEGFR-2/VEGFR-3 (Harris et al.,
2013) ligand complexes, where one interacting face is rigid and
fully conserved and the other more ﬂexible, allowing for differen-
tial bond formation.
Here, we show detailed structural information for the isolated
ECD of VEGFR-1 in complex with ligand. In cells, however, the
receptor ECD is membrane bound and separated from the trans-
membrane domain (TMD) via a short linker. We showed earlier
that a distinct conformation of the TMD is required for VEGFR
activation (Manni et al., 2014; Dell’Era Dosch and Ballmer-Hofer,
2010). It is therefore likely that the conformation of the most
membrane-proximal D7 domain and the linker separating it
from the TMD is affected by the presence of the TMD. In other
words, the exact structure of D7 in a ligand-bound, mem-
brane-associated receptor might differ from the structure deter-
mined for the soluble ECD described here. So far, only low-res-
olution single-particle electron microscopy structures are
available for such membrane-proximal domains in the epidermal
growth factor receptor (Mi et al., 2008) and KIT (Opatowsky et al.,
2014), respectively. We propose that the D7 interactions initially
observed in VEGFR-2 (Yang et al., 2010; Ruch et al., 2007), and
now conﬁrmed for VEGFR-1, represent a checkpoint during
formation of active receptor dimers. The restriction ofmobility to-
ward the TMD imposed by homotypic contacts in D5 andD7may
be responsible for stringent control of VEGFR activation.
Taken together, the availability of the structural details of the
full-length VEGFR-1 ECD in complex with VEGF-A presented
Figure 5. Homotypic Interactions between Ig domains 4 and 5 of VEGFR-1
(A) Surface representation of the D4–5 dimer. D4 on two chains are colored in pale yellow and light magenta and D5 is shown in yellow-orange and purple. The
rotation axis relating the views is shown. The twist angle between D4 and D5 within the same chain is 60.
(B) Cartoon representation of the D4–5 dimer with labeled b strands. The E-F loop in D4 is colored in green, illustrating that residues that are part of this loop in
VEGFR-1 do not interact.
(C) Zoom-in view into the interface of D4 (top) and D5 (bottom). Interacting residues are shown as sticks and hydrogen bonds and salt bridges as green
dashed lines.
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here allow a detailed mechanistic interpretation of the role of in-
dividual Ig domains in receptor dimerization and activation. Most
drugs targeting VEGF receptors to interfere with aberrant vascu-
larization available today are speciﬁc for VEGFR-2. The role of
VEGFR-1 in angiogenesis, and particularly in tumor angiogen-
esis, has recently attracted high attention as it seems to be rele-
vant for de novo vascularization as demonstrated for instance by
Massena et al. (2015). Additional relevance of VEGFR-1 in path-
ological angiogenesis has been observed in cancer models (Van
de Veire et al., 2010; Schomber et al., 2007). The discovery of the
mechanism of receptor activity modulation by domains 4–7
described here opens new possibilities for developing novel,
highly speciﬁc VEGF receptor antagonists for future medical
applications.
EXPERIMENTAL PROCEDURES
Crystallization and Structure Determination
Crystallization
The VEGFR-1 D1–6/VEGF-A and the VEGFR-1 D2–7/VEGF-A complexes used
for crystallizationwere partially deglycosylated with PNG-ase F and puriﬁed by
SEC. Both complexes were crystallized in sitting drops at 20C. The best dif-
fracting crystals of the VEGFR-1 D1–6/VEGF-A complex were obtained from a
reservoir solution containing 200 mM CaI2, 100 mM 2-(N-morpholino)ethane-
sulfonic acid (pH 6.5), and 10–14% PEG 3000 (w/v) and of the VEGFR-1 D2–7/
VEGF-A complex from a reservoir solution containing 200 mM NaCl, 100 mM
Na/K-phosphate (pH 6.2), and 10% PEG 8000 (w/v). The crystals of both com-
plexes belonged to space group C2 with one complex per asymmetric unit, a
solvent content of 70%, and the following cell parameters: VEGFR-1 D1–6/
VEGF-A a = 166.7, b = 123.1, c = 167.4 A˚, b = 109.6; VEGFR-1 D2–7/
VEGF-A a = 163.5, b = 121.5, c = 141.6 A˚, b = 90.02. Iodide derivatives of
the VEGFR-1 D1–6/VEGF-A complex were prepared by soaking the crystals
in a reservoir solution containing 100 mM CaI2 for 3 hr. For cryoprotection,
the crystals were transferred stepwise into mother liquor containing increasing
concentrations of glycerol to a ﬁnal concentration of 20%, ﬂash frozen, and
stored in liquid nitrogen.
Structure Determination
All datasets were collected on the X06DA beamline at the Swiss Light Source
(SLS) at the Paul Scherrer Institute in Villigen, Switzerland on a PILATUS 2M
detector (Dectris). A complete dataset to 4 A˚ resolution was collected from a
single native crystal of the VEGFR-1 D1–6/VEGF-A complex. Highly redundant
anomalous data were obtained from a single large crystal derivatized with io-
dide that was measured on multiple positions and orientations using the high-
precision multi-axis goniometer PRIGo (Waltersperger et al., 2015).
Data were indexed, integrated, and scaled with XDS (Kabsch, 1993) and
further processed with CCP4 programs (Collaborative Computational Project,
Number 4, 1994). The structure of the VEGFR-1 D1–6/VEGF-A complex was
Figure 6. Quantiﬁcation of VEGFR-1/VEGF-A Interaction by Isothermal Titration Calorimetry and Receptor Activity of D5 Mutant
(A) Raw titration data and integrated and concentration normalized isothermograms of VEGF-A binding to the VEGFR-1 D1–3 (left panels) and VEGFR-1 D1–7
(right panels). Solid lines in the isothermograms represent the best ﬁt according to the ‘‘One Set of Sites’’ model.
(B) Thermodynamic signature of complex formation (enthalpy and entropy contribution to the Gibbs free energy of binding) differs between the two constructs of
the receptor.
(C) Ligand-mediated activation of wild-type and VEGFR-2 D5 mutant receptor. Shown are western blots for wild-type and mutant T446E/K512A VEGFR-2.
Activities were determined with phospho-speciﬁc antibodies as described in Supplemental Experimental Procedures.
(D) Sequence alignment of subdomain D5 involved in homotypic contacts in VEGFR-1, -2, and -3. Asterisks indicate conserved amino acids in D5 of VEGFR-1, -2,
and -3, and colored residues indicate residues involved in homotypic contacts.
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determined by MR-SAD, as implemented in the program suite PHASER
(McCoy et al., 2007). The partial molecular replacement solution obtained us-
ing the structure of the VEGFR-1 D2/VEGF-A complex (PDB: 1QTY) as a
search model allowed for the identiﬁcation of heavy atom sites and substruc-
ture completion. Initial phases were improved by solvent ﬂattening and
extended to 4 A˚ by 2-fold non-crystallographic symmetry averaging with the
program DM (Cowtan et al., 2012). The missing Ig-homology domains were
positioned by phased molecular replacement in MOLREP (Vagin and Teplya-
kov, 2010) using the following structures as search models in the following or-
der: for D4 VEGFR-3 D4 (PDB: 4BSJ), for D5 VEGFR-3 D5 (PDB: 4BSJ), and for
D3 VEGFR-2 D3 (PDB: 2X1X). To construct a model with the full VEGFR-1
sequence, we created homology models for the Ig domains D3-D5 using the
corresponding MR search models as templates in SWISS-MODEL (Biasini
et al., 2014). The homology models were superimposed onto the domains
positioned by molecular replacement and single Ig domains were connected
generating the VEGFR-1 D2-D5/VEGF-A model.
We ﬁrst attempted to ﬁt D1 and D6 using homology models as well, but the
resulting models had a poor ﬁt without clear difference density to guide model
building. To overcome this, D1 and D6 were submitted to the Foldit structure
prediction game (Cooper et al., 2010). Players were provided a set of ﬁve start-
ing models from I-TASSER (Zhang, 2008). Players then modiﬁed the structure
to minimize the Rosetta energy function; 339 and 443 players participated in
the D1 and D6 puzzles, respectively, over a 2-week period. A very diverse
set of models was generated, which were clustered to within 2 A˚ RMSD.
The 1,000 top-scoring models were then used for molecular replacement
with PHASER. A candidate model was chosen with high log likelihood gain
and translational function Z score for further manual reﬁnement (Figure S2).
The D6 and D1 models were added sequentially to the VEGFR-1 D2-D5/
VEGF-A model, followed by manual rebuilding in COOT (Emsley and Cowtan,
2004) and reﬁnement in PHENIX (Adams et al., 2002) as for the homology
models. NCS, secondary structure, and reference structure restraints were
applied throughout the reﬁnement process. For the ﬁnal reﬁned structure,
Ramachandran values were 83.6% favored, 13.8% allowed, and 2.6% outlier.
The structure of the VEGFR-1 D2–7/VEGF-A complex was determined to
4.8-A˚ resolution by molecular replacement in PHASER using the D2–6 part
of the VEGFR-1 D1–6/VEGF-A structure and the structure of the VEGFR-2
D7 dimer (PDB: 3KVQ) as search models. The structure was improved by
rigid-body reﬁnement in PHENIX. A composite model of the full-length
VEGFR-1 ECD/VEGF-A complex was constructed in COOT by secondary
structure match superposition of the D1–6 and D2–7 structures (RMSD of
1.76 A˚ for 1,128 residues of the D2–6 region).
Native SAD Experiments
Highly redundant diffraction data were collected from a very large native crys-
tal (700 mm) of the VEGFR-1 D1–6/VEGF-A complex at an X-ray energy of 6 keV
(2.0663 A˚ wavelength) applying a recently described method (Weinert et al.,
2015). Individual datasets of 360 were measured from multiple positions
and orientations of the crystal giving 4,320 in total with the anomalous signal
extending to 4.5 A˚. The ﬁnal VEGFR-1 D1–6/VEGF-A model was reﬁned
against these long-wavelength data in PHENIX, which allowed for calculation
of anomalous difference Fourier maps for sulfur. The anomalous peaks around
all disulﬁde bridges in Ig domains and in the VEGF ligand and additionally
around several methionine sulfurs conﬁrmed the accuracy of the model.
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Figure S1 related to Figure 1 and 6. Purification and biophysical characterization of the VEGFR-1 ECD monomer and the VEGFR-
1 ECD/VEGF-A complex in solution.  
A, SDS-PAGE analysis of purified VEGFR-1 ECD, VEGF-A121 and the VEGFR-1 ECD/VEGF-A121 complex. The preformed complex was 
purified by size exclusion chromatography (SEC) on Superdex 200 and used for further biophysical and structural analyses. B, Size exclusion 
coupled to multi-angle light scattering (SEC-MALS) of VEGFR-1 ECD alone and in complex with VEGF-A121. The UV-profiles are shown 
along with the mass distribution of each peak calculated from the MALS data. Experimentally determined Mr values were, for the VEGFR-1 
ECD 89.7 kDa and for the VEGFR-1 ECD/VEGF-A121 complex 206.3 kDa (theoretical values 83.3 and 196.8 kDa, respectively). C, SAXS 
analysis of VEGFR-1 ECD and of the complex with VEGF-A121. Left panel: Scattering intensity as a function of scattering vectors. Right 
panel: GNOM distance distribution functions.  
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Figure S2, related to Figure 1. Quality of the experimental electron density map. 
Electron density map as obtained from MR-SAD phasing in PHASER and subsequent density modification in DM. The map is contoured at 
1.5 σ and exhibits clear solvent-protein boundaries. The figure is centered on two VEGFR-1 D2/VEGF-A complexes positioned by molecular 
replacement and related by 2-fold crystallographic symmetry around y axis (VEGFR-1 D2 is colored red, VEGF-A is colored yellow). A, view 
on the whole unit cell along the y axis. B, Zoom-in of panel a. The density corresponding to Ig-domains D1, D3 and D4 is indicated by labels. 
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Figure S3 related to Figure 1. PHASER scores for molecular replacement of Foldit models for Ig-domain 1 (A) and Ig-domain 6 (B).  
Translation function z-scores (TFZ) and log-likelihood gains for the fitted domain (LLG1) were used to select a model for further use (red 
circle). Electron density fit only weakly correlated with Rosetta energy (Total Energy, color with labels giving ranked energy). 
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Figure S4 related to Figure 1. Comparison of the VEGFR-1 ECD/VEGF-A complex with known partial structures of VEGFR-2 and 
VEGFR-3.  
A, Top, and B, side views of the VEGFR-1 ECD / VEGF-A model (pink/yellow) with four known partial structures of VEGFR-2 (green) or 
VEGFR-3 (cyan) superimposed. From N- to C-terminus: VEGFR-3 D1-2 (PDB: 4BSK); VEGFR-2 D2-3/VEGF-A complex (PDB: 3V2A) 
(green/orange); VEGFR-3 D4-5 dimer (PDB: 4BSJ); and VEGFR-2 D7 dimer (PDB: 3KVQ). Structural alignments were obtained by SSM 
superposition in Coot. C, The same four superpositions presented separately. Rotations relative to the orientation in B are designated. 
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Figure S5. Related to Figure 4. Structural comparison of receptor binding epitopes in VEGF-A, PlGF and VEGF-B. 
A-C, Interaction of VEGF-A (orange) with VEGFR-1 D2-3 (yellow) as in Figure 4b. VEGFR-1 D2 complexes with PlGF (PDB: 1RV6) and 
VEGF-B (PDB: 2XAC) were superimposed onto D2 of the VEGFR-1 D1-6/VEGF-A complex structure. Parts of the ligands are shown: A, 
monomer A, helix α1 and loop 2; B and C, monomer B, loops 1 and 3. D, Interaction of E64 of VEGF-A with VEGFR-1 D3 and comparison 
with the corresponding residues in PlGF (E72) and VEGF-B (D64). Hydrogen bonds and salt bridges are shown as gray dashed lines. E, F, 
Interaction of VEGF-A L1 and L3 with VEGFR-1 D3 with the same loops of PlGF (E) and VEGF-B (F) superimposed. There is a high 
sequence and structure homology between L1 and L3 of VEGF-A and PlGF. L1 and L3 of VEGF-B have clearly different structural features. 
G, Structure-based sequence alignement of VEGF-A (13-109), PlGF (21-115) and VEGF-B (13-109). Residues that interact with VEGFR-1 
D2 are colored in red. VEGF-A residues that interact with VEGFR-1 D3 are colored in blue and underlined and the homologues residues in 
PlGF and VEGF-B that could play similar roles are colored in blue.  
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Figure S6 related to Figure 4. Structural comparison of the loops L1 and L3 of different VEGF family members. 
A, Interactions between the loops L1 and L3 of VEGF-A (purple) and VEGFR-1 D3 (yellow). The key interacting residues are shown as sticks 
and hydrogen bonds as gray dashed lines. VEGF-C (magenta, PDB: 2X1W), VEGF-D (deep teal, PDB: 2XV7) and VEGF-E (salmon, PDB: 
3V6B) were superimposed onto our VEGFR-1 structure to compare L1 and L3 loops. B, Sequence alignement of the L1 and L3 regions of 
different VEGFs. VEGF-A residues E44 and K84 that interact with Q263 of VEGFR-1 and their counterparts in other VEGFs are highlighted 
in yellow. 
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Supplemental Experimental Procedures 
 
Production and purification of recombinant proteins 
Human VEGF-A121 (here denoted as VEGF-A) was produced in Pichia pastoris as described before (Scheidegger 
et al., 1999). Human VEGFR-1 D1-3 (residues 1-339), D1-6 (residues 1-660), D2-7 (residues 132-750) and D1-7 
(residues 1-750) were expressed as secreted proteins in Sf21 insect cells, as described previously (Brozzo et al., 
2012). The proteins were purified from culture supernatant by immobilized metal affinity chromatography (IMAC) 
followed by size exclusion chromatography (SEC) on Superdex 200 HR 16/600 (GE Healthcare) equilibrated in 
25 mM HEPES pH 7.5 and 500 mM NaCl. For the formation of VEGFR-1 ECD/VEGF-A complexes, an equimolar 
amount of receptor and ligand were mixed and the complexes were purified by SEC. 
 
Size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) 
100 μl protein samples at a concentration of 1 mg/ml were injected onto a Superdex 200 HR 10/300 column for 
SEC-MALS determination (GE Healthcare). The column was equilibrated in 25 mM HEPES pH 7.5, 500 mM 
NaCl at 20°C, using an Agilent 1100 HPLC system. Light scattering and differential refractive index were recorded 
using a Wyatt miniDAWN Tristar detector and a Wyatt Optilab rRex detector, respectively. Wyatt Astra software 
was used to collect and process the data and to calculate the molar mass from a global fit of the light scattering 
signals from three detectors at different angles and the differential refractive index signal.  
 
Small angle X-ray solution scattering (SAXS) 
SAXS data acquisition was performed at the X12SA-beamline (cSAXS) at the Swiss Light Source at the Paul 
Scherrer Institute in Villigen, Switzerland. The intensities of the scattered X-rays were recorded on a Pilatus 2M 
detector using a wavelength of λ = 1 Å. Data was collected in the scattering vector range of 0.008 Å-1 - 0.4 Å-1, 
where the length of the scattering vector is given as s = 4πsinθ/λ (2θ is the scattering angle). Silver behenate was 
used as a standard for calibration of the s-range (Huang et al., 1993). Three concentrations were measured per 
protein sample using quartz capillaries with a diameter of 1 mm (Hilgenberg GmbH). To record background 
scattering, the protein buffer was measured in the same capillaries prior to protein data acquisition. Exposures of 
0.5 s were taken at ten different spots along the capillary. The data was monitored for radiation damage and all 
frames showing no radiation damage were merged and averaged for further data processing. The collected SAXS 
data were integrated and radially averaged utilizing our own MATLAB-scripts (J. Missimer & K. Kisko, 
unpublished). Using PRIMUS from the ATSAS (Petoukhov et al., 2012) program package14, the background 
scattering was subtracted and data of different concentrations were merged. In order to check for proper protein 
folding of all measured samples Kratky-plots were calculated. The distance distribution function P(r) was 
calculated using GNOM and the program AUTOGNOM. 
 
Negative stain single particle electron microscopy (EM) 
In order to stabilize the VEGFR-1 D1-7/VEGF-A complex for negative stain EM, samples were prepared using 
GraFix (Kastner et al., 2008). Briefly, 150 pmol of the complex were applied onto a 5-20 % glycerol gradient 
containing 20 mM HEPES pH 7.5, 150 mM NaCl in the presence or absence of 0.2% glutaraldehyde. The samples 
were centrifuged for 18 hrs at 40’000 rpm in a SW60Ti rotor (Beckman-Coulter), which correlates to an average 
RCF value of 164’326 x g. The gradients were harvested from bottom to top with a peristaltic pump collecting 120 
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μl fractions. Protein containing fractions were detected using Roti®-Quant reagent (Carl Roth GmbH + Co. KG) 
for protein quantitation according to Bradford. In addition, protein containing fractions were analyzed by SDS-
PAGE to verify the presence of the complex. Cross-linking reactions were quenched with the addition of 5x 
quenching buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 0.4 M glycine). For negative stain EM, 5 μl of undiluted 
sample was adsorbed to a freshly glow discharged thin carbon film supported on a 200 mesh copper grid and 
incubated for 1 min. at room temperature. The excess sample was blotted away using filter paper. Three 
consecutive washes using 20 mM HEPES pH 7.5, 150 mM NaCl and one wash with 2% uranyl acetate was 
performed followed by 20 s staining with fresh 2% uranyl acetate. Negative stain EM data were collected on a 
CM-100 microscope (Philips) equipped with a Veleta 2k x 2k CCD camera (Olympus). The voltage used was 80 
kV and the magnification was set to a nominal value of 130’000 x. From 126 micrographs 4883 particles were 
picked manually using XMIPP (Scheres et al., 2008). Inferior particles and particles with a z-score >3 were 
discarded. 4536 particles were boxed in 100 x 100 pixel boxes and subjected to alignment and classification into 
24 2D class averages using maximum-likelihood target function (ML2D) implemented in XMIPP using 100 
iterations (Scheres et al., 2005). After 49 iterations ML2D reached convergence. 
 
Comparison of the crystal and EM structure of the VEGFR-1 D1-7/VEGF-A complex  
The composite model of the VEGFR-1 D1-7/VEGF-A complex was converted into density volume filtered to 25 
Å resolution using the Bsoft software package  (Heymann and Belnap, 2007). The volume was then used to 
calculate projections at an angular interval of 15° with the SPIDER image processing suite (Frank et al., 1996). 
The projections with the most similar features to the experimental 2D averages were selected. Density volumes 
and ribbon diagrams were displayed and oriented with the UCSF Chimera package (Pettersen et al., 2004). 
 
Isothermal titration calorimetry (ITC) 
The measurements on VEGFR-1 were performed at 20°C in 25 mM HEPES pH 7.5, and 150 mM NaCl (ITC-
buffer) using an iTC200 calorimeter (MicroCal®, GE Healthcare). The proteins were purified on a Superdex 200 
10/300 column (GE Healthcare) equilibrated in ITC-buffer and dialyzed against ITC-buffer overnight at 4°C prior 
to analysis. The calorimeter cell contained VEGFR-1 D1-7 or VEGFR-1 D1-3 at concentrations ranging from 4.4 
to 30 μM and the ligand VEGF-A121 was used in the syringe at concentrations ranging from 22.5 to 100 μM. All 
samples were equilibrated to the measurement temperature and degassed prior to ITC analysis. The following 
settings were applied: one initial injection of 1 μl followed by 15 injections of 2.6 μl at an injection speed of 1 μl/s 
with a data filter of 1 s and 300 s recovery time between each peak. The software Origin 7.0 (OriginLab®) was 
used for data analysis. 
 
Cell transfection and determination of receptor activity 
NIH 3T3 cells were grown in 10% calf serum in Dulbecco’s Modified Eagle’s Medium (DMEM) and transfected 
using a modified peGFP-N1 vectors (Takara Bio Europe/Clontech) carrying either wt VEGFR-2, or a mutant 
T446E/K512A where residue K512 was replaced by A and T446 by E. All expression vectors were generated by 
Gibson assembly (Gibson et al., 2009). 8 μg DNA in 0.8 ml serum-free medium were mixed with 16 μl PEI 
(Polyethyleneimine, stock 1 mg/ml, Aldrich 408727, 25 kDa branched), incubated for 10 minutes at RT for the 
complex to form. The medium in the culture dishes was replaced with 1.6 ml DMEM containing 0.5% serum and 
the DNA/PEI complex was added for 5 hrs. Cells were incubated for 20 hrs after addition of 1 ml DME with 10% 
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serum. The cells were serum-starved in DMEM supplemented with 1% bovine serum albumin (BSA) and 
stimulated with 1.5 nM VEGF-A for 10 min at 37°C. Cell lysates were prepared in lysis buffer (50 mM Tris pH 
7.5, 100 mM NaCl, and 0.5% w/v Triton X-100) supplemented with protease inhibitor cocktail (Roche diagnostics, 
Risch-Rotkreuz Switzerland), phosphatase inhibitors (200 μM Na3VO4, 10 mM NaF, 10 mM sodium 
pyrophosphate, 30 mM p-nitrophenyl-phosphate, 80 mM glycerophosphate, and 20 μM phenylarsine oxide), and 
10% glycerol. Cell lysates were diluted with Lämmli buffer (20 mM Tris pH 6.8, 5% SDS, 10% mercaptoethanol, 
0.02% bromphenol blue) and the proteins separated on 8% SDS polyacrylamide gels and blotted to Polyvinylidene 
(PVDF, Thermofisher Scientific, Zug Switzerland) membranes. We used 55B11 (2479, Cell Signaling Technology 
Europe) and phospho-Y1175 (2478, Cell Signaling Technology Europe) for determining VEGFR-2 activity. All 
primary antibodies were used at dilutions of 1:1’000, followed by secondary alkaline phosphatase-coupled 
antibodies (6440-04, Southern Biotech, Birmingham USA) at a dilution of 1:10’000. The blots were developed 
with AP chemiluminescent detection substrate (Life Technologies, Carlsbad USA) and the immunoblots were 
analyzed on a GE Healthcare ImageQuant RT ECL scanner and densitometrically quantified using the ImageJ gel 
analysis plugin. Relative activity is given as the ratio of the intensities of the bands corresponding to VEGF treated 
versus non-treated receptor detected by phospho-Y1175 antibody. 
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8. Discussion and Outlook 
VEGFRs, upon binding to their cognate ligands, initiate signaling cascades across the 
plasma membrane for carrying out processes such as angiogenesis and 
lymphangiogenesis. The ligand binds to the receptor ECD and induces distinct 
conformational changes promoting dimerization and instigating TM signaling resulting 
in intracellular kinase activation. Low-resolution structural information on the VEGFR-
2 ECD/ligand complex, derived from single particle EM and SAXS, revealed that Ig-
homology domains 1-3 are involved in ligand binding while membrane proximal 
domains 4-7 form homotypic contacts presumably required for receptor activation 
(Kisko et al., 2011; Ruch et al., 2007). High-resolution structural data on ligand binding 
to subdomains 1-3 show the details of the interactions between the variable loops 
present in VEGF ligands and the receptor domains. A high-resolution crystal structure 
and functional studies of the membrane proximal Ig-homology domain 7 document the 
relevance of the homotypic contacts mediated by conserved charged residues, namely 
R726 and D731 present in the βE-F loop, in activation of the VEGFR-2 complexed with 
ligand (Hyde et al., 2012; Yang et al., 2010). Structural information of Ig-homology 
domains 4-5 of VEGFR-3 show weak lateral interactions in domain 4 and close 
homotypic contacts in domain 5 between receptor monomers (Leppänen et al., 2013). 
Thus, although information on small isolated subdomains for VEGFR-2 exists, the 
exact mechanism of how the ligand induces interactions in the membrane proximal 
domain leading to receptor activation remains unclear. 
8.1. Crystallization of VEGFR-2 ECD ligand complexes 
A great motivation for this thesis was to identify conformational changes present in the 
membrane proximal Ig-homology domains of VEGFR-2 which are triggered by ligand 
binding. To carry out such a structural study, appropriate systems for the expression, 
purification and characterization of various VEGFR-2 constructs were required. In this 
thesis, we describe the successful establishment of such systems, as well as initial 
approaches employed for their crystallization. 
Protein expression in Pichia pastoris was not pursued because earlier expression trials 
in the laboratory resulted in the generation of degraded protein. E.coli expression also 
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lead to misfolded protein in inclusion bodies (Stuttfeld, 2011). In earlier studies carried 
out for determining the crystal structures of single VEGFR Ig-homology domains, E.coli 
expression could be used only after refolding (Christinger et al., 2004; Iyer et al., 2010; 
Wiesmann et al., 1997; Yang et al., 2010). In order to produce larger VEGFR ECD 
fragments, eukaryotic expression systems are more suitable to achieve properly folded 
recombinant proteins (Aricescu et al., 2006). Therefore, we chose to express the 
recombinant receptor proteins in mammalian or insect cells, and we achieved protein 
yields up to several milligrams (0.5-13 mg/l). It is known that there are several potential 
N-glycosylation sites within the ECD of the VEGFRs (Terman et al., 1991), which might 
hamper protein crystallization. Moreover, recombinant proteins produced in insect cells 
are heterogeneously glycosylated, which makes deglycosylation by EndoF or PNGase 
only partially successful (Hollister et al., 2002). Thus, expression in HEK293S GnTi- 
cells is a promising option in order to obtain homogeneously glycosylated proteins. As 
a matter of fact, there are some reported structures of RTK ECDs where the 
recombinant proteins were expressed in HEK293S GnTi- cells (Shim et al., 2010; 
Verstraete et al., 2011).  In order to overcome the low expression yields in 
glycosylation-deficient HEK293S GnTi- cells, a baculovirus-mediated gene 
transduction system for mammalian cells (BacMam) has been developed (Dukkipati et 
al., 2008), and successfully applied to solve the structure of the platelet-derived growth 
factor receptor (PDGFR) Ig-homology domains 1-3 in complex with PDGF (Shim et al., 
2010). In this thesis, I adapted this system for establishing recombinant protein 
production of VEGFR-2 ECD subdomain constructs. However, even using high-titer 
virus in high volumes did not yield high protein expression in mammalian cells when 
compared to chemically transfected HEK293T or HEK293S GnTi- cells, possibly due 
to poor efficiency of our recombinant baculoviruses for transducing mammalian cells 
(Figure 8). There are only a few recently published studies exploring factors for 
improving the entry of baculoviruses in mammalian cells, for which the mechanism has 
been less well known (Mansouri et al., 2016; O'Flynn et al., 2012).   
Since we were unable to generate enough protein for crystallization studies from 
HEK293S GnTi- cells using the BacMam system, we explored alternative stable 
mammalian expression systems, such as the HEK293 EBNA system. HEK293 EBNA 
cells express the EBNA-1 protein, which drives the episomal amplification of 
expression plasmids carrying the origin of replication derived from the EBV. Thus, 
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these cells under selection pressure (Puromycin) are expected to increase 
recombinant protein expression levels by permitting more plasmid copies to persist in 
the transfected cells throughout the production phase. We established high expression 
suspension cultures and obtained homogeneous protein of high purity from 
mammalian HEK293 EBNA cells for the mouse VEGFR-2 ECD constructs, which 
share a sequence identity of 80% with the human VEGFR-2 ECD. Unfortunately, 
excessive crystallization trials of both glycosylated and deglycosylated mouse VEGFR-
2 ECD proteins did not give rise to any crystals. On the other hand, using the above 
established HEK293 EBNA expression system in a followup study from our lab gave 
for the first time highly diffracting crystals of domains 4-5 (allosteric site) of human 
VEGFR-2 (Thieltges et al., 2018).  
Since our extensive crystallization trials with differently glycosylated constructs were 
unsuccessful, we sought an alternative method to facilitate crystallization. We 
successfully generated VEGFR-2 ECD/VEGF-A/antibody fragment complexes for co-
crystallization trials (Griffin et al., 2011). The antibody fragments aid in stabilizing 
flexible protein domains to a distinct conformation leading to improved structural 
homogeneity of the sample. ScFvs have been commonly used for crystallization 
studies. A comparative evaluation of scFv and Fab fragments showed that the 
presence of both constant domains can further stabilize the variable domains in the 
Fab fragment (Rothlisberger et al., 2005).  Crystallization of the extracellular region of 
another RTK, HER2 (also known as Neu receptor), was aided by a Fab called herceptin 
(Cho et al., 2003). The need for such crystallization chaperones for VEGFR-2 becomes 
evident when one considers that the Ig-homology domains present in the ECD are 
connected with flexible linkers, particularly domains 1-2, which exist in a bent 
conformation, as suggested by the structural data on VEGFR-3 and VEGFR-1 
(Leppänen et al., 2013) (Section 7.4). This structural conservation indicates that the 
flexibility in domain 1 may be physiologically essential, for receptor function, and might 
be required for interacting with co-receptors such as neuropilins. Also, binding studies 
on VEGFR-2 ECD/VEGF complexes suggest a regulatory role of Ig-homology domain 
1 (Shinkai et al., 1998). Therefore, we chose scFv and Fab fragments of antibodies 
targeting either domain 1 or domains 2-3 of VEGFR-2 ECD to stabilize the highly 
flexible ligand-binding region of the receptor (Figures 12 and 14). In addition to the 
flexibility due to the linker regions, VEGFR-2 ECD complexes also lack the stability in 
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the membrane proximal regions, which in the physiologically relevant form of the 
receptor is provided by the TMD embedded in the cell membrane. It has been shown 
earlier by our lab that distinct conformation of the TMD is crucial for stabilizing ligand-
receptor complex formation and activation (Dell'Era Dosch et al., 2010; Manni et al., 
2014b).  We therefore sought to mimic this stabilization by generating complexes with 
receptor constructs containing a GCN-4 leucine zipper domain at the C-terminal of the 
membrane proximal domain 7. 
Extensive crystallization trials of VEGFR-2 ECD/VEGF-A complexes with or without 
stabilizing antibody fragments did not yield crystals. It is possible that flexible loops 
other than those in the ligand-binding domain and other unstructured regions in the 
protein impair crystallization. Indeed, bioinformatics analysis predicted the presence of 
extensive disordered regions in VEGFR-2 ECD domains 3 and 5 (Figure 15). New 
constructs with redefined domain boundaries based on a preliminary limited proteolysis 
study presented in this thesis on hVEGFR-2 ECD/VEGF-A complex might be helpful. 
Treatment with subtilisin, α-chymotrypsin and trypsin gave a stable, lower molecular 
weight fragment after longer incubation times, which contains presumably fewer 
disordered regions than the intact protein (Figure 16). The fragments and interfaces 
obtained by limited proteolysis can be identified by a mass spectrometry analysis. 
Other strategies to design new constructs include replacing flexible tails and 
interdomain regions and rational mutagenesis of surface residues, which could make 
proteins amenable for crystallization, were also not pursued for time reasons during 
this thesis. Finally, crystallization trials of isolated Ig-homology domains could be 
beneficial, although this strategy would fail to unravel the interplay between the ligand 
binding domains and membrane proximal domains. 
8.2. Role of VEGFR-2 ECD in receptor dimerization and activation 
It has been shown that VEGFR-2 forms dimers even in the absence of ligand when 
expressed at physiological levels, but complete phosphorylation in the kinase domain 
is only achieved upon ligand binding to the ECD (Sarabipour et al., 2016). ITC and 
MST studies presented here gave us insight into the distinct roles of individual 
extracellular subdomains in ligand-mediated dimerization of VEGFR-2 (Figures 18 and 
19). The biophysical studies confirmed the ability of complex formation between 
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VEGFR-2 ECD and VEGF-A in a 2:1 stoichiometry, considering the disulfide-linked 
ligand dimer as a single molecule. Thermodynamic analysis of receptor binding to 
VEGF, carried out by ITC, revealed the counterintutive finding that the Gibbs free 
energy of ligand binding to full length ECD is less negative by 1.12 kcal/mol compared 
to that of ligand binding with domains 1-3. The comparative data from the two 
biophysical studies also show that the presence of membrane proximal domains (4-7) 
attenuate the receptor affinity for the ligand by approximately 10 fold, although the 
precise value for ligand binding to VEGFR-2 domains 1-3 could not be determined by 
MST, due to reaching the detection limit of the technique,. The study shows that ligand 
interactions with domains 2-3 are thermodynamically highly favourable, whereas 
homotypic interactions in domains 4-7 occur with an enthalpic penalty. This result is in 
agreement with a previous study, which demonstrated that binding of VEGF to 
recombinantly produced ECD protein, encompassing Ig-homology domains 1-7 of 
VEGFR-2 is 1.0-1.7 kcal/mol less favourable than binding to Ig-homology domains 2-
3 (Brozzo et al., 2012). It is also in agreement with another system, fibroblast growth 
factor receptor 3, where the ECD prevents dimerization in the absence of ligand with 
a ΔG of 1 kcal/mol (Chen et al., 2010).  A previous study also shows that deletion of 
domains 4-7 of VEGFR-2 leads to constitutive ligand independent receptor activation 
(Tao et al., 2001). It can be postulated that the energetically unfavorable interactions 
in domains 4-7 are required for proofreading, to prevent ligand-independent self-
association of VEGFR-2 monomers, while properly positioning inactive dimers upon 
ligand activation. It is essential to prevent any erroneous signaling by VEGF that might 
disrupt homeostasis of blood and lymph vessels. 
On the other hand, ITC shows that the homologous VEGFR-1 ECD binds VEGF-A with 
10 fold higher affinity compared to VEGFR-2 ECD (Section 7.4). Moreover, the 
presence of the membrane proximal domains 4-7 in VEGFR-1 increases ligand binding 
affinity by 20 fold when compared with ligand binding affinity to domains 1-3. This is in 
contrast to VEGFR-2, where domains 4-7 significantly reduce ligand binding affinity. 
These studies show that membrane proximal Ig-homology domains enhance ligand 
binding to VEGFR-1 in line with the fact that VEGFR-1 acts as a strong decoy for 
VEGF-A. In addition, the soluble splice variant of VEGFR-1 (sVEGFR-1) comprising 
domains 1-6, has been shown to act as a strong VEGF binding antagonist  (Kendall et 
al., 1993). ITC analysis showed that the presence of the membrane proximal domains 
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4-7 in VEGFR-3 also enhance affinity for VEGF-C and the thermodynamic data 
suggest that ligand binding is both enthalpically and entropically favourable (Leppänen 
et al., 2013). Several knock out studies in mice showed that precisely regulated VEGF-
A concentrations are required for spatially and temporally tightly controlled vessel 
homeostasis (Fong et al., 1995; Fong et al., 1999; Hiratsuka et al., 2005). Thus, RTKs 
follow a strictly ordered sequence of receptor activation where ligand binding allows 
the exact positioning of the subdomains present in the ECD and consequently promote 
a stable thermodynamic state distinct from preformed inactive ligand-free dimers. 
8.3. Functional role of homotypic interactions in the VEGFR-1 ECD 
Structural characterization of the full-length VEGFR-1 ECD complexed with VEGF-A 
revealed for the first time the details of ligand binding and ligand-induced interactions 
between the receptor monomers at the molecular level (Section 7.4). The structure 
shows homotypic interactions taking place in domains 4 and 5 in the ligand bound 
receptor, which seem to be essential for maintaining the conformation of receptor 
dimers that are essential for activation. Our latest VEGFR-1 structure and the already 
existing structural data on other VEGFR homologues show that the interface of domain 
5 is large and the interactions involve fully conserved residues forming hydrogen bonds 
with residues in the adjacent receptor monomer (Brozzo et al., 2012; Leppänen et al., 
2013; Ruch et al., 2007). Therefore, we hypothesized that domain 5 interactions are 
indispensable for receptor function. In order to understand their role in receptor 
activation, we designed cell-based assays comparing the activity of mutant constructs 
that interfere with the homotypic contacts in VEGFR-1 domain 5. In order to perform 
these studies, we needed to optimize the cell expression system for VEGFR-1 to be 
able to detect ligand-induced receptor activation. Initially, we created stably expressing 
PAE cells using chemical transfections as well as lentiviral transductions (Figure 23). 
The advantage of stable transgene expression is that it permanently integrates the 
plasmid DNA into the genome of the host cells, leading to constitutive expression of 
the protein of interest. The PAE cell line was chosen as it is suitable for in vitro studies 
of EC function. Stable PAE cells expressing wild-type VEGFR-1 were used for 
identifying and optimizing the antibodies required for functional assays (Figure 21). 
Furthermore, these cells were used for carrying out time course studies of VEGFR-1 
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activation induced by various ligands (PlGF and VEGF-A165), which revealed very 
quick maximal activitation of VEGFR-1 upon binding to PlGF (Figure 22). It appears 
that the cells maintain a narrow window of receptor activation, which is crucial to 
prevent overstimulation and deregulation. Our findings are in agreement with those of 
another study, where VEGFR-1 expressed in human umbilical vein ECs, achieved 
maximal activation 5 min after PlGF-1 stimulation (the PlGF-1 used in this study was 
expressed in-house in HEK293 cells) (Hoffmann et al., 2013).  The weak kinase activity 
of VEGFR-1 in PAE cells led us to explore alternative ways to assess ligand-induced 
VEGFR-1 activation. One such approach was to co-immunoprecipitate (Co-IP) 
VEGFR-1 (using antibodies against VEGFR-1 or pan phosphoantibodies) and p85. 
p85 is the regulatory subunit of PI-3 KINASE, whose activity is required for the 
cytoskeletal changes occurring during migration of fibroblasts and epithelial cells, and 
is activated downstream of VEGFR-1 (Toker et al., 1997). However, PAE cell lysates 
co-immunoprecipitated with anti-VEGFR-1 did not show any PI-3 KINASE activity (data 
not shown). It is possible that the antibodies used for Co-IP might have interfered with 
the interaction site, preventing p85 binding. Successful pull-down experiments of 
VEGFR-1 have been performed on lysates of primary dermal microvascular ECs, 
which however, have usually high expression levels of VEGFR-1 and hence make 
detection easier (Anisimov et al., 2013). Since the results with PI-3 KINASE were 
inconclusive, we sought an alternative target for probing VEGFR-1 activity. The 
serine/threonine kinase Akt is known to be activated downstream of PI-3 KINASE by 
VEGFR-2 to mediate EC survival signals (Dayanir et al., 2001). It has been postulated 
that it may be one of the targets of VEGFR-1 activation as well (Hudson et al., 2014; 
Tchaikovski et al., 2008). However, we did not observe any Akt phosphorylation upon 
PlGF stimulation of PAE cells expressing wild-type VEGFR-1 (data not shown). Natalie 
Hudson and colleagues could only observe significant Akt phosphorylation in whole-
cell lysates of retinal tissues after a prolonged stimulation of 25 min (Hudson et al., 
2014). As these were primary cells with sufficiently high levels of endogenously 
expressed VEGFR-1, detection of Akt activation might have been easier in this study. 
As an alternative approach to study the role of domain 5 interactions in VEGFR-1 
activation, we also introduced these mutations in the juxtamembrane activated 
VEGFR-1 constructs. These either lacked the three serines or had a replacement with 
ANGG sequence from VEGFR-2, in the JMD for enhancing the receptor activity. These 
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constructs were made in accordance with an earlier study by Gille et al, which attributes 
the divergence in the juxtamembrane region for the strikingly different kinase activity 
of the two homologous receptors (Gille et al., 2000). We also made PAE stable cell 
lines expressing chimeric VEGFR-1/2 constructs comprising the ECD of VEGFR-1 and 
the intracellular domain of VEGFR-2, harbouring the K517A/E513K mutations in 
domain 5, which were expected to show disruption in the homotypic contacts identified 
in the high-resolution VEGFR-1 ECD structure. However, we could not use stable PAE 
cells for studying receptor kinase activity of the domain 5 mutants due to unequal 
expression levels of wild-type and mutant constructs of either VEGFR-1 or chimeric 
VEGFR-1/2 because of inconsistent genomic integration (Figure 23a and 24). Hence 
we shifted our system of study to transiently expressing HEK293 and NIH3T3 cells. 
Although transient transfections have their own limitations, including the requirement 
for new cell transfections for each experiment, the need for large amounts of 
recombinant DNA and the heterogeneity of expression between different DNA batches, 
they have the ability for rapid protein expression within days compared to several 
months, required for stable gene expression. Addressing the lower efficiency 
associated with transient transfection, we optimized two parameters: cell-seeding 
density and transfection reagents: Lipofectamine 2000 and Lipofectamine 3000 
showed improved transfection efficiency in HEK293 cells. However, VEGFR-1 
overexpression in transiently transfected HEK293 cells led to constitutive receptor 
activation and was therefore, unsuitable for ligand-induced functional assays. On the 
other hand, NIH3T3 cells transiently transfected using branched PEI (25kDa) gave 
sharper protein bands and expression levels that allowed the detection of ligand-
induced phosphorylation activity.  
Based on these results, we generated NIH3T3 cells expressing the chimeric VEGFR-
1/2 constructs. When stimulated by PlGF, these cells showed drastically reduced 
phosphorylation activity at Y1175 when compared to the wild-type receptor (Figure 25). 
The kinase activity of these chimeric constructs depends on domain 5 interactions in 
the VEGFR-1 ECD, as the kinase domains of VEGFR-1 and VEGFR-2 are highly 
conserved with 70.1% homology (Rahimi, 2006). Indeed, substitution of the C-terminal 
kinase domain present in VEGFR-1 with that of VEGFR-2 promotes VEGFR-1 
activation and EC proliferation (Meyer et al., 2006). We could further show that 
homologous mutations in domain 5 of VEGFR-2 severely reduced Y1175 
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autophosphorylation activity upon ligand stimulation (Figure 28). Interestingly, the triple 
mutants (T446E/E508A/K512A) did not show further reduction in phosphorylation 
activity when compared to the double VEGFR-2 mutants (T446E/K512A).  This 
suggests that disrupting the hydrogen bonds formed by residues T455 and K517 of 
VEGFR-1 and the corresponding residues T446 and K512 in VEGFR-2 are sufficient 
to destabilize the conformation of the ECD and prevent kinase activation. These in vitro 
kinase assays validate the molecular interactions suggested by the VEGFR-1 
ECD/VEGF-A structure and emphasize that domain 5 mediated homotypic interactions 
are crucial for the activation of VEGFRs. Our study is also in agreement with the work 
of Veli-Matti Leppanen and colleagues who showed the partial structure of another 
receptor homologue, VEGFR-3, as a homodimer of domains 4-5 (Leppänen et al., 
2013). Based on their data, residues T446 and K516 on domain 5 are essential for 
receptor activity. Taken together these data show that these homotypic interactions 
are very well conserved amongst all three VEGFRs. Similar homotypic interactions 
were also shown to be present in the membrane proximal Ig-homology domain 7 of 
VEGFR-2 ECD, and they were also shown to fulfill a regulatory function for receptor 
activation (Yang et al., 2010). Our group has also shown previously that mutating 
domain 4 in VEGFR-2 leads to complete receptor inhibition (Hyde et al., 2012). Similar 
activation mechanisms requiring formation of homotypic interactions are also observed 
in other type III RTKs, such as stem cell growth factor receptor (c-Kit) and PDGFR, 
where the ECD is comprised of five Ig-homology domains (Yang et al., 2008; Yuzawa 
et al., 2007). Crystallographic data for c-Kit showed that ligand binding to Ig-homology 
domains 1-3 does not lead to any significant conformational changes in this region. 
However, ligand binding induces conformational rearrangements in Ig-homology 
domains 4-5, leading to salt bridge formation by residues E386 and R381 located in 
Ig-homology domain 4. The functional relevance of these residues was proven by 
mutational analyses (Yuzawa et al., 2007). The only exception is the Fms-like tyrosine 
kinase 3, where  the crystal structure of the receptor ECD in complex with its ligand 
suggests a novel ligand binding mechanism where the receptor monomers are not 
involved in homotypic interactions (Verstraete et al., 2011).  
Several studies showed that receptor dimerization is essential but not sufficient for 
kinase activation (Bell et al., 2000; Dell'Era Dosch et al., 2010). The described 
homotypic interactions may represent a proofreading mechanism requiring distinct 
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orientation of receptor monomers in active, ligand-bound dimeric receptors. On the 
other hand, inhibition of receptor activity in the absence of ligand may also depend on 
domains 4-7. Correct dimerization of the ECD is further transmitted to the TMD to 
achieve the precise orientation of the two receptors required for full kinase activation 
(Manni et al., 2014b). A recent NMR and molecular dynamics simulation study showed 
that a specific TMD helix conformation is associated with receptor activity. The data 
revealed that TMDs in active constructs were rotated by 180° relative to the inactive 
state (Manni et al., 2014b). 
In conclusion, the structural and thermodynamic studies of VEGFR-2 and the 
biochemical studies on VEGFR-1 presented in this study show that ligand binding to 
Ig-homology domains 2-3 of two receptor protomers promotes further conformational 
changes in the membrane proximal Ig-homology domains 4, 5 and 7 (Figure 29). This 
leads to precise positioning of monomers in the active receptor kinase dimer. These 
findings open new possibilities for developing novel anti-angiogenic compounds 
specifically targeting the homotypic interactions described here. 
 
Figure 29: Schematic representation of VEGFR-1 and -2 dimerization and activation 
induced by ligand VEGF-A. 
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9. Conclusion 
VEGFRs and their ligands are among the most prominent regulators of angiogenic and 
lymphatic development. Disturbance of their tight and multi-level regulation of 
downstream signaling results in numerous pathological conditions and are relevant in 
cancer progression and in various ischemic and inflammatory diseases (Carmeliet et 
al., 2000). Biophysical and structure-function studies of this receptor system will 
contribute highly relevant information for elucidating the exact molecular mechanisms 
involved in receptor activation. Distinct Ig-homology domains are promising target sites 
for the development of highly specific compounds for future medical applications such 
as for instance therapies restricting aberrant angiogenesis. 
We could verify by two in solution native-like environment based biophysical methods 
that dimerization of the VEGFR-2 ECD upon ligand binding depends on two types of 
modules interacting with each other: ligand binding to Ig-homology domains 2-3 are 
highly favourable thermodynamic interactions while homotypic interactions arising in 
Ig-homology domains 4-7 comes with an unfavourable endothermic enthalpy. Hence 
we propose that the membrane proximal domains in the ECD play an important role in 
maintaining the receptor in an inactive state in the absence of ligand while being 
essential for receptor activation by VEGF. These findings document that dimerization 
per se is not sufficient for receptor activation. We assume that specific orientation of 
distinct subdomains is required to accomplish receptor interactions acting as 
checkpoints for kinase activation.  
The molecular details revealed by X-ray crystallography on VEGFR-1 were analyzed 
by carrying out functional experiments involving ligand binding and receptor activation. 
In vitro EC assays showed that VEGFR-1, upon binding to PlGF, leads to 
autophosphorylation of tyrosine residue 1213 present in the C-terminal domain. The 
introduction of mutations in the residues involved in the observed domain 5 interactions 
following ligand binding to VEGFR-1, resulted in reduced phosphorylation activity of 
VEGFR-1/2 chimeric constructs. In addition, similar mutations in the homologous 
residues in domain 5 of VEGFR-2 significantly decreased autophosphorylation activity. 
The above results suggest that Ig-homology domain 5 interactions are well conserved 
among the VEGFR family members. We propose that the hydrogen bonds and salt 
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bridges involved in homotypic interactions in domains 5 and 7 lead to local structural 
rigidity and alignment of the ECD thereby promoting TMD reorientation which then 
leads to VEGFR kinase activation. 
Based on the conformational and functional insights acquired in this thesis on VEGFR-
1 and 2, novel drugs either suppressing or activating vessel growth can be developed 
in the future. 
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